

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York State**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	114167.4	483.1	481.8-484.3	56613.6	528.0	526.0-530.0	57553.8	454.8	453.1-456.5	34446.4	142.1	141.5-142.8	17257.6	167.0	165.9-168.2	17188.8	125.3	124.5-126.2
Oral cavity and pharynx	2700.8	11.3	11.1-11.5	1842.2	16.8	16.4-17.1	858.6	6.7	6.5-6.9	515.2	2.1	2.0-2.2	356.2	3.3	3.2-3.5	159.0	1.2	1.1-1.2
Lip	97.4	0.4	0.4-0.4	62.6	0.6	0.5-0.7	34.8	0.3	0.2-0.3	4.2	0.0	0.0-0.0	2.0	0.0	0.0-0.0	2.2	0.0	0.0-0.0
Tongue	819.4	3.4	3.3-3.5	566.2	5.1	4.9-5.2	253.2	2.0	1.8-2.1	121.6	0.5	0.5-0.5	78.2	0.7	0.6-0.8	43.4	0.3	0.3-0.4
Salivary gland	317.0	1.4	1.3-1.4	173.0	1.7	1.6-1.8	144.0	1.2	1.1-1.3	52.0	0.2	0.2-0.2	32.0	0.3	0.3-0.4	20.0	0.1	0.1-0.2
Floor of mouth	115.2	0.5	0.4-0.5	76.6	0.7	0.6-0.8	38.6	0.3	0.2-0.3	4.2	0.0	0.0-0.0	2.2	0.0	0.0-0.0	2.0	0.0	0.0-0.0
Gum & other mouth	385.4	1.6	1.5-1.7	208.2	2.0	1.8-2.1	177.2	1.3	1.2-1.4	73.4	0.3	0.3-0.3	45.0	0.4	0.4-0.5	28.4	0.2	0.2-0.2
Nasopharynx	174.0	0.8	0.7-0.8	124.2	1.2	1.1-1.3	49.8	0.4	0.4-0.5	54.0	0.2	0.2-0.3	38.4	0.3	0.3-0.4	15.6	0.1	0.1-0.2
Tonsil	471.0	1.9	1.8-2.0	383.6	3.4	3.2-3.5	87.4	0.7	0.6-0.7	44.8	0.2	0.2-0.2	38.2	0.3	0.3-0.4	6.6	0.0	0.0-0.1
Oropharynx	138.4	0.6	0.5-0.6	105.4	0.9	0.9-1.0	33.0	0.2	0.2-0.3	67.2	0.3	0.2-0.3	50.0	0.5	0.4-0.5	17.2	0.1	0.1-0.2
Hypopharynx	146.2	0.6	0.6-0.6	116.0	1.1	1.0-1.2	30.2	0.2	0.2-0.3	26.6	0.1	0.1-0.1	21.2	0.2	0.2-0.2	5.4	0.0	0.0-0.1
Other buccal cavity and pharynx	36.8	0.1	0.1-0.2	26.4	0.2	0.2-0.3	10.4	0.1	0.1-0.1	67.2	0.3	0.2-0.3	49.0	0.5	0.4-0.5	18.2	0.1	0.1-0.2
Digestive system	20125.6	84.2	83.7-84.8	10985.8	103.0	102.1-103.8	9139.8	69.1	68.5-69.8	9355.8	38.4	38.1-38.8	5188.8	49.2	48.6-49.8	4167.0	30.0	29.6-30.4
Esophagus	1089.4	4.5	4.3-4.6	820.2	7.5	7.3-7.8	269.2	2.0	1.9-2.1	851.4	3.5	3.4-3.6	658.0	6.1	5.9-6.3	193.4	1.4	1.3-1.5
Stomach	2021.8	8.6	8.4-8.7	1206.0	11.5	11.2-11.8	815.8	6.3	6.1-6.5	815.0	3.4	3.3-3.5	487.2	4.7	4.5-4.9	327.8	2.4	2.3-2.6
Small intestine	647.8	2.7	2.7-2.8	339.8	3.2	3.0-3.3	308.0	2.4	2.3-2.6	93.0	0.4	0.4-0.4	50.6	0.5	0.4-0.5	42.4	0.3	0.3-0.4
Colorectal	8979.2	38.1	37.8-38.5	4603.8	43.9	43.3-44.4	4375.4	33.5	33.0-33.9	2996.8	12.4	12.2-12.6	1499.8	14.6	14.2-14.9	1497.0	10.7	10.4-10.9
Colon excluding rectum	6345.8	26.9	26.6-27.2	3097.2	29.8	29.3-30.3	3248.6	24.6	24.2-25.0	2409.8	9.9	9.7-10.1	1170.4	11.4	11.1-11.7	1239.4	8.8	8.6-9.0
Cecum	1254.6	5.2	5.1-5.4	546.6	5.3	5.1-5.5	708.0	5.1	5.0-5.3									
Appendix	373.0	1.7	1.6-1.8	153.4	1.5	1.4-1.6	219.6	1.9	1.8-2.1									
Ascending colon	1226.6	5.1	5.0-5.3	559.2	5.4	5.2-5.6	667.4	4.9	4.7-5.1									
Hepatic flexure	286.0	1.2	1.1-1.3	146.8	1.4	1.3-1.6	139.2	1.0	0.9-1.1									
Transverse colon	576.0	2.4	2.3-2.5	280.4	2.7	2.6-2.9	295.6	2.1	2.0-2.3									
Splenic flexure	181.0	0.8	0.7-0.8	101.2	1.0	0.9-1.1	79.8	0.6	0.5-0.7									
Descending colon	400.6	1.7	1.6-1.8	223.2	2.1	2.0-2.3	177.4	1.4	1.3-1.5									
Sigmoid colon	1624.2	6.9	6.8-7.1	884.0	8.3	8.0-8.5	740.2	5.9	5.7-6.1									
Large intestine, NOS	423.8	1.7	1.7-1.8	202.4	2.0	1.9-2.1	221.4	1.6	1.5-1.7									
Rectum & rectosigmoid	2633.4	11.2	11.0-11.4	1506.6	14.1	13.8-14.4	1126.8	8.9	8.7-9.1	587.0	2.4	2.4-2.5	329.4	3.2	3.0-3.3	257.6	1.9	1.8-2.0
Rectosigmoid junction	642.2	2.7	2.6-2.8	354.8	3.3	3.2-3.5	287.4	2.3	2.1-2.4									
Rectum	1991.2	8.5	8.3-8.7	1151.8	10.8	10.5-11.1	839.4	6.6	6.4-6.8									
Anus, anal canal & anorectum	516.2	2.2	2.1-2.2	200.6	1.9	1.7-2.0	315.6	2.4	2.3-2.5	65.8	0.3	0.2-0.3	31.0	0.3	0.2-0.3	34.8	0.3	0.2-0.3
Liver and intrahepatic bile duct	2234.8	9.0	8.8-9.2	1590.6	14.1	13.7-14.4	644.2	4.8	4.6-4.9	1443.6	5.8	5.7-6.0	970.6	8.8	8.6-9.1	473.0	3.4	3.3-3.6

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018  
New York State**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	1840.2	7.4	7.2-7.5	1386.4	12.2	11.9-12.5	453.8	3.3	3.2-3.5	1028.8	4.1	4.0-4.2	762.4	6.8	6.6-7.1	266.4	1.9	1.8-2.0
Intrahepatic bile duct	394.6	1.6	1.6-1.7	204.2	1.9	1.8-2.0	190.4	1.4	1.3-1.5	414.8	1.7	1.7-1.8	208.2	2.0	1.9-2.1	206.6	1.5	1.4-1.6
Gallbladder	347.6	1.4	1.4-1.5	110.6	1.1	1.0-1.2	237.0	1.8	1.7-1.9	178.8	0.7	0.7-0.8	60.8	0.6	0.5-0.7	118.0	0.9	0.8-0.9
Other biliary	443.4	1.8	1.8-1.9	237.0	2.3	2.1-2.4	206.4	1.5	1.4-1.6	109.8	0.4	0.4-0.5	54.2	0.5	0.5-0.6	55.6	0.4	0.3-0.4
Pancreas	3471.6	14.3	14.1-14.5	1735.6	16.3	16.0-16.7	1736.0	12.7	12.4-13.0	2652.4	10.9	10.7-11.1	1313.0	12.5	12.2-12.8	1339.4	9.6	9.3-9.8
Retroperitoneum	103.2	0.5	0.4-0.5	53.6	0.5	0.5-0.6	49.6	0.4	0.4-0.5	15.8	0.1	0.1-0.1	9.4	0.1	0.1-0.1	6.4	0.0	0.0-0.1
Peritoneum, omentum & mesentery	98.2	0.4	0.4-0.4	6.0	0.1	0.0-0.1	92.2	0.7	0.6-0.8	53.2	0.2	0.2-0.2	9.8	0.1	0.1-0.1	43.4	0.3	0.3-0.4
Other digestive organs	172.4	0.7	0.7-0.8	82.0	0.8	0.7-0.9	90.4	0.7	0.6-0.7	80.2	0.3	0.3-0.4	44.4	0.4	0.4-0.5	35.8	0.3	0.2-0.3
Respiratory system	15044.8	62.0	61.6-62.5	7598.6	71.5	70.7-72.2	7446.2	55.2	54.6-55.8	8288.6	34.1	33.8-34.4	4342.0	41.5	41.0-42.1	3946.6	28.7	28.2-29.1
Nasal cavity, middle ear & sinuses	169.4	0.7	0.7-0.8	94.6	0.9	0.8-1.0	74.8	0.6	0.5-0.7	25.4	0.1	0.1-0.1	14.2	0.1	0.1-0.2	11.2	0.1	0.1-0.1
Larynx	753.6	3.1	3.0-3.2	593.0	5.4	5.2-5.6	160.6	1.2	1.1-1.3	221.2	0.9	0.8-0.9	174.4	1.6	1.5-1.7	46.8	0.3	0.3-0.4
Lung and bronchus	14069.2	58.0	57.6-58.4	6875.0	64.8	64.1-65.5	7194.2	53.2	52.7-53.8	8016.4	33.0	32.7-33.3	4137.6	39.6	39.1-40.2	3878.8	28.2	27.8-28.6
Pleura	7.0	0.0	0.0-0.0	4.4	0.0	0.0-0.1	2.6	0.0	0.0-0.0	12.0	0.0	0.0-0.1	9.4	0.1	0.1-0.1	2.6	0.0	0.0-0.0
Trachea, mediastinum, other respiratory	45.6	0.2	0.2-0.3	31.6	0.3	0.3-0.4	14.0	0.1	0.1-0.2	13.6	0.1	0.0-0.1	6.4	0.1	0.0-0.1	7.2	0.1	0.0-0.1
Bones & joints	232.4	1.1	1.1-1.2	129.0	1.3	1.2-1.4	103.4	1.0	0.9-1.1	82.8	0.4	0.3-0.4	46.4	0.5	0.4-0.5	36.4	0.3	0.3-0.4
Soft tissue (including heart)	792.4	3.6	3.5-3.7	443.6	4.4	4.2-4.6	348.8	3.0	2.8-3.1	290.0	1.3	1.2-1.3	150.4	1.5	1.4-1.6	139.6	1.1	1.0-1.2
Skin*	4633.2	20.0	19.7-20.3	2689.8	26.0	25.5-26.4	1943.4	15.8	15.5-16.1	598.4	2.5	2.4-2.6	390.2	3.8	3.6-4.0	208.2	1.5	1.4-1.6
Melanoma of the skin	4186.8	18.1	17.8-18.3	2423.4	23.3	22.9-23.7	1763.4	14.4	14.1-14.7	408.0	1.7	1.6-1.8	257.6	2.5	2.4-2.6	150.4	1.1	1.0-1.2
Breast	16643.6	72.6	72.1-73.1	160.8	1.5	1.4-1.6	16482.8	133.9	132.9-134.8	2533.8	10.6	10.4-10.8	28.8	0.3	0.2-0.3	2505.0	18.7	18.4-19.1
Breast (in situ)#	4994.2	22.3	22.0-22.6	17.6	0.2	0.1-0.2	4976.6	42.1	41.6-42.7									
Female genital system							7151.0	56.3	55.7-56.9							2088.6	15.5	15.2-15.8
Cervix uteri							843.4	7.7	7.4-7.9							254.8	2.1	2.0-2.2
Corpus uterus and NOS							4170.6	31.8	31.4-32.3							801.4	5.8	5.6-6.0
Ovary							1453.8	11.7	11.4-11.9							886.0	6.6	6.4-6.8
Vagina							80.6	0.6	0.6-0.7							21.8	0.2	0.1-0.2
Vulva							343.8	2.6	2.5-2.7							74.8	0.5	0.5-0.6
Other female genital organs							258.8	2.0	1.9-2.1							49.8	0.4	0.3-0.4
Male genital system				15173.2	133.7	132.8-134.7							1766.6	18.0	17.6-18.3			
Prostate				14479.2	126.5	125.6-127.5							1724.6	17.5	17.2-17.9			
Testis				577.6	6.1	5.9-6.3							19.0	0.2	0.2-0.2			
Penis				91.8	0.9	0.8-1.0							19.4	0.2	0.2-0.2			
Other male genital organs				24.6	0.2	0.2-0.3							3.6	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York State**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	9615.0	40.2	39.8-40.6	6735.0	64.2	63.5-64.9	2880.0	21.8	21.4-22.2	1743.8	7.1	7.0-7.3	1168.4	11.6	11.3-11.9	575.4	4.0	3.9-4.2
Urinary bladder (including in situ)	5405.0	22.4	22.1-22.6	4030.8	39.0	38.5-39.6	1374.2	10.0	9.8-10.3	1008.6	4.1	4.0-4.2	695.6	7.1	6.8-7.3	313.0	2.1	2.0-2.2
Kidney and renal pelvis	3978.0	16.9	16.6-17.1	2560.4	23.8	23.3-24.2	1417.6	11.1	10.8-11.4	690.8	2.8	2.7-2.9	446.4	4.3	4.1-4.5	244.4	1.7	1.6-1.9
Ureter	137.8	0.6	0.5-0.6	83.0	0.8	0.7-0.9	54.8	0.4	0.4-0.5	21.0	0.1	0.1-0.1	10.4	0.1	0.1-0.1	10.6	0.1	0.1-0.1
Other urinary organs	94.2	0.4	0.4-0.4	60.8	0.6	0.5-0.7	33.4	0.2	0.2-0.3	23.4	0.1	0.1-0.1	16.0	0.2	0.1-0.2	7.4	0.1	0.0-0.1
Eye & orbit	197.8	0.9	0.8-0.9	99.4	0.9	0.9-1.0	98.4	0.8	0.7-0.9	17.0	0.1	0.1-0.1	8.4	0.1	0.1-0.1	8.6	0.1	0.0-0.1
Brain / other central nervous system (all behaviors)	4891.2	21.8	21.5-22.1	1935.4	19.0	18.6-19.4	2955.8	24.2	23.8-24.6	1072.8	4.6	4.5-4.7	576.6	5.5	5.3-5.7	496.2	3.9	3.7-4.0
Malignant brain / other central nervous system	1445.2	6.6	6.5-6.8	802.2	7.9	7.6-8.1	643.0	5.6	5.4-5.8	887.0	3.8	3.7-3.9	490.6	4.6	4.5-4.8	396.4	3.1	3.0-3.3
Malignant brain	1345.2	6.1	6.0-6.3	750.4	7.3	7.1-7.6	594.8	5.1	4.9-5.3									
Malignant other central nervous system	100.0	0.5	0.5-0.5	51.8	0.5	0.5-0.6	48.2	0.5	0.4-0.5									
Benign brain / other central nervous system#	3446.0	15.2	15.0-15.4	1133.2	11.1	10.8-11.4	2312.8	18.7	18.3-19.0	185.8	0.8	0.7-0.8	86.0	0.9	0.8-0.9	99.8	0.7	0.7-0.8
Benign brain	327.6	1.6	1.5-1.7	160.6	1.7	1.5-1.8	167.0	1.6	1.5-1.7									
Benign other central nervous system	3118.4	13.6	13.4-13.8	972.6	9.4	9.2-9.7	2145.8	17.1	16.8-17.4									
Endocrine system	4293.2	20.5	20.2-20.8	1170.2	11.5	11.2-11.8	3123.0	29.1	28.7-29.6	182.2	0.8	0.7-0.8	77.8	0.8	0.7-0.8	104.4	0.8	0.7-0.9
Thyroid	4057.4	19.4	19.2-19.7	1044.0	10.2	9.9-10.5	3013.4	28.2	27.7-28.7	122.8	0.5	0.5-0.5	51.4	0.5	0.4-0.6	71.4	0.5	0.5-0.6
Other endocrine (including thymus)	235.8	1.1	1.0-1.2	126.2	1.2	1.1-1.3	109.6	0.9	0.9-1.0	59.4	0.3	0.2-0.3	26.4	0.3	0.2-0.3	33.0	0.3	0.2-0.3
Lymphomas	5662.0	24.7	24.4-25.0	3042.6	29.5	29.0-30.0	2619.4	20.9	20.5-21.3	1284.6	5.4	5.2-5.5	713.2	7.1	6.9-7.3	571.4	4.1	4.0-4.3
Hodgkin lymphoma	640.4	3.1	3.0-3.3	344.8	3.5	3.3-3.7	295.6	2.8	2.7-3.0	66.0	0.3	0.3-0.3	36.0	0.4	0.3-0.4	30.0	0.2	0.2-0.3
Non-Hodgkin lymphomas	5021.6	21.6	21.3-21.8	2697.8	26.0	25.5-26.4	2323.8	18.1	17.7-18.4	1218.6	5.1	5.0-5.2	677.2	6.7	6.5-7.0	541.4	3.9	3.7-4.0
Myeloma	1981.8	8.3	8.1-8.4	1075.6	10.1	9.9-10.4	906.2	6.8	6.6-7.0	714.2	2.9	2.8-3.0	371.2	3.6	3.4-3.8	343.0	2.4	2.3-2.6
Leukemias	3761.0	16.3	16.0-16.5	2173.6	21.2	20.8-21.6	1587.4	12.5	12.2-12.8	1392.2	5.9	5.7-6.0	773.8	7.8	7.5-8.0	618.4	4.5	4.4-4.7
Lymphocytic leukemias	1947.8	8.4	8.2-8.6	1178.0	11.4	11.1-11.7	769.8	6.0	5.8-6.2	359.8	1.5	1.4-1.6	210.2	2.1	2.0-2.3	149.6	1.1	1.0-1.1
Acute lymphocytic leukemia	314.4	1.7	1.6-1.8	179.4	1.9	1.8-2.1	135.0	1.4	1.3-1.5	88.0	0.4	0.4-0.5	50.2	0.5	0.4-0.6	37.8	0.3	0.3-0.4
Chronic lymphocytic leukemia	1526.0	6.3	6.1-6.4	918.2	8.6	8.4-8.9	607.8	4.4	4.3-4.6	248.8	1.0	0.9-1.1	147.0	1.5	1.4-1.6	101.8	0.7	0.6-0.7
Other lymphocytic leukemias	107.4	0.5	0.4-0.5	80.4	0.8	0.7-0.9	27.0	0.2	0.2-0.2	23.0	0.1	0.1-0.1	13.0	0.1	0.1-0.2	10.0	0.1	0.1-0.1
Myeloid and monocytic leukemias	1620.2	7.1	6.9-7.2	895.8	8.8	8.6-9.1	724.4	5.8	5.6-6.0	774.6	3.3	3.2-3.4	424.6	4.2	4.0-4.4	350.0	2.6	2.5-2.8
Acute myeloid leukemia	1070.8	4.7	4.5-4.8	586.8	5.8	5.6-6.0	484.0	3.8	3.7-4.0	667.0	2.8	2.7-2.9	365.2	3.6	3.5-3.8	301.8	2.3	2.2-2.4
Acute monocytic leukemia	44.8	0.2	0.2-0.2	25.0	0.2	0.2-0.3	19.8	0.2	0.1-0.2	3.6	0.0	0.0-0.0	1.4	0.0	0.0-0.0	2.2	0.0	0.0-0.0
Chronic myeloid leukemia	473.0	2.1	2.0-2.2	267.0	2.6	2.5-2.8	206.0	1.6	1.5-1.8	58.4	0.2	0.2-0.3	31.4	0.3	0.3-0.4	27.0	0.2	0.2-0.2
Other myeloid/monocytic leukemias	31.6	0.1	0.1-0.2	17.0	0.2	0.1-0.2	14.6	0.1	0.1-0.1	45.6	0.2	0.2-0.2	26.6	0.3	0.2-0.3	19.0	0.1	0.1-0.2
Other leukemias	193.0	0.8	0.8-0.9	99.8	1.0	0.9-1.1	93.2	0.7	0.6-0.8	257.8	1.1	1.0-1.1	139.0	1.4	1.3-1.5	118.8	0.9	0.8-0.9
Other acute leukemias	50.2	0.2	0.2-0.2	25.6	0.3	0.2-0.3	24.6	0.2	0.2-0.2	87.0	0.4	0.3-0.4	46.4	0.5	0.4-0.5	40.6	0.3	0.2-0.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York State**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	142.8	0.6	0.6-0.7	74.2	0.7	0.7-0.8	68.6	0.5	0.5-0.6	170.8	0.7	0.7-0.8	92.6	0.9	0.9-1.0	78.2	0.6	0.5-0.6
Mesothelioma	189.4	0.8	0.8-0.9	137.0	1.4	1.3-1.5	52.4	0.4	0.4-0.5									
Kaposi sarcoma	140.2	0.6	0.6-0.7	121.0	1.2	1.1-1.3	19.2	0.1	0.1-0.2									
Myelodysplastic syndromes	1135.2	4.7	4.6-4.9	644.4	6.6	6.4-6.8	490.8	3.5	3.3-3.6									
Chronic myeloproliferative disorders <sup>^</sup>	1147.8	5.0	4.8-5.1	557.4	5.4	5.2-5.6	590.4	4.6	4.4-4.8									
Ill defined and unspecified sites	2101.8	8.7	8.5-8.9	1032.2	10.0	9.8-10.3	1069.6	7.7	7.5-7.9	2705.6	11.1	10.9-11.3	1384.8	13.5	13.2-13.8	1320.8	9.4	9.1-9.6

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

<sup>^</sup> Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York City**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	41482.4	442.5	440.6-444.5	19903.6	484.9	481.9-488.0	21578.8	417.9	415.4-420.5	12537.6	132.5	131.5-133.6	6128.0	156.9	155.1-158.7	6409.6	116.8	115.5-118.1
Oral cavity and pharynx	934.6	9.9	9.6-10.2	610.4	14.6	14.1-15.2	324.2	6.2	5.9-6.5	202.4	2.1	2.0-2.3	140.2	3.4	3.2-3.7	62.2	1.1	1.0-1.3
Lip	21.8	0.2	0.2-0.3	13.2	0.3	0.2-0.4	8.6	0.2	0.1-0.2	1.6	0.0	0.0-0.0	0.6	0.0	0.0-0.0	1.0	0.0	0.0-0.0
Tongue	249.0	2.6	2.5-2.8	165.0	3.9	3.6-4.2	84.0	1.6	1.5-1.8	44.0	0.5	0.4-0.5	28.8	0.7	0.6-0.8	15.2	0.3	0.2-0.3
Salivary gland	118.2	1.3	1.2-1.4	60.0	1.5	1.3-1.7	58.2	1.2	1.0-1.3	18.6	0.2	0.2-0.2	10.6	0.3	0.2-0.4	8.0	0.2	0.1-0.2
Floor of mouth	31.4	0.3	0.3-0.4	19.8	0.5	0.4-0.6	11.6	0.2	0.2-0.3	1.6	0.0	0.0-0.0	0.8	0.0	0.0-0.0	0.8	0.0	0.0-0.0
Gum & other mouth	149.8	1.6	1.5-1.7	78.2	1.9	1.7-2.1	71.6	1.3	1.2-1.5	24.0	0.3	0.2-0.3	15.6	0.4	0.3-0.5	8.4	0.1	0.1-0.2
Nasopharynx	110.4	1.2	1.1-1.3	78.2	1.9	1.7-2.1	32.2	0.6	0.5-0.7	35.0	0.4	0.3-0.4	26.0	0.6	0.5-0.7	9.0	0.2	0.1-0.2
Tonsil	132.6	1.4	1.3-1.5	105.0	2.4	2.2-2.6	27.6	0.5	0.4-0.6	12.2	0.1	0.1-0.2	10.8	0.3	0.2-0.3	1.4	0.0	0.0-0.1
Oropharynx	53.0	0.6	0.5-0.6	38.2	0.9	0.8-1.1	14.8	0.3	0.2-0.4	28.4	0.3	0.2-0.3	19.2	0.5	0.4-0.6	9.2	0.2	0.1-0.2
Hypopharynx	57.2	0.6	0.5-0.7	44.8	1.1	1.0-1.3	12.4	0.2	0.2-0.3	11.8	0.1	0.1-0.2	9.2	0.2	0.2-0.3	2.6	0.1	0.0-0.1
Other buccal cavity and pharynx	11.2	0.1	0.1-0.1	8.0	0.2	0.1-0.3	3.2	0.1	0.0-0.1	25.2	0.3	0.2-0.3	18.6	0.5	0.4-0.6	6.6	0.1	0.1-0.2
Digestive system	8125.4	86.1	85.3-87.0	4387.8	107.5	106.0-108.9	3737.6	69.8	68.8-70.8	3784.8	39.8	39.2-40.4	2049.0	51.4	50.4-52.4	1735.8	31.2	30.5-31.9
Esophagus	324.8	3.4	3.2-3.6	232.4	5.7	5.3-6.0	92.4	1.7	1.5-1.8	237.8	2.5	2.3-2.6	171.4	4.3	4.0-4.6	66.4	1.2	1.1-1.3
Stomach	982.0	10.5	10.2-10.8	563.2	14.0	13.5-14.6	418.8	7.9	7.5-8.2	440.6	4.7	4.5-4.9	260.0	6.7	6.3-7.0	180.6	3.3	3.1-3.5
Small intestine	228.2	2.5	2.3-2.6	115.4	2.8	2.6-3.1	112.8	2.2	2.0-2.4	29.6	0.3	0.3-0.4	15.0	0.4	0.3-0.5	14.6	0.3	0.2-0.3
Colorectal	3522.4	37.7	37.1-38.2	1807.0	44.7	43.8-45.6	1715.4	32.4	31.7-33.1	1195.4	12.6	12.3-12.9	588.4	15.1	14.5-15.6	607.0	10.8	10.4-11.2
Colon excluding rectum	2471.0	26.4	25.9-26.9	1221.4	30.5	29.7-31.3	1249.6	23.4	22.8-24.0	976.6	10.3	10.0-10.6	468.6	12.0	11.5-12.5	508.0	9.0	8.7-9.4
Cecum	456.6	4.9	4.7-5.1	200.0	5.1	4.8-5.4	256.6	4.7	4.4-5.0									
Appendix	118.6	1.3	1.2-1.4	48.4	1.2	1.0-1.3	70.2	1.5	1.3-1.6									
Ascending colon	478.4	5.1	4.9-5.3	222.4	5.7	5.3-6.0	256.0	4.7	4.4-5.0									
Hepatic flexure	109.0	1.2	1.1-1.3	57.8	1.5	1.3-1.6	51.2	0.9	0.8-1.1									
Transverse colon	214.4	2.3	2.1-2.4	105.2	2.7	2.4-2.9	109.2	2.0	1.8-2.2									
Splenic flexure	71.8	0.8	0.7-0.9	41.0	1.0	0.9-1.2	30.8	0.6	0.5-0.7									
Descending colon	181.4	2.0	1.8-2.1	99.6	2.5	2.3-2.7	81.8	1.6	1.4-1.7									
Sigmoid colon	671.4	7.2	6.9-7.4	365.8	8.9	8.5-9.3	305.6	5.9	5.6-6.2									
Large intestine, NOS	169.4	1.8	1.7-1.9	81.2	2.1	1.9-2.3	88.2	1.6	1.4-1.7									
Rectum & rectosigmoid	1051.4	11.3	11.0-11.6	585.6	14.2	13.7-14.7	465.8	9.0	8.6-9.4	218.8	2.3	2.2-2.5	119.8	3.1	2.8-3.3	99.0	1.8	1.6-2.0
Rectosigmoid junction	268.8	2.9	2.7-3.1	145.4	3.6	3.3-3.8	123.4	2.4	2.2-2.6									
Rectum	782.6	8.4	8.1-8.6	440.2	10.6	10.2-11.1	342.4	6.6	6.3-6.9									
Anus, anal canal & anorectum	210.6	2.2	2.1-2.4	95.4	2.3	2.1-2.5	115.2	2.1	2.0-2.3	26.6	0.3	0.2-0.3	14.2	0.4	0.3-0.5	12.4	0.2	0.2-0.3
Liver and intrahepatic bile duct	1085.0	11.1	10.8-11.4	760.0	17.7	17.1-18.2	325.0	5.9	5.6-6.2	669.2	6.9	6.7-7.2	448.8	10.7	10.3-11.2	220.4	4.0	3.7-4.2

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York City**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	917.6	9.4	9.1-9.7	674.8	15.6	15.1-16.2	242.8	4.4	4.2-4.7	501.0	5.1	4.9-5.4	367.6	8.7	8.3-9.1	133.4	2.4	2.2-2.6
Intrahepatic bile duct	167.4	1.8	1.6-1.9	85.2	2.1	1.9-2.3	82.2	1.5	1.4-1.7	168.2	1.8	1.7-1.9	81.2	2.0	1.8-2.2	87.0	1.6	1.4-1.8
Gallbladder	180.6	1.9	1.8-2.0	54.2	1.4	1.2-1.5	126.4	2.3	2.1-2.5	100.4	1.1	1.0-1.2	33.2	0.8	0.7-1.0	67.2	1.2	1.1-1.4
Other biliary	184.6	2.0	1.8-2.1	96.2	2.4	2.2-2.7	88.4	1.6	1.5-1.8	43.4	0.5	0.4-0.5	22.4	0.6	0.5-0.7	21.0	0.4	0.3-0.5
Pancreas	1278.8	13.5	13.2-13.8	616.6	15.3	14.8-15.9	662.2	12.0	11.6-12.5	993.2	10.4	10.1-10.7	473.8	12.0	11.5-12.5	519.4	9.3	8.9-9.7
Retroperitoneum	42.8	0.5	0.4-0.5	21.4	0.5	0.4-0.6	21.4	0.4	0.4-0.5	7.6	0.1	0.1-0.1	4.4	0.1	0.1-0.2	3.2	0.1	0.0-0.1
Peritoneum, omentum & mesentery	32.6	0.3	0.3-0.4	1.0	0.0	0.0-0.1	31.6	0.6	0.5-0.7	17.8	0.2	0.1-0.2	3.6	0.1	0.1-0.1	14.2	0.3	0.2-0.3
Other digestive organs	53.0	0.6	0.5-0.6	25.0	0.6	0.5-0.8	28.0	0.5	0.4-0.6	23.2	0.2	0.2-0.3	13.8	0.3	0.3-0.4	9.4	0.2	0.1-0.2
Respiratory system	4743.0	50.1	49.4-50.7	2476.0	61.7	60.6-62.8	2267.0	41.8	41.1-42.6	2551.8	26.9	26.4-27.4	1380.0	35.1	34.3-36.0	1171.8	21.1	20.6-21.7
Nasal cavity, middle ear & sinuses	63.6	0.7	0.6-0.8	34.2	0.8	0.7-1.0	29.4	0.6	0.5-0.7	9.0	0.1	0.1-0.1	4.6	0.1	0.1-0.2	4.4	0.1	0.1-0.1
Larynx	269.2	2.8	2.6-3.0	212.0	5.1	4.8-5.4	57.2	1.1	1.0-1.2	85.0	0.9	0.8-1.0	68.2	1.7	1.5-1.9	16.8	0.3	0.2-0.4
Lung and bronchus	4389.4	46.4	45.7-47.0	2215.0	55.4	54.4-56.5	2174.4	40.1	39.3-40.8	2447.0	25.8	25.3-26.3	1301.6	33.2	32.3-34.0	1145.4	20.6	20.1-21.2
Pleura	2.8	0.0	0.0-0.1	1.8	0.0	0.0-0.1	1.0	0.0	0.0-0.0	4.2	0.0	0.0-0.1	3.2	0.1	0.0-0.1	1.0	0.0	0.0-0.0
Trachea, mediastinum, other respiratory	18.0	0.2	0.2-0.3	13.0	0.3	0.2-0.4	5.0	0.1	0.1-0.2	6.6	0.1	0.0-0.1	2.4	0.1	0.0-0.1	4.2	0.1	0.1-0.1
Bones & joints	93.2	1.1	1.0-1.2	52.0	1.4	1.2-1.5	41.2	0.9	0.8-1.1	36.6	0.4	0.3-0.5	20.4	0.5	0.4-0.6	16.2	0.3	0.3-0.4
Soft tissue (including heart)	328.4	3.6	3.5-3.8	173.8	4.3	4.0-4.6	154.6	3.2	2.9-3.4	109.2	1.2	1.1-1.3	54.0	1.3	1.2-1.5	55.2	1.1	0.9-1.2
Skin*	1045.0	11.3	11.0-11.6	575.4	14.6	14.1-15.2	469.6	9.1	8.7-9.5	151.4	1.6	1.5-1.7	95.2	2.5	2.2-2.7	56.2	1.0	0.9-1.1
Melanoma of the skin	918.6	9.9	9.6-10.2	506.6	12.8	12.3-13.4	412.0	7.9	7.6-8.3	96.6	1.0	0.9-1.1	58.8	1.5	1.3-1.7	37.8	0.7	0.6-0.8
Breast	6340.6	69.1	68.4-69.9	62.4	1.5	1.4-1.7	6278.2	124.7	123.3-126.1	1040.4	11.1	10.8-11.4	11.2	0.3	0.2-0.4	1029.2	19.2	18.7-19.7
Breast (in situ)#	2092.2	23.2	22.8-23.7	9.0	0.2	0.2-0.3	2083.2	42.8	41.9-43.6									
Female genital system							2917.6	56.3	55.4-57.2							897.4	16.6	16.1-17.1
Cervix uteri							430.0	9.0	8.6-9.4							129.0	2.5	2.3-2.7
Corpus uteri and NOS							1665.8	31.3	30.7-32.0							381.4	6.9	6.6-7.2
Ovary							584.2	11.5	11.1-11.9							341.4	6.3	6.0-6.6
Vagina							32.4	0.6	0.5-0.7							10.2	0.2	0.1-0.2
Vulva							111.8	2.1	1.9-2.3							22.4	0.4	0.3-0.5
Other female genital organs							93.4	1.8	1.6-1.9							13.0	0.2	0.2-0.3
Male genital system				5590.4	130.1	128.6-131.7							722.0	19.6	18.9-20.2			
Prostate				5330.6	124.0	122.5-125.6							705.4	19.2	18.5-19.8			
Testis				212.6	4.9	4.6-5.2							7.6	0.2	0.1-0.3			
Penis				38.6	1.0	0.8-1.1							8.0	0.2	0.1-0.3			
Other male genital organs				8.6	0.2	0.2-0.3							1.0	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York City**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	2991.0	31.8	31.3-32.3	2063.0	51.7	50.7-52.7	928.0	17.4	16.9-17.9	572.0	6.0	5.8-6.3	381.4	10.1	9.7-10.6	190.6	3.3	3.1-3.6
Urinary bladder (including in situ)	1563.0	16.6	16.2-17.0	1156.2	29.8	29.1-30.6	406.8	7.4	7.1-7.7	326.6	3.4	3.3-3.6	219.8	6.0	5.7-6.4	106.8	1.8	1.7-2.0
Kidney and renal pelvis	1359.2	14.5	14.1-14.8	868.8	20.9	20.2-21.5	490.4	9.4	9.0-9.8	232.4	2.5	2.3-2.6	154.4	3.9	3.6-4.2	78.0	1.4	1.3-1.5
Ureter	35.0	0.4	0.3-0.4	18.6	0.5	0.4-0.6	16.4	0.3	0.2-0.4	5.6	0.1	0.0-0.1	2.8	0.1	0.0-0.1	2.8	0.0	0.0-0.1
Other urinary organs	33.8	0.4	0.3-0.4	19.4	0.5	0.4-0.6	14.4	0.3	0.2-0.3	7.4	0.1	0.1-0.1	4.4	0.1	0.1-0.2	3.0	0.1	0.0-0.1
Eye & orbit	71.6	0.8	0.7-0.9	37.0	0.9	0.8-1.0	34.6	0.7	0.6-0.8	6.8	0.1	0.1-0.1	3.4	0.1	0.0-0.1	3.4	0.1	0.0-0.1
Brain / other central nervous system (all behaviors)	1875.0	20.6	20.2-21.1	715.8	17.7	17.1-18.3	1159.2	22.9	22.3-23.5	343.6	3.7	3.6-3.9	182.2	4.6	4.3-4.9	161.4	3.1	2.9-3.3
Malignant brain / other central nervous system	524.6	5.9	5.7-6.1	290.0	7.1	6.8-7.5	234.6	4.9	4.6-5.1	288.0	3.1	3.0-3.3	155.4	3.9	3.6-4.2	132.6	2.6	2.4-2.8
Malignant brain	486.4	5.4	5.2-5.7	270.6	6.6	6.3-7.0	215.8	4.4	4.2-4.7									
Malignant other central nervous system	38.2	0.4	0.4-0.5	19.4	0.5	0.4-0.6	18.8	0.4	0.3-0.5									
Benign brain / other central nervous system#	1350.4	14.7	14.4-15.1	425.8	10.6	10.1-11.1	924.6	18.0	17.5-18.6	55.6	0.6	0.5-0.7	26.8	0.7	0.6-0.8	28.8	0.5	0.4-0.6
Benign brain	115.4	1.4	1.2-1.5	56.4	1.4	1.2-1.6	59.0	1.3	1.1-1.5									
Benign other central nervous system	1235.0	13.4	13.1-13.7	369.4	9.2	8.8-9.6	865.6	16.7	16.2-17.3									
Endocrine system	1940.2	21.8	21.3-22.2	488.0	11.7	11.2-12.2	1452.2	30.9	30.1-31.6	79.6	0.9	0.8-0.9	29.4	0.7	0.6-0.9	50.2	0.9	0.8-1.1
Thyroid	1831.6	20.6	20.1-21.0	434.0	10.4	10.0-10.9	1397.6	29.7	29.0-30.5	52.8	0.6	0.5-0.6	18.4	0.5	0.4-0.6	34.4	0.6	0.5-0.7
Other endocrine (including thymus)	108.6	1.2	1.1-1.3	54.0	1.3	1.2-1.5	54.6	1.1	1.0-1.3	26.8	0.3	0.3-0.4	11.0	0.3	0.2-0.4	15.8	0.3	0.3-0.4
Lymphomas	2107.2	22.9	22.5-23.4	1117.0	27.7	27.0-28.5	990.2	19.3	18.7-19.8	460.8	4.9	4.7-5.1	251.0	6.5	6.1-6.9	209.8	3.8	3.6-4.0
Hodgkin lymphoma	265.8	3.0	2.9-3.2	143.8	3.5	3.2-3.8	122.0	2.6	2.4-2.8	26.6	0.3	0.2-0.3	14.2	0.4	0.3-0.5	12.4	0.2	0.2-0.3
Non-Hodgkin lymphomas	1841.4	19.9	19.5-20.3	973.2	24.2	23.5-24.9	868.2	16.7	16.1-17.2	434.2	4.6	4.4-4.8	236.8	6.1	5.8-6.5	197.4	3.6	3.3-3.8
Myeloma	848.4	9.0	8.7-9.2	436.8	10.8	10.3-11.2	411.6	7.7	7.3-8.0	285.0	3.0	2.8-3.2	146.6	3.7	3.5-4.0	138.4	2.5	2.3-2.7
Leukemias	1282.8	14.0	13.7-14.4	705.0	17.8	17.2-18.4	577.8	11.3	10.8-11.7	504.0	5.4	5.2-5.7	265.8	6.9	6.6-7.3	238.2	4.4	4.2-4.7
Lymphocytic leukemias	628.2	6.9	6.7-7.2	368.2	9.3	8.9-9.7	260.0	5.1	4.8-5.4	126.6	1.4	1.3-1.5	70.8	1.9	1.7-2.1	55.8	1.0	0.9-1.1
Acute lymphocytic leukemia	139.2	1.7	1.6-1.9	79.2	2.1	1.9-2.3	60.0	1.5	1.3-1.6	39.8	0.5	0.4-0.5	22.4	0.6	0.5-0.7	17.4	0.4	0.3-0.4
Chronic lymphocytic leukemia	457.8	4.8	4.6-5.0	265.8	6.7	6.3-7.1	192.0	3.5	3.3-3.7	80.4	0.8	0.8-0.9	45.4	1.2	1.1-1.4	35.0	0.6	0.5-0.7
Other lymphocytic leukemias	31.2	0.3	0.3-0.4	23.2	0.6	0.5-0.7	8.0	0.1	0.1-0.2	6.4	0.1	0.0-0.1	3.0	0.1	0.0-0.1	3.4	0.1	0.0-0.1
Myeloid and monocytic leukemias	576.6	6.3	6.1-6.5	297.6	7.5	7.2-7.9	279.0	5.4	5.1-5.7	286.8	3.1	2.9-3.3	148.6	3.9	3.6-4.2	138.2	2.6	2.4-2.8
Acute myeloid leukemia	377.4	4.1	4.0-4.3	190.0	4.9	4.6-5.2	187.4	3.7	3.4-3.9	250.4	2.7	2.6-2.9	130.4	3.4	3.1-3.7	120.0	2.3	2.1-2.5
Acute monocytic leukemia	13.2	0.1	0.1-0.2	7.0	0.2	0.1-0.2	6.2	0.1	0.1-0.2	0.6	0.0	0.0-0.0	0.4	0.0	0.0-0.0	0.2	0.0	0.0-0.0
Chronic myeloid leukemia	171.8	1.9	1.7-2.0	92.4	2.3	2.1-2.5	79.4	1.5	1.4-1.7	22.2	0.2	0.2-0.3	12.0	0.3	0.2-0.4	10.2	0.2	0.1-0.2
Other myeloid/monocytic leukemias	14.2	0.2	0.1-0.2	8.2	0.2	0.1-0.3	6.0	0.1	0.1-0.2	13.6	0.1	0.1-0.2	5.8	0.1	0.1-0.2	7.8	0.1	0.1-0.2
Other leukemias	78.0	0.8	0.8-0.9	39.2	1.0	0.9-1.1	38.8	0.7	0.6-0.9	90.6	1.0	0.9-1.1	46.4	1.2	1.1-1.4	44.2	0.8	0.7-0.9
Other acute leukemias	20.6	0.2	0.2-0.3	11.0	0.3	0.2-0.4	9.6	0.2	0.1-0.3	23.2	0.2	0.2-0.3	11.2	0.3	0.2-0.4	12.0	0.2	0.2-0.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018  
New York City**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	57.4	0.6	0.5-0.7	28.2	0.7	0.6-0.8	29.2	0.6	0.5-0.7	67.4	0.7	0.7-0.8	35.2	0.9	0.8-1.1	32.2	0.6	0.5-0.7
Mesothelioma	52.8	0.6	0.5-0.6	35.0	0.9	0.8-1.1	17.8	0.3	0.3-0.4									
Kaposi sarcoma	109.0	1.2	1.1-1.3	95.4	2.3	2.1-2.5	13.6	0.2	0.2-0.3									
Myelodysplastic syndromes	331.0	3.6	3.4-3.8	184.6	5.0	4.7-5.4	146.4	2.6	2.4-2.8									
Chronic myeloproliferative disorders <sup>^</sup>	388.8	4.2	4.0-4.4	182.2	4.5	4.2-4.8	206.6	4.0	3.7-4.2									
All defined and unspecified sites	716.8	7.6	7.3-7.8	341.4	8.7	8.3-9.1	375.4	6.8	6.4-7.1	845.4	8.9	8.7-9.2	423.0	10.9	10.4-11.3	422.4	7.6	7.2-7.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

<sup>^</sup> Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.



**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York State Excl New York City**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	72674.6	509.4	507.7-511.1	36704.0	554.0	551.4-556.6	35970.6	480.4	478.1-482.7	21908.8	148.2	147.3-149.1	11129.6	173.0	171.5-174.5	10779.2	131.0	129.9-132.2
Oral cavity and pharynx	1765.8	12.1	11.9-12.4	1231.4	18.1	17.6-18.5	534.4	7.0	6.7-7.2	312.8	2.1	2.0-2.2	216.0	3.2	3.0-3.4	96.8	1.2	1.1-1.3
Lip	75.6	0.5	0.5-0.6	49.4	0.8	0.7-0.9	26.2	0.3	0.3-0.4	2.6	0.0	0.0-0.0	1.4	0.0	0.0-0.1	1.2	0.0	0.0-0.0
Tongue	570.0	3.9	3.7-4.0	400.8	5.8	5.5-6.0	169.2	2.2	2.1-2.4	77.6	0.5	0.5-0.6	49.4	0.7	0.6-0.8	28.2	0.3	0.3-0.4
Salivary gland	198.8	1.4	1.3-1.5	113.0	1.8	1.7-2.0	85.8	1.2	1.1-1.3	33.4	0.2	0.2-0.3	21.4	0.4	0.3-0.4	12.0	0.1	0.1-0.2
Floor of mouth	83.8	0.6	0.5-0.6	56.8	0.8	0.7-0.9	27.0	0.3	0.3-0.4	2.6	0.0	0.0-0.0	1.4	0.0	0.0-0.0	1.2	0.0	0.0-0.0
Gum & other mouth	235.6	1.6	1.5-1.7	130.0	2.0	1.8-2.1	105.6	1.3	1.2-1.5	49.4	0.3	0.3-0.4	29.4	0.4	0.4-0.5	20.0	0.2	0.2-0.3
Nasopharynx	63.6	0.5	0.4-0.5	46.0	0.7	0.6-0.8	17.6	0.3	0.2-0.3	19.0	0.1	0.1-0.2	12.4	0.2	0.1-0.2	6.6	0.1	0.1-0.1
Tonsil	338.4	2.3	2.2-2.4	278.6	3.9	3.7-4.2	59.8	0.8	0.7-0.9	32.6	0.2	0.2-0.3	27.4	0.4	0.3-0.5	5.2	0.1	0.0-0.1
Oropharynx	85.4	0.6	0.5-0.6	67.2	0.9	0.8-1.0	18.2	0.2	0.2-0.3	38.8	0.3	0.2-0.3	30.8	0.4	0.4-0.5	8.0	0.1	0.1-0.1
Hypopharynx	89.0	0.6	0.5-0.7	71.2	1.0	0.9-1.2	17.8	0.2	0.2-0.3	14.8	0.1	0.1-0.1	12.0	0.2	0.1-0.2	2.8	0.0	0.0-0.1
Other buccal cavity and pharynx	25.6	0.2	0.1-0.2	18.4	0.3	0.2-0.3	7.2	0.1	0.1-0.1	42.0	0.3	0.2-0.3	30.4	0.5	0.4-0.5	11.6	0.1	0.1-0.2
Digestive system	11998.6	83.0	82.3-83.6	6596.8	100.0	98.9-101.2	5401.8	68.8	67.9-69.6	5571.0	37.5	37.1-38.0	3139.8	47.8	47.0-48.5	2431.2	29.2	28.6-29.7
Esophagus	764.4	5.1	5.0-5.3	587.6	8.7	8.4-9.0	176.8	2.2	2.0-2.3	613.6	4.1	4.0-4.3	486.6	7.3	7.0-7.6	127.0	1.5	1.4-1.7
Stomach	1039.2	7.3	7.1-7.5	642.4	9.8	9.5-10.2	396.8	5.2	5.0-5.5	374.4	2.6	2.5-2.7	227.2	3.5	3.3-3.7	147.2	1.8	1.7-2.0
Small intestine	419.6	2.9	2.8-3.1	224.4	3.4	3.2-3.6	195.2	2.6	2.4-2.8	63.4	0.4	0.4-0.5	35.6	0.6	0.5-0.6	27.8	0.3	0.3-0.4
Colorectal	5456.4	38.4	38.0-38.9	2796.4	43.4	42.7-44.1	2660.0	34.3	33.7-34.9	1801.4	12.2	12.0-12.5	911.4	14.3	13.8-14.7	890.0	10.6	10.3-10.9
Colon excluding rectum	3874.6	27.2	26.8-27.6	1875.6	29.4	28.8-30.0	1999.0	25.4	24.9-26.0	1433.2	9.7	9.5-9.9	701.8	11.0	10.6-11.4	731.4	8.6	8.4-8.9
Cecum	798.0	5.5	5.3-5.6	346.6	5.4	5.2-5.7	451.4	5.5	5.2-5.7									
Appendix	254.4	2.0	1.9-2.1	105.0	1.7	1.6-1.9	149.4	2.3	2.2-2.5									
Ascending colon	748.2	5.1	5.0-5.3	336.8	5.3	5.0-5.6	411.4	5.0	4.8-5.3									
Hepatic flexure	177.0	1.2	1.2-1.3	89.0	1.4	1.3-1.6	88.0	1.1	1.0-1.2									
Transverse colon	361.6	2.5	2.4-2.6	175.2	2.8	2.6-3.0	186.4	2.3	2.1-2.4									
Splenic flexure	109.2	0.8	0.7-0.8	60.2	0.9	0.8-1.0	49.0	0.6	0.5-0.7									
Descending colon	219.0	1.6	1.5-1.7	123.4	1.9	1.8-2.1	95.6	1.3	1.2-1.4									
Sigmoid colon	952.8	6.8	6.6-7.0	518.2	7.9	7.6-8.3	434.6	5.9	5.6-6.1									
Large intestine, NOS	254.4	1.7	1.6-1.8	121.2	1.9	1.8-2.1	133.2	1.6	1.4-1.7									
Rectum & rectosigmoid	1581.8	11.2	11.0-11.5	920.8	14.0	13.6-14.4	661.0	8.8	8.5-9.2	368.2	2.5	2.4-2.6	209.6	3.2	3.0-3.4	158.6	2.0	1.8-2.1
Rectosigmoid junction	373.4	2.6	2.5-2.8	209.4	3.2	3.0-3.4	164.0	2.2	2.0-2.3									
Rectum	1208.4	8.6	8.4-8.8	711.4	10.8	10.5-11.2	497.0	6.7	6.4-6.9									
Anus, anal canal & anorectum	305.6	2.1	2.0-2.2	105.2	1.6	1.4-1.7	200.4	2.6	2.4-2.8	39.2	0.3	0.2-0.3	16.8	0.3	0.2-0.3	22.4	0.3	0.2-0.3
Liver and intrahepatic bile duct	1149.4	7.6	7.4-7.8	830.4	11.8	11.4-12.2	319.0	4.0	3.8-4.2	774.4	5.1	5.0-5.3	521.8	7.6	7.3-7.9	252.6	3.1	2.9-3.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York State Excl New York City**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	922.2	6.0	5.8-6.2	711.4	10.0	9.6-10.3	210.8	2.6	2.5-2.8	527.8	3.5	3.3-3.6	394.8	5.7	5.4-5.9	133.0	1.6	1.5-1.7
Intrahepatic bile duct	227.2	1.6	1.5-1.7	119.0	1.8	1.7-2.0	108.2	1.4	1.2-1.5	246.6	1.7	1.6-1.8	127.0	2.0	1.8-2.1	119.6	1.5	1.4-1.6
Gallbladder	167.0	1.1	1.1-1.2	56.4	0.9	0.8-1.0	110.6	1.4	1.3-1.5	78.4	0.5	0.5-0.6	27.6	0.4	0.4-0.5	50.8	0.6	0.5-0.7
Other biliary	258.8	1.8	1.7-1.9	140.8	2.2	2.0-2.3	118.0	1.4	1.3-1.6	66.4	0.4	0.4-0.5	31.8	0.5	0.4-0.6	34.6	0.4	0.3-0.5
Pancreas	2192.8	14.9	14.6-15.2	1119.0	16.9	16.4-17.3	1073.8	13.2	12.8-13.6	1659.2	11.1	10.9-11.4	839.2	12.8	12.4-13.2	820.0	9.8	9.5-10.1
Retroperitoneum	60.4	0.4	0.4-0.5	32.2	0.5	0.4-0.6	28.2	0.4	0.3-0.5	8.2	0.1	0.0-0.1	5.0	0.1	0.0-0.1	3.2	0.0	0.0-0.1
Peritoneum, omentum & mesentery	65.6	0.4	0.4-0.5	5.0	0.1	0.1-0.1	60.6	0.7	0.7-0.8	35.4	0.2	0.2-0.3	6.2	0.1	0.1-0.1	29.2	0.4	0.3-0.4
Other digestive organs	119.4	0.8	0.7-0.9	57.0	0.9	0.8-1.0	62.4	0.8	0.7-0.9	57.0	0.4	0.3-0.4	30.6	0.5	0.4-0.6	26.4	0.3	0.3-0.4
Respiratory system	10301.4	69.7	69.1-70.3	5122.4	77.3	76.3-78.3	5179.0	64.2	63.4-65.0	5736.8	38.7	38.2-39.2	2962.0	45.4	44.6-46.1	2774.8	33.7	33.1-34.3
Nasal cavity, middle ear & sinuses	105.8	0.7	0.7-0.8	60.4	0.9	0.8-1.0	45.4	0.6	0.5-0.7	16.4	0.1	0.1-0.1	9.6	0.2	0.1-0.2	6.8	0.1	0.1-0.1
Larynx	484.4	3.3	3.1-3.4	381.0	5.6	5.3-5.8	103.4	1.3	1.2-1.5	136.2	0.9	0.8-1.0	106.2	1.6	1.4-1.7	30.0	0.4	0.3-0.4
Lung and bronchus	9679.4	65.4	64.8-66.0	4659.8	70.5	69.5-71.4	5019.6	62.1	61.3-62.9	5569.4	37.6	37.1-38.0	2836.0	43.5	42.8-44.2	2733.4	33.2	32.7-33.8
Pleura	4.2	0.0	0.0-0.0	2.6	0.0	0.0-0.1	1.6	0.0	0.0-0.0	7.8	0.1	0.0-0.1	6.2	0.1	0.1-0.1	1.6	0.0	0.0-0.0
Trachea, mediastinum, other respiratory	27.6	0.2	0.2-0.3	18.6	0.3	0.3-0.4	9.0	0.1	0.1-0.2	7.0	0.0	0.0-0.1	4.0	0.1	0.0-0.1	3.0	0.0	0.0-0.1
Bones & joints	139.2	1.2	1.1-1.3	77.0	1.3	1.2-1.5	62.2	1.0	0.9-1.1	46.2	0.4	0.3-0.4	26.0	0.4	0.4-0.5	20.2	0.3	0.2-0.4
Soft tissue (including heart)	464.0	3.5	3.4-3.7	269.8	4.4	4.2-4.6	194.2	2.8	2.6-3.0	180.8	1.3	1.2-1.4	96.4	1.6	1.4-1.7	84.4	1.1	1.0-1.2
Skin*	3588.0	25.9	25.5-26.3	2114.4	33.0	32.4-33.7	1473.6	20.8	20.3-21.3	447.0	3.0	2.9-3.1	295.0	4.6	4.4-4.9	152.0	1.8	1.7-2.0
Melanoma of the skin	3268.0	23.6	23.2-24.0	1916.8	29.8	29.2-30.5	1351.2	19.2	18.7-19.7	311.4	2.1	2.0-2.2	198.8	3.1	2.9-3.3	112.6	1.4	1.3-1.5
Breast	10300.8	74.7	74.1-75.4	98.4	1.5	1.4-1.6	10202.4	140.1	138.8-141.4	1493.4	10.2	10.0-10.5	17.6	0.3	0.2-0.3	1475.8	18.4	18.0-18.9
Breast (in situ)#	2901.8	21.7	21.4-22.1	8.6	0.1	0.1-0.2	2893.2	41.7	40.9-42.4									
Female genital system							4233.2	56.4	55.6-57.2							1191.2	14.8	14.4-15.2
Cervix uteri							413.4	6.8	6.5-7.1							125.8	1.8	1.6-1.9
Corpus uterus and NOS							2504.6	32.1	31.6-32.7							420.0	5.1	4.9-5.3
Ovary							869.6	11.8	11.4-12.1							544.6	6.7	6.5-7.0
Vagina							48.2	0.6	0.6-0.7							11.6	0.1	0.1-0.2
Vulva							232.0	3.0	2.8-3.1							52.4	0.6	0.5-0.7
Other female genital organs							165.4	2.1	2.0-2.3							36.8	0.4	0.4-0.5
Male genital system				9579.8	136.1	134.9-137.4							1044.6	17.0	16.5-17.5			
Prostate				9145.6	127.9	126.7-129.1							1019.2	16.6	16.1-17.0			
Testis				365.0	7.1	6.7-7.4							11.4	0.2	0.1-0.3			
Penis				53.2	0.9	0.8-1.0							11.4	0.2	0.1-0.2			
Other male genital organs				16.0	0.3	0.2-0.3							2.6	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York State Excl New York City**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	6624.0	45.7	45.2-46.2	4672.0	71.8	70.9-72.8	1952.0	24.9	24.3-25.4	1171.8	7.8	7.6-8.0	787.0	12.4	12.1-12.8	384.8	4.5	4.3-4.7
Urinary bladder (including in situ)	3842.0	26.1	25.7-26.5	2874.6	44.6	43.8-45.3	967.4	11.8	11.4-12.1	682.0	4.5	4.4-4.7	475.8	7.7	7.4-8.0	206.2	2.3	2.2-2.5
Kidney and renal pelvis	2618.8	18.5	18.2-18.8	1691.6	25.6	25.0-26.1	927.2	12.4	12.0-12.7	458.4	3.1	2.9-3.2	292.0	4.5	4.2-4.7	166.4	2.0	1.9-2.1
Ureter	102.8	0.7	0.6-0.8	64.4	1.0	0.9-1.1	38.4	0.5	0.4-0.6	15.4	0.1	0.1-0.1	7.6	0.1	0.1-0.2	7.8	0.1	0.1-0.1
Other urinary organs	60.4	0.4	0.4-0.5	41.4	0.7	0.6-0.7	19.0	0.2	0.2-0.3	16.0	0.1	0.1-0.1	11.6	0.2	0.1-0.2	4.4	0.0	0.0-0.1
Eye & orbit	126.2	0.9	0.9-1.0	62.4	1.0	0.9-1.1	63.8	0.9	0.8-1.0	10.2	0.1	0.1-0.1	5.0	0.1	0.0-0.1	5.2	0.1	0.0-0.1
Brain / other central nervous system (all behaviors)	3015.8	22.7	22.4-23.1	1219.4	19.8	19.3-20.3	1796.4	25.4	24.8-25.9	729.2	5.2	5.0-5.4	394.4	6.1	5.8-6.4	334.8	4.4	4.2-4.6
Malignant brain / other central nervous system	920.4	7.2	6.9-7.4	512.0	8.3	8.0-8.7	408.4	6.1	5.8-6.4	599.0	4.3	4.1-4.5	335.2	5.1	4.9-5.4	263.8	3.5	3.3-3.8
Malignant brain	858.6	6.6	6.4-6.8	479.6	7.8	7.5-8.1	379.0	5.6	5.3-5.9									
Malignant other central nervous system	61.8	0.5	0.5-0.6	32.4	0.6	0.5-0.7	29.4	0.5	0.4-0.6									
Benign brain / other central nervous system#	2095.4	15.6	15.3-15.9	707.4	11.5	11.1-11.9	1388.0	19.2	18.8-19.7	130.2	0.9	0.8-1.0	59.2	0.9	0.8-1.1	71.0	0.9	0.8-1.0
Benign brain	212.2	1.8	1.7-1.9	104.2	1.9	1.7-2.0	108.0	1.8	1.6-2.0									
Benign other central nervous system	1883.2	13.8	13.5-14.0	603.2	9.6	9.3-10.0	1280.0	17.5	17.0-17.9									
Endocrine system	2352.6	19.7	19.3-20.1	682.2	11.3	10.9-11.7	1670.4	28.0	27.4-28.7	102.6	0.7	0.7-0.8	48.4	0.8	0.7-0.9	54.2	0.7	0.6-0.8
Thyroid	2225.4	18.7	18.4-19.1	610.0	10.1	9.7-10.5	1615.4	27.2	26.6-27.9	70.0	0.5	0.4-0.5	33.0	0.5	0.4-0.6	37.0	0.4	0.4-0.5
Other endocrine (including thymus)	127.2	1.0	0.9-1.1	72.2	1.2	1.1-1.3	55.0	0.8	0.7-0.9	32.6	0.2	0.2-0.3	15.4	0.3	0.2-0.3	17.2	0.2	0.2-0.3
Lymphomas	3554.0	25.7	25.4-26.1	1925.2	30.5	29.8-31.1	1628.8	22.0	21.5-22.5	823.8	5.6	5.5-5.8	462.2	7.4	7.1-7.7	361.6	4.3	4.1-4.5
Hodgkin lymphoma	374.4	3.2	3.1-3.4	200.8	3.5	3.3-3.8	173.6	3.0	2.8-3.2	39.4	0.3	0.2-0.3	21.8	0.4	0.3-0.4	17.6	0.2	0.2-0.3
Non-Hodgkin lymphomas	3179.6	22.5	22.2-22.9	1724.4	26.9	26.3-27.5	1455.2	19.0	18.6-19.5	784.4	5.3	5.2-5.5	440.4	7.1	6.8-7.4	344.0	4.1	3.9-4.3
Myeloma	1133.4	7.8	7.6-8.0	638.8	9.7	9.4-10.1	494.6	6.2	6.0-6.5	429.2	2.9	2.8-3.0	224.6	3.5	3.3-3.7	204.6	2.4	2.3-2.6
Leukemias	2477.8	17.7	17.4-18.1	1468.2	23.2	22.7-23.8	1009.6	13.3	12.9-13.7	888.2	6.1	5.9-6.3	508.0	8.3	7.9-8.6	380.2	4.6	4.3-4.8
Lymphocytic leukemias	1319.4	9.4	9.1-9.6	809.6	12.6	12.2-13.0	509.8	6.7	6.4-6.9	233.2	1.6	1.5-1.7	139.4	2.3	2.1-2.5	93.8	1.1	1.0-1.2
Acute lymphocytic leukemia	175.2	1.6	1.5-1.7	100.2	1.9	1.7-2.0	75.0	1.4	1.2-1.5	48.2	0.4	0.3-0.4	27.8	0.5	0.4-0.6	20.4	0.3	0.2-0.4
Chronic lymphocytic leukemia	1068.0	7.2	7.0-7.4	652.2	9.8	9.5-10.2	415.8	5.0	4.8-5.3	168.4	1.1	1.0-1.2	101.6	1.7	1.5-1.8	66.8	0.7	0.6-0.8
Other lymphocytic leukemias	76.2	0.6	0.5-0.6	57.2	0.9	0.8-1.0	19.0	0.3	0.2-0.3	16.6	0.1	0.1-0.1	10.0	0.2	0.1-0.2	6.6	0.1	0.1-0.1
Myeloid and monocytic leukemias	1043.4	7.6	7.4-7.8	598.0	9.6	9.3-10.0	445.4	6.0	5.7-6.3	487.8	3.4	3.2-3.5	276.0	4.4	4.2-4.7	211.8	2.6	2.5-2.8
Acute myeloid leukemia	693.4	5.0	4.8-5.2	396.8	6.4	6.1-6.7	296.6	4.0	3.8-4.2	416.6	2.9	2.8-3.0	234.8	3.8	3.6-4.0	181.8	2.3	2.1-2.4
Acute monocytic leukemia	31.6	0.2	0.2-0.3	18.0	0.3	0.2-0.4	13.6	0.2	0.1-0.2	3.0	0.0	0.0-0.0	1.0	0.0	0.0-0.0	2.0	0.0	0.0-0.0
Chronic myeloid leukemia	301.0	2.2	2.1-2.3	174.4	2.8	2.6-3.0	126.6	1.7	1.6-1.9	36.2	0.2	0.2-0.3	19.4	0.3	0.3-0.4	16.8	0.2	0.2-0.2
Other myeloid/monocytic leukemias	17.4	0.1	0.1-0.2	8.8	0.1	0.1-0.2	8.6	0.1	0.1-0.1	32.0	0.2	0.2-0.3	20.8	0.3	0.3-0.4	11.2	0.1	0.1-0.2
Other leukemias	115.0	0.8	0.7-0.9	60.6	1.0	0.9-1.1	54.4	0.7	0.6-0.8	167.2	1.1	1.1-1.2	92.6	1.5	1.4-1.7	74.6	0.9	0.8-1.0
Other acute leukemias	29.6	0.2	0.2-0.2	14.6	0.2	0.2-0.3	15.0	0.2	0.1-0.2	63.8	0.4	0.4-0.5	35.2	0.6	0.5-0.7	28.6	0.3	0.3-0.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York State Excl New York City**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	85.4	0.6	0.5-0.7	46.0	0.7	0.6-0.8	39.4	0.5	0.4-0.6	103.4	0.7	0.6-0.8	57.4	0.9	0.8-1.1	46.0	0.5	0.5-0.6
Mesothelioma	136.6	1.0	0.9-1.0	102.0	1.7	1.5-1.8	34.6	0.5	0.4-0.5									
Kaposi sarcoma	31.2	0.2	0.2-0.3	25.6	0.4	0.3-0.5	5.6	0.1	0.0-0.1									
Myelodysplastic syndromes	804.2	5.5	5.3-5.7	459.8	7.5	7.2-7.8	344.4	4.1	3.9-4.3									
Chronic myeloproliferative disorders <sup>^</sup>	758.6	5.5	5.3-5.7	375.0	6.0	5.7-6.2	383.6	5.0	4.8-5.2									
Ill defined and unspecified sites	1384.8	9.4	9.2-9.6	690.8	10.9	10.5-11.2	694.0	8.3	8.0-8.6	1860.2	12.5	12.2-12.7	961.8	15.1	14.6-15.5	898.4	10.5	10.2-10.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

<sup>^</sup> Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Bronx**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	6416.2	441.2	436.3-446.1	3099.6	505.2	497.0-513.4	3316.6	401.1	394.9-407.3	2264.6	158.1	155.2-161.1	1112.4	196.3	191.0-201.6	1152.2	134.9	131.4-138.5
Oral cavity and pharynx	145.6	9.9	9.2-10.6	97.6	15.5	14.1-17.0	48.0	5.7	5.0-6.5	43.4	3.0	2.6-3.4	29.8	5.0	4.2-5.9	13.6	1.6	1.2-2.0
Lip	3.0	0.2	0.1-0.3	2.4	0.4	0.2-0.7	0.6	0.1	0.0-0.2	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Tongue	34.4	2.3	2.0-2.7	24.6	3.8	3.2-4.6	9.8	1.2	0.9-1.6	8.8	0.6	0.4-0.8	6.0	1.0	0.7-1.4	2.8	0.3	0.2-0.6
Salivary gland	15.2	1.1	0.8-1.3	7.2	1.2	0.8-1.6	8.0	1.0	0.7-1.3	3.6	0.3	0.2-0.4	1.0	0.2	0.1-0.4	2.6	0.3	0.2-0.6
Floor of mouth	6.4	0.4	0.3-0.6	3.8	0.6	0.3-0.9	2.6	0.3	0.2-0.5	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Gum & other mouth	22.0	1.5	1.2-1.8	11.4	1.9	1.4-2.5	10.6	1.3	0.9-1.6	5.6	0.4	0.2-0.5	3.8	0.6	0.4-1.0	1.8	0.2	0.1-0.4
Nasopharynx	12.2	0.8	0.6-1.1	9.2	1.5	1.1-2.0	3.0	0.3	0.2-0.6	5.2	0.4	0.2-0.5	3.0	0.5	0.3-0.8	2.2	0.3	0.1-0.5
Tonsil	28.2	1.9	1.6-2.2	21.0	3.3	2.7-4.0	7.2	0.8	0.6-1.2	4.4	0.3	0.2-0.4	4.2	0.7	0.4-1.0	0.2	0.0	0.0-0.1
Oropharynx	10.4	0.7	0.5-0.9	8.0	1.2	0.9-1.7	2.4	0.3	0.1-0.5	6.2	0.4	0.3-0.6	4.4	0.8	0.5-1.2	1.8	0.2	0.1-0.4
Hypopharynx	13.0	0.9	0.7-1.1	9.4	1.6	1.1-2.1	3.6	0.4	0.3-0.7	3.8	0.3	0.2-0.4	2.8	0.5	0.3-0.9	1.0	0.1	0.0-0.3
Other buccal cavity and pharynx	0.8	0.1	0.0-0.1	0.6	0.1	0.0-0.3	0.2	0.0	0.0-0.1	5.8	0.4	0.3-0.6	4.6	0.8	0.5-1.2	1.2	0.1	0.1-0.3
Digestive system	1331.2	91.7	89.5-94.0	720.4	118.3	114.4-122.4	610.8	72.6	70.0-75.2	686.0	47.7	46.1-49.3	378.8	65.0	62.0-68.0	307.2	35.8	34.0-37.7
Esophagus	50.6	3.5	3.0-3.9	35.8	6.0	5.1-6.9	14.8	1.7	1.4-2.2	43.0	3.0	2.6-3.4	29.8	5.1	4.3-6.0	13.2	1.6	1.2-2.0
Stomach	141.8	10.0	9.2-10.8	75.0	12.9	11.6-14.3	66.8	8.1	7.2-9.0	66.0	4.7	4.2-5.3	39.0	6.9	6.0-8.0	27.0	3.3	2.8-3.9
Small intestine	41.6	2.9	2.5-3.3	20.6	3.6	2.9-4.3	21.0	2.5	2.0-3.0	5.4	0.4	0.2-0.5	3.2	0.6	0.3-0.9	2.2	0.3	0.1-0.5
Colorectal	536.0	37.3	35.9-38.7	270.8	45.0	42.6-47.5	265.2	31.8	30.1-33.6	211.6	14.8	13.9-15.8	106.0	18.8	17.2-20.5	105.6	12.2	11.2-13.4
Colon excluding rectum	377.8	26.4	25.2-27.6	185.0	31.2	29.2-33.3	192.8	23.0	21.6-24.5	171.8	12.0	11.2-12.8	81.8	14.5	13.1-16.1	90.0	10.4	9.5-11.5
Cecum	74.6	5.3	4.7-5.8	30.8	5.3	4.5-6.3	43.8	5.2	4.5-5.9									
Appendix	18.8	1.4	1.1-1.7	6.0	1.0	0.6-1.4	12.8	1.7	1.3-2.1									
Ascending colon	69.4	4.9	4.4-5.5	33.8	5.9	5.0-6.9	35.6	4.3	3.6-4.9									
Hepatic flexure	19.6	1.3	1.1-1.6	9.8	1.7	1.2-2.2	9.8	1.1	0.8-1.5									
Transverse colon	33.2	2.3	1.9-2.7	17.8	2.9	2.3-3.6	15.4	1.8	1.4-2.3									
Splenic flexure	12.4	0.9	0.7-1.1	7.2	1.2	0.8-1.7	5.2	0.6	0.4-0.9									
Descending colon	25.0	1.7	1.4-2.1	12.8	2.2	1.7-2.8	12.2	1.4	1.1-1.8									
Sigmoid colon	104.0	7.2	6.6-7.9	57.0	9.3	8.2-10.5	47.0	5.8	5.1-6.6									
Large intestine, NOS	20.8	1.4	1.2-1.7	9.8	1.8	1.3-2.3	11.0	1.2	0.9-1.6									
Rectum & rectosigmoid	158.2	10.9	10.1-11.7	85.8	13.8	12.5-15.2	72.4	8.8	7.9-9.7	39.8	2.8	2.5-3.3	24.2	4.3	3.5-5.1	15.6	1.8	1.4-2.3
Rectosigmoid junction	37.4	2.6	2.2-3.0	19.8	3.2	2.6-3.9	17.6	2.1	1.7-2.6									
Rectum	120.8	8.3	7.6-9.0	66.0	10.6	9.5-11.8	54.8	6.6	5.9-7.5									
Anus, anal canal & anorectum	43.4	2.9	2.6-3.4	20.8	3.2	2.6-3.9	22.6	2.7	2.2-3.3	8.2	0.6	0.4-0.8	4.0	0.6	0.4-1.0	4.2	0.5	0.3-0.8
Liver and intrahepatic bile duct	237.4	15.7	14.8-16.6	166.8	25.7	24.0-27.6	70.6	8.1	7.3-9.0	147.4	9.9	9.2-10.7	102.0	16.4	15.0-17.9	45.4	5.2	4.5-5.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Bronx**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	214.4	14.1	13.2-15.0	155.2	23.8	22.1-25.6	59.2	6.8	6.0-7.6	120.8	8.1	7.4-8.8	90.2	14.4	13.1-15.9	30.6	3.5	2.9-4.1
Intrahepatic bile duct	23.0	1.6	1.3-1.9	11.6	1.9	1.4-2.4	11.4	1.3	1.0-1.8	26.6	1.8	1.5-2.2	11.8	2.0	1.5-2.6	14.8	1.7	1.3-2.1
Gallbladder	34.8	2.4	2.1-2.8	12.0	2.0	1.5-2.6	22.8	2.7	2.2-3.2	18.8	1.3	1.1-1.6	6.4	1.1	0.7-1.5	12.4	1.4	1.1-1.9
Other biliary	30.6	2.1	1.8-2.5	15.2	2.6	2.0-3.2	15.4	1.8	1.4-2.3	7.8	0.5	0.4-0.7	4.0	0.7	0.4-1.1	3.8	0.4	0.3-0.7
Pancreas	192.0	13.4	12.5-14.2	94.8	16.0	14.6-17.6	97.2	11.4	10.4-12.5	169.6	11.8	11.0-12.7	81.6	14.2	12.8-15.7	88.0	10.3	9.3-11.3
Retroperitoneum	6.2	0.4	0.3-0.6	3.2	0.5	0.3-0.8	3.0	0.4	0.2-0.6	1.0	0.1	0.0-0.2	0.4	0.1	0.0-0.3	0.6	0.1	0.0-0.2
Peritoneum, omentum & mesentery	5.8	0.4	0.3-0.6	0.4	0.0	0.0-0.2	5.4	0.6	0.4-0.9	3.0	0.2	0.1-0.3	0.4	0.1	0.0-0.2	2.6	0.3	0.2-0.5
Other digestive organs	11.0	0.8	0.6-1.0	5.0	0.9	0.6-1.3	6.0	0.7	0.5-1.0	4.2	0.3	0.2-0.5	2.0	0.4	0.2-0.7	2.2	0.3	0.1-0.5
Respiratory system	748.2	51.6	50.0-53.3	392.8	66.3	63.3-69.3	355.4	41.6	39.7-43.6	464.8	32.4	31.1-33.8	253.0	44.1	41.6-46.7	211.8	24.7	23.2-26.2
Nasal cavity, middle ear & sinuses	11.0	0.8	0.6-1.0	6.8	1.1	0.7-1.5	4.2	0.5	0.3-0.8	2.4	0.2	0.1-0.3	1.0	0.2	0.1-0.4	1.4	0.2	0.1-0.4
Larynx	58.6	4.0	3.5-4.5	43.0	7.0	6.1-8.0	15.6	1.9	1.5-2.3	21.6	1.5	1.2-1.8	17.0	3.0	2.4-3.7	4.6	0.5	0.3-0.8
Lung and bronchus	674.0	46.6	45.0-48.2	339.2	57.6	54.8-60.5	334.8	39.1	37.3-41.1	438.8	30.6	29.3-31.9	233.8	40.7	38.4-43.2	205.0	23.8	22.4-25.4
Pleura	0.6	0.0	0.0-0.1	0.4	0.1	0.0-0.2	0.2	0.0	0.0-0.1	0.4	0.0	0.0-0.1	0.4	0.1	0.0-0.3	0.0	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	4.0	0.3	0.2-0.4	3.4	0.5	0.3-0.9	0.6	0.1	0.0-0.2	1.6	0.1	0.1-0.2	0.8	0.1	0.0-0.4	0.8	0.1	0.0-0.3
Bones & joints	17.2	1.2	1.0-1.5	8.4	1.3	0.9-1.7	8.8	1.2	0.9-1.6	9.8	0.7	0.5-0.9	5.6	0.9	0.6-1.2	4.2	0.5	0.3-0.8
Soft tissue (including heart)	48.2	3.4	3.0-3.8	24.0	3.9	3.2-4.6	24.2	3.1	2.5-3.7	15.6	1.1	0.8-1.3	6.8	1.0	0.7-1.5	8.8	1.1	0.8-1.4
Skin*	79.0	5.6	5.1-6.2	41.2	7.4	6.4-8.5	37.8	4.6	4.0-5.3	21.8	1.5	1.3-1.9	13.4	2.4	1.8-3.0	8.4	1.0	0.7-1.3
Melanoma of the skin	59.2	4.3	3.8-4.8	30.8	5.6	4.7-6.5	28.4	3.4	2.9-4.1	11.8	0.8	0.6-1.1	6.8	1.2	0.8-1.7	5.0	0.6	0.4-0.8
Breast	941.0	65.5	63.7-67.5	9.2	1.5	1.1-2.1	931.8	114.2	110.9-117.5	192.2	13.4	12.6-14.3	2.0	0.3	0.2-0.6	190.2	22.5	21.1-24.0
Breast (in situ)#	290.4	20.1	19.1-21.2	1.0	0.2	0.1-0.5	289.4	35.7	33.8-37.6									
Female genital system							461.8	55.8	53.5-58.1							165.6	19.5	18.2-20.9
Cervix uteri							75.8	9.8	8.8-10.8							26.6	3.3	2.7-3.9
Corpus uteri and NOS							262.4	31.0	29.3-32.7							74.4	8.7	7.8-9.6
Ovary							86.0	10.5	9.5-11.5							54.6	6.5	5.7-7.3
Vagina							6.0	0.7	0.5-1.0							2.4	0.3	0.1-0.5
Vulva							18.2	2.2	1.8-2.8							4.4	0.5	0.3-0.7
Other female genital organs							13.4	1.6	1.2-2.0							3.2	0.4	0.2-0.6
Male genital system				958.6	149.9	145.6-154.4							143.6	28.1	26.0-30.3			
Prostate				925.0	144.8	140.5-149.1							139.4	27.4	25.3-29.5			
Testis				24.2	3.6	2.9-4.3							2.6	0.4	0.2-0.7			
Penis				8.0	1.3	0.9-1.8							1.4	0.3	0.1-0.5			
Other male genital organs				1.4	0.2	0.1-0.5							0.2	0.0	0.0-0.2			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Bronx**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	436.2	30.2	28.9-31.5	280.6	47.6	45.1-50.2	155.6	18.4	17.1-19.7	96.2	6.8	6.2-7.5	61.4	11.3	10.1-12.7	34.8	4.0	3.4-4.6
Urinary bladder (including in situ)	192.4	13.5	12.7-14.4	131.6	23.4	21.6-25.3	60.8	7.1	6.4-8.0	51.6	3.7	3.3-4.2	31.8	6.2	5.2-7.2	19.8	2.2	1.8-2.7
Kidney and renal pelvis	235.2	16.1	15.2-17.0	144.8	23.5	21.7-25.3	90.4	10.7	9.7-11.7	43.4	3.0	2.6-3.5	29.2	5.1	4.3-6.0	14.2	1.6	1.3-2.1
Ureter	4.0	0.3	0.2-0.4	1.8	0.3	0.1-0.6	2.2	0.3	0.1-0.5	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Other urinary organs	4.6	0.3	0.2-0.5	2.4	0.4	0.2-0.7	2.2	0.3	0.1-0.5	1.0	0.1	0.0-0.2	0.4	0.1	0.0-0.3	0.6	0.1	0.0-0.2
Eye & orbit	9.6	0.7	0.5-0.9	5.6	0.9	0.6-1.3	4.0	0.5	0.3-0.8	0.8	0.1	0.0-0.1	0.6	0.1	0.0-0.3	0.2	0.0	0.0-0.1
Brain / other central nervous system (all behaviors)	306.6	21.5	20.4-22.6	106.2	17.3	15.8-18.8	200.4	24.7	23.2-26.3	60.0	4.1	3.7-4.7	29.4	5.0	4.2-5.9	30.6	3.6	3.1-4.2
Malignant brain / other central nervous system	75.0	5.3	4.8-5.9	38.2	6.1	5.2-7.0	36.8	4.6	4.0-5.4	49.4	3.4	3.0-3.9	24.8	4.2	3.5-5.0	24.6	2.9	2.4-3.5
Malignant brain	69.4	4.9	4.4-5.4	35.6	5.7	4.9-6.6	33.8	4.2	3.6-4.9									
Malignant other central nervous system	5.6	0.4	0.3-0.6	2.6	0.4	0.2-0.7	3.0	0.4	0.2-0.7									
Benign brain / other central nervous system#	231.6	16.2	15.3-17.2	68.0	11.2	10.0-12.4	163.6	20.1	18.7-21.5	10.6	0.7	0.5-1.0	4.6	0.8	0.5-1.2	6.0	0.7	0.5-1.0
Benign brain	21.8	1.5	1.3-1.9	11.0	1.7	1.3-2.2	10.8	1.4	1.1-1.9									
Benign other central nervous system	209.8	14.7	13.8-15.6	57.0	9.5	8.4-10.7	152.8	18.6	17.3-20.0									
Endocrine system	243.0	17.2	16.2-18.2	47.4	7.6	6.6-8.6	195.6	25.2	23.6-26.9	14.0	1.0	0.8-1.2	5.2	0.9	0.6-1.3	8.8	1.1	0.8-1.5
Thyroid	227.4	16.1	15.1-17.0	40.4	6.4	5.6-7.4	187.0	24.1	22.6-25.7	10.0	0.7	0.5-0.9	3.8	0.7	0.4-1.0	6.2	0.7	0.5-1.0
Other endocrine (including thymus)	15.6	1.1	0.9-1.4	7.0	1.1	0.8-1.6	8.6	1.1	0.8-1.5	4.0	0.3	0.2-0.4	1.4	0.2	0.1-0.5	2.6	0.3	0.2-0.6
Lymphomas	323.0	22.5	21.4-23.6	166.6	27.3	25.4-29.2	156.4	19.0	17.7-20.4	79.4	5.6	5.1-6.2	44.0	7.8	6.8-8.9	35.4	4.2	3.6-4.9
Hodgkin lymphoma	44.4	3.1	2.7-3.5	23.8	3.7	3.1-4.5	20.6	2.6	2.1-3.2	4.6	0.3	0.2-0.5	2.2	0.4	0.2-0.7	2.4	0.3	0.1-0.5
Non-Hodgkin lymphomas	278.6	19.4	18.4-20.4	142.8	23.6	21.8-25.4	135.8	16.4	15.2-17.7	74.8	5.3	4.8-5.9	41.8	7.4	6.4-8.5	33.0	3.9	3.3-4.6
Myeloma	167.4	11.5	10.7-12.3	86.8	14.3	12.9-15.7	80.6	9.6	8.7-10.6	52.4	3.6	3.2-4.1	28.0	4.8	4.0-5.7	24.4	2.8	2.3-3.4
Leukemias	182.8	12.7	11.9-13.5	95.4	15.8	14.4-17.3	87.4	10.6	9.7-11.7	77.0	5.4	4.9-6.0	40.8	7.2	6.2-8.3	36.2	4.2	3.6-4.9
Lymphocytic leukemias	84.4	5.8	5.3-6.4	47.4	7.6	6.6-8.7	37.0	4.5	3.9-5.2	16.6	1.2	0.9-1.5	10.4	1.8	1.4-2.4	6.2	0.7	0.5-1.0
Acute lymphocytic leukemia	28.6	2.0	1.7-2.3	16.6	2.3	1.9-2.9	12.0	1.6	1.2-2.1	8.4	0.6	0.4-0.8	5.6	0.9	0.6-1.3	2.8	0.4	0.2-0.6
Chronic lymphocytic leukemia	51.6	3.5	3.1-4.0	28.2	4.8	4.1-5.7	23.4	2.7	2.2-3.2	7.8	0.5	0.4-0.8	4.8	1.0	0.6-1.4	3.0	0.3	0.2-0.5
Other lymphocytic leukemias	4.2	0.3	0.2-0.4	2.6	0.4	0.2-0.7	1.6	0.2	0.1-0.4	0.4	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.4	0.0	0.0-0.2
Myeloid and monocytic leukemias	87.0	6.1	5.5-6.7	43.2	7.3	6.4-8.4	43.8	5.3	4.6-6.1	43.4	3.0	2.6-3.4	22.2	3.9	3.2-4.7	21.2	2.5	2.0-3.0
Acute myeloid leukemia	56.2	4.0	3.5-4.5	28.2	5.0	4.2-5.9	28.0	3.5	2.9-4.1	38.0	2.6	2.3-3.0	20.4	3.6	2.9-4.4	17.6	2.1	1.7-2.6
Acute monocytic leukemia	1.6	0.1	0.0-0.2	1.2	0.2	0.1-0.4	0.4	0.1	0.0-0.2	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Chronic myeloid leukemia	26.0	1.8	1.5-2.1	12.4	2.0	1.5-2.6	13.6	1.6	1.2-2.0	3.6	0.3	0.1-0.4	1.2	0.2	0.1-0.5	2.4	0.3	0.1-0.5
Other myeloid/monocytic leukemias	3.2	0.2	0.1-0.3	1.4	0.2	0.1-0.4	1.8	0.2	0.1-0.4	1.6	0.1	0.1-0.2	0.6	0.1	0.0-0.3	1.0	0.1	0.0-0.3
Other leukemias	11.4	0.8	0.6-1.0	4.8	0.9	0.5-1.3	6.6	0.8	0.6-1.2	17.0	1.2	1.0-1.5	8.2	1.5	1.1-2.0	8.8	1.1	0.8-1.4
Other acute leukemias	2.8	0.2	0.1-0.3	1.2	0.2	0.1-0.5	1.6	0.2	0.1-0.4	4.0	0.3	0.2-0.4	2.0	0.3	0.2-0.6	2.0	0.2	0.1-0.5

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Bronx**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	8.6	0.6	0.4-0.8	3.6	0.6	0.4-1.0	5.0	0.6	0.4-0.9	13.0	0.9	0.7-1.2	6.2	1.2	0.8-1.7	6.8	0.8	0.6-1.1
Mesothelioma	6.4	0.5	0.3-0.7	4.6	0.9	0.5-1.3	1.8	0.2	0.1-0.4									
Kaposi sarcoma	20.6	1.4	1.2-1.7	17.6	2.7	2.1-3.3	3.0	0.4	0.2-0.7									
Myelodysplastic syndromes	46.0	3.3	2.8-3.7	25.0	4.6	3.8-5.5	21.0	2.5	2.0-3.0									
Chronic myeloproliferative disorders <sup>^</sup>	68.6	4.8	4.3-5.3	28.0	4.6	3.8-5.4	40.6	4.9	4.3-5.7									
Ill defined and unspecified sites	106.8	7.4	6.8-8.0	51.6	8.9	7.8-10.1	55.2	6.3	5.6-7.1	152.6	10.6	9.9-11.4	74.6	13.2	11.9-14.6	78.0	9.0	8.1-9.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

<sup>^</sup> Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.



**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**Kings (Brooklyn)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	12082.6	441.7	438.1-445.3	5758.6	487.8	482.0-493.6	6324.0	414.4	409.8-419.1	3543.2	129.5	127.5-131.4	1707.8	152.9	149.7-156.3	1835.4	114.5	112.1-116.9
Oral cavity and pharynx	256.0	9.4	8.9-9.9	167.0	14.0	13.0-15.0	89.0	5.8	5.3-6.4	52.2	1.9	1.7-2.2	37.2	3.2	2.8-3.7	15.0	0.9	0.7-1.2
Lip	6.6	0.2	0.2-0.3	3.4	0.3	0.2-0.5	3.2	0.2	0.1-0.3	0.4	0.0	0.0-0.0	0.0	0.0	0.0-0.1	0.4	0.0	0.0-0.1
Tongue	56.2	2.1	1.8-2.3	36.2	3.0	2.5-3.4	20.0	1.3	1.1-1.6	8.4	0.3	0.2-0.4	6.2	0.5	0.4-0.8	2.2	0.1	0.1-0.2
Salivary gland	30.0	1.1	0.9-1.3	13.6	1.2	0.9-1.5	16.4	1.1	0.8-1.3	3.8	0.1	0.1-0.2	1.8	0.2	0.1-0.3	2.0	0.1	0.1-0.2
Floor of mouth	7.2	0.3	0.2-0.4	4.2	0.3	0.2-0.5	3.0	0.2	0.1-0.3	0.6	0.0	0.0-0.1	0.2	0.0	0.0-0.1	0.4	0.0	0.0-0.1
Gum & other mouth	43.8	1.6	1.4-1.8	25.6	2.2	1.8-2.6	18.2	1.1	0.9-1.4	6.0	0.2	0.1-0.3	3.0	0.3	0.1-0.4	3.0	0.2	0.1-0.3
Nasopharynx	45.0	1.7	1.5-1.9	32.4	2.7	2.3-3.1	12.6	0.8	0.6-1.1	12.8	0.5	0.4-0.6	11.0	0.9	0.7-1.2	1.8	0.1	0.1-0.2
Tonsil	30.4	1.1	0.9-1.3	23.6	1.9	1.6-2.3	6.8	0.4	0.3-0.6	3.0	0.1	0.1-0.2	2.4	0.2	0.1-0.4	0.6	0.0	0.0-0.1
Oropharynx	16.8	0.6	0.5-0.7	12.2	1.0	0.7-1.3	4.6	0.3	0.2-0.4	8.6	0.3	0.2-0.4	6.0	0.5	0.3-0.7	2.6	0.2	0.1-0.3
Hypopharynx	16.4	0.6	0.5-0.8	13.2	1.2	0.9-1.5	3.2	0.2	0.1-0.4	2.0	0.1	0.0-0.1	1.8	0.2	0.1-0.3	0.2	0.0	0.0-0.1
Other buccal cavity and pharynx	3.6	0.1	0.1-0.2	2.6	0.2	0.1-0.4	1.0	0.1	0.0-0.2	6.6	0.3	0.2-0.4	4.8	0.4	0.3-0.7	1.8	0.1	0.1-0.2
Digestive system	2393.0	87.3	85.7-88.9	1271.8	108.9	106.2-111.7	1121.2	71.2	69.3-73.2	1075.2	39.1	38.0-40.2	572.0	50.2	48.3-52.1	503.2	31.0	29.7-32.2
Esophagus	88.2	3.2	2.9-3.5	62.8	5.4	4.8-6.1	25.4	1.6	1.3-1.9	58.0	2.1	1.9-2.4	43.2	3.8	3.3-4.4	14.8	0.9	0.7-1.2
Stomach	309.0	11.4	10.8-12.0	179.2	15.6	14.6-16.7	129.8	8.3	7.6-8.9	143.0	5.3	5.0-5.8	82.8	7.5	6.8-8.3	60.2	3.8	3.3-4.2
Small intestine	69.6	2.6	2.3-2.9	33.4	2.9	2.4-3.3	36.2	2.4	2.0-2.7	8.8	0.3	0.2-0.4	4.0	0.4	0.2-0.6	4.8	0.3	0.2-0.5
Colorectal	1076.8	39.5	38.4-40.6	541.0	46.8	45.0-48.6	535.8	34.3	33.0-35.6	352.4	12.8	12.2-13.4	169.0	15.1	14.1-16.2	183.4	11.1	10.4-11.9
Colon excluding rectum	754.6	27.6	26.7-28.5	364.2	31.6	30.2-33.2	390.4	24.9	23.8-26.0	294.0	10.6	10.1-11.2	139.0	12.4	11.5-13.4	155.0	9.4	8.7-10.0
Cecum	132.0	4.8	4.5-5.2	57.8	5.1	4.5-5.7	74.2	4.6	4.1-5.1									
Appendix	31.0	1.2	1.0-1.4	11.8	1.0	0.7-1.3	19.2	1.3	1.1-1.6									
Ascending colon	148.8	5.5	5.1-5.9	65.2	5.7	5.1-6.4	83.6	5.3	4.8-5.8									
Hepatic flexure	31.0	1.1	1.0-1.3	15.6	1.4	1.1-1.7	15.4	1.0	0.8-1.2									
Transverse colon	68.2	2.5	2.2-2.8	34.4	3.0	2.6-3.5	33.8	2.1	1.8-2.4									
Splenic flexure	21.4	0.8	0.6-0.9	11.0	1.0	0.7-1.3	10.4	0.6	0.5-0.8									
Descending colon	58.6	2.2	1.9-2.4	32.2	2.8	2.3-3.2	26.4	1.7	1.4-2.1									
Sigmoid colon	202.0	7.4	6.9-7.8	106.8	9.0	8.2-9.8	95.2	6.2	5.6-6.8									
Large intestine, NOS	61.6	2.3	2.0-2.5	29.4	2.7	2.3-3.2	32.2	2.0	1.7-2.3									
Rectum & rectosigmoid	322.2	11.9	11.3-12.5	176.8	15.1	14.1-16.2	145.4	9.4	8.7-10.1	58.4	2.1	1.9-2.4	30.0	2.7	2.2-3.1	28.4	1.8	1.5-2.1
Rectosigmoid junction	78.8	2.9	2.6-3.2	43.2	3.7	3.3-4.3	35.6	2.3	2.0-2.7									
Rectum	243.4	8.9	8.4-9.5	133.6	11.4	10.5-12.3	109.8	7.1	6.5-7.7									
Anus, anal canal & anorectum	49.8	1.8	1.6-2.1	20.2	1.7	1.4-2.0	29.6	1.9	1.6-2.2	4.8	0.2	0.1-0.3	2.6	0.2	0.1-0.4	2.2	0.1	0.1-0.3
Liver and intrahepatic bile duct	287.4	10.2	9.7-10.7	204.8	16.6	15.6-17.7	82.6	5.2	4.7-5.7	175.2	6.3	5.9-6.7	118.0	9.8	9.0-10.7	57.2	3.6	3.2-4.0

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018  
Kings (Brooklyn)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	243.6	8.6	8.1-9.1	182.6	14.8	13.8-15.8	61.0	3.8	3.4-4.3	132.0	4.7	4.3-5.1	95.8	7.9	7.2-8.7	36.2	2.2	1.9-2.6
Intrahepatic bile duct	43.8	1.6	1.4-1.8	22.2	1.8	1.5-2.2	21.6	1.4	1.1-1.7	43.2	1.6	1.4-1.8	22.2	1.9	1.6-2.3	21.0	1.3	1.1-1.6
Gallbladder	52.2	1.9	1.7-2.2	15.2	1.4	1.1-1.7	37.0	2.3	2.0-2.7	25.2	0.9	0.8-1.1	6.2	0.6	0.4-0.8	19.0	1.2	1.0-1.5
Other biliary	47.6	1.7	1.5-2.0	24.6	2.1	1.8-2.6	23.0	1.5	1.2-1.8	14.8	0.5	0.4-0.7	7.4	0.7	0.5-0.9	7.4	0.5	0.3-0.7
Pancreas	378.2	13.7	13.1-14.4	177.4	15.2	14.2-16.3	200.8	12.5	11.8-13.4	275.6	10.0	9.5-10.6	130.0	11.4	10.5-12.3	145.6	9.0	8.3-9.7
Retroperitoneum	12.6	0.5	0.4-0.6	6.8	0.6	0.4-0.8	5.8	0.4	0.3-0.6	3.6	0.1	0.1-0.2	2.0	0.2	0.1-0.3	1.6	0.1	0.0-0.2
Peritoneum, omentum & mesentery	7.2	0.3	0.2-0.4	0.2	0.0	0.0-0.1	7.0	0.4	0.3-0.6	4.0	0.1	0.1-0.2	0.6	0.0	0.0-0.1	3.4	0.2	0.1-0.3
Other digestive organs	14.4	0.5	0.4-0.7	6.2	0.5	0.4-0.8	8.2	0.5	0.4-0.7	9.8	0.3	0.2-0.5	6.2	0.5	0.4-0.8	3.6	0.2	0.1-0.4
Respiratory system	1345.2	49.1	47.9-50.3	745.6	65.1	63.0-67.3	599.6	37.9	36.5-39.3	709.0	26.0	25.1-26.9	405.6	36.3	34.7-38.0	303.4	18.8	17.9-19.8
Nasal cavity, middle ear & sinuses	18.2	0.7	0.5-0.8	11.2	1.0	0.7-1.3	7.0	0.5	0.3-0.6	1.8	0.1	0.0-0.1	1.4	0.1	0.0-0.2	0.4	0.0	0.0-0.1
Larynx	75.6	2.7	2.4-3.0	60.6	5.1	4.5-5.7	15.0	0.9	0.7-1.2	22.6	0.8	0.7-1.0	18.8	1.6	1.3-2.0	3.8	0.2	0.1-0.4
Lung and bronchus	1245.4	45.5	44.3-46.6	669.4	58.7	56.6-60.7	576.0	36.4	35.0-37.8	682.0	25.0	24.1-25.9	383.8	34.4	32.9-36.0	298.2	18.5	17.6-19.5
Pleura	1.2	0.0	0.0-0.1	0.8	0.1	0.0-0.2	0.4	0.0	0.0-0.1	0.6	0.0	0.0-0.1	0.6	0.1	0.0-0.2	0.0	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	4.8	0.2	0.1-0.3	3.6	0.3	0.2-0.4	1.2	0.1	0.0-0.2	2.0	0.1	0.0-0.1	1.0	0.1	0.0-0.2	1.0	0.1	0.0-0.2
Bones & joints	28.6	1.1	0.9-1.3	16.8	1.4	1.1-1.8	11.8	0.9	0.7-1.1	9.2	0.3	0.2-0.4	4.4	0.3	0.2-0.5	4.8	0.3	0.2-0.5
Soft tissue (including heart)	97.0	3.7	3.3-4.0	49.0	4.2	3.6-4.7	48.0	3.3	2.9-3.8	29.4	1.1	0.9-1.3	12.6	1.1	0.9-1.4	16.8	1.1	0.8-1.3
Skin*	264.0	9.8	9.3-10.4	137.6	12.1	11.2-13.1	126.4	8.3	7.6-9.0	34.0	1.2	1.0-1.4	21.2	1.9	1.5-2.3	12.8	0.8	0.6-1.0
Melanoma of the skin	228.6	8.5	8.0-9.0	118.0	10.4	9.5-11.3	110.6	7.2	6.6-7.9	20.0	0.7	0.6-0.9	12.4	1.1	0.8-1.4	7.6	0.5	0.3-0.7
Breast	1810.4	67.7	66.3-69.2	19.0	1.7	1.3-2.0	1791.4	120.5	118.0-123.1	320.4	11.8	11.2-12.4	3.8	0.3	0.2-0.5	316.6	20.2	19.2-21.3
Breast (in situ)#	561.6	21.4	20.6-22.2	2.6	0.2	0.1-0.4	559.0	38.7	37.3-40.2									
Female genital system							919.8	59.8	58.0-61.6							284.2	17.9	16.9-18.8
Cervix uteri							140.6	9.8	9.1-10.6							41.2	2.7	2.4-3.2
Corpus uteri and NOS							528.4	33.7	32.4-35.0							124.2	7.7	7.1-8.3
Ovary							176.6	11.6	10.8-12.4							106.2	6.7	6.1-7.3
Vagina							10.4	0.6	0.5-0.9							2.8	0.2	0.1-0.3
Vulva							36.4	2.3	2.0-2.7							6.8	0.4	0.3-0.6
Other female genital organs							27.4	1.8	1.5-2.1							3.0	0.2	0.1-0.3
Male genital system				1630.8	132.5	129.6-135.5							213.2	20.1	18.9-21.4			
Prostate				1551.8	126.3	123.5-129.2							209.4	19.8	18.6-21.0			
Testis				64.2	4.9	4.4-5.5							1.6	0.1	0.1-0.2			
Penis				12.2	1.1	0.8-1.4							2.2	0.2	0.1-0.4			
Other male genital organs				2.6	0.3	0.1-0.4							0.0	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**Kings (Brooklyn)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	855.0	31.2	30.3-32.2	596.8	52.0	50.1-53.9	258.2	16.6	15.7-17.5	155.0	5.6	5.2-6.1	104.2	9.6	8.8-10.5	50.8	3.1	2.7-3.5
Urinary bladder (including in situ)	433.2	15.9	15.3-16.6	329.8	29.7	28.3-31.2	103.4	6.6	6.0-7.2	90.4	3.3	3.0-3.6	60.8	5.8	5.1-6.5	29.6	1.7	1.5-2.1
Kidney and renal pelvis	402.4	14.6	14.0-15.3	257.2	21.4	20.2-22.6	145.2	9.4	8.7-10.1	61.4	2.2	2.0-2.5	41.4	3.6	3.2-4.2	20.0	1.2	1.0-1.5
Ureter	8.6	0.3	0.2-0.4	4.4	0.4	0.2-0.6	4.2	0.3	0.2-0.4	1.0	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.6	0.0	0.0-0.1
Other urinary organs	10.8	0.4	0.3-0.5	5.4	0.5	0.3-0.7	5.4	0.3	0.2-0.5	2.2	0.1	0.0-0.1	1.6	0.1	0.1-0.3	0.6	0.0	0.0-0.1
Eye & orbit	20.4	0.7	0.6-0.9	9.2	0.7	0.5-1.0	11.2	0.7	0.5-1.0	2.0	0.1	0.0-0.1	1.4	0.1	0.0-0.3	0.6	0.0	0.0-0.1
Brain / other central nervous system (all behaviors)	581.2	21.6	20.8-22.4	215.2	18.2	17.1-19.3	366.0	24.1	23.0-25.3	96.8	3.6	3.3-3.9	53.0	4.5	4.0-5.1	43.8	2.8	2.5-3.3
Malignant brain / other central nervous system	159.2	5.9	5.5-6.3	86.4	7.1	6.4-7.8	72.8	5.0	4.5-5.5	77.8	2.9	2.6-3.2	43.6	3.7	3.2-4.2	34.2	2.3	1.9-2.6
Malignant brain	143.2	5.3	4.9-5.7	78.6	6.5	5.8-7.2	64.6	4.4	3.9-5.0									
Malignant other central nervous system	16.0	0.6	0.5-0.7	7.8	0.6	0.4-0.9	8.2	0.6	0.4-0.8									
Benign brain / other central nervous system#	422.0	15.7	15.0-16.4	128.8	11.1	10.2-12.0	293.2	19.1	18.2-20.2	19.0	0.7	0.6-0.9	9.4	0.9	0.6-1.2	9.6	0.6	0.4-0.8
Benign brain	37.6	1.5	1.3-1.7	16.4	1.4	1.1-1.7	21.2	1.6	1.3-1.9									
Benign other central nervous system	384.4	14.2	13.6-14.9	112.4	9.7	8.9-10.6	272.0	17.6	16.6-18.6									
Endocrine system	613.0	22.9	22.1-23.8	152.8	12.4	11.6-13.4	460.2	32.1	30.8-33.5	23.2	0.8	0.7-1.0	8.4	0.7	0.5-1.0	14.8	0.9	0.7-1.1
Thyroid	575.6	21.5	20.7-22.4	133.2	10.9	10.1-11.8	442.4	30.8	29.5-32.2	14.8	0.5	0.4-0.7	4.4	0.4	0.2-0.6	10.4	0.6	0.5-0.8
Other endocrine (including thymus)	37.4	1.4	1.2-1.6	19.6	1.6	1.3-1.9	17.8	1.2	1.0-1.5	8.4	0.3	0.2-0.4	4.0	0.3	0.2-0.5	4.4	0.3	0.2-0.4
Lymphomas	597.6	22.1	21.3-22.9	315.8	26.6	25.3-28.0	281.8	18.5	17.6-19.5	109.8	4.1	3.7-4.4	53.8	4.9	4.3-5.5	56.0	3.5	3.1-4.0
Hodgkin lymphoma	84.8	3.2	2.9-3.5	43.8	3.5	3.1-4.0	41.0	2.9	2.5-3.3	7.0	0.3	0.2-0.4	3.4	0.3	0.2-0.5	3.6	0.2	0.1-0.4
Non-Hodgkin lymphomas	512.8	18.9	18.2-19.7	272.0	23.1	21.9-24.4	240.8	15.7	14.8-16.6	102.8	3.8	3.5-4.1	50.4	4.6	4.0-5.2	52.4	3.3	2.9-3.7
Myeloma	259.0	9.5	9.0-10.0	129.0	11.2	10.3-12.1	130.0	8.3	7.6-8.9	79.6	2.9	2.6-3.2	38.4	3.5	3.0-4.0	41.2	2.5	2.2-2.9
Leukemias	364.8	13.6	12.9-14.2	194.4	16.8	15.7-17.9	170.4	11.2	10.4-12.0	125.2	4.6	4.3-5.0	63.2	5.7	5.1-6.4	62.0	3.9	3.5-4.4
Lymphocytic leukemias	173.8	6.4	6.0-6.9	97.6	8.4	7.6-9.2	76.2	5.0	4.5-5.5	34.2	1.3	1.1-1.5	16.6	1.5	1.2-1.9	17.6	1.1	0.9-1.3
Acute lymphocytic leukemia	40.0	1.6	1.4-1.8	22.6	1.9	1.5-2.2	17.4	1.3	1.0-1.6	8.8	0.3	0.2-0.5	3.6	0.3	0.2-0.5	5.2	0.4	0.2-0.5
Chronic lymphocytic leukemia	126.8	4.6	4.3-5.0	70.4	6.1	5.5-6.8	56.4	3.5	3.1-4.0	23.6	0.9	0.7-1.0	12.2	1.1	0.9-1.5	11.4	0.7	0.5-0.9
Other lymphocytic leukemias	7.0	0.2	0.2-0.3	4.6	0.4	0.2-0.6	2.4	0.2	0.1-0.3	1.8	0.1	0.0-0.1	0.8	0.1	0.0-0.2	1.0	0.1	0.0-0.1
Myeloid and monocytic leukemias	163.0	6.1	5.7-6.5	84.0	7.3	6.6-8.1	79.0	5.2	4.7-5.8	65.8	2.4	2.2-2.7	34.4	3.1	2.7-3.6	31.4	2.0	1.7-2.3
Acute myeloid leukemia	105.4	4.0	3.6-4.3	52.0	4.6	4.1-5.2	53.4	3.5	3.1-4.0	56.6	2.1	1.9-2.4	29.6	2.7	2.3-3.2	27.0	1.7	1.4-2.0
Acute monocytic leukemia	3.4	0.1	0.1-0.2	1.8	0.2	0.1-0.3	1.6	0.1	0.0-0.2	0.0	0.0	0.0-0.0	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Chronic myeloid leukemia	50.8	1.9	1.7-2.1	27.8	2.3	2.0-2.8	23.0	1.5	1.2-1.8	6.2	0.2	0.2-0.3	4.2	0.4	0.2-0.6	2.0	0.1	0.1-0.2
Other myeloid/monocytic leukemias	3.4	0.1	0.1-0.2	2.4	0.2	0.1-0.3	1.0	0.1	0.0-0.2	3.0	0.1	0.1-0.2	0.6	0.0	0.0-0.1	2.4	0.2	0.1-0.3
Other leukemias	28.0	1.0	0.9-1.2	12.8	1.1	0.8-1.4	15.2	1.0	0.8-1.2	25.2	0.9	0.8-1.1	12.2	1.1	0.8-1.4	13.0	0.9	0.7-1.1
Other acute leukemias	6.4	0.2	0.2-0.3	2.8	0.3	0.1-0.4	3.6	0.2	0.1-0.4	5.2	0.2	0.1-0.3	2.0	0.2	0.1-0.3	3.2	0.2	0.1-0.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018  
Kings (Brooklyn)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	21.6	0.8	0.6-1.0	10.0	0.8	0.6-1.1	11.6	0.8	0.6-1.0	20.0	0.8	0.6-0.9	10.2	0.9	0.7-1.2	9.8	0.7	0.5-0.9
Mesothelioma	16.6	0.6	0.5-0.8	10.8	1.0	0.7-1.3	5.8	0.4	0.3-0.5									
Kaposi sarcoma	28.2	1.0	0.8-1.2	23.0	1.9	1.5-2.3	5.2	0.3	0.2-0.4									
Myelodysplastic syndromes	84.6	3.2	2.9-3.5	46.6	4.5	3.9-5.1	38.0	2.4	2.0-2.7									
Chronic myeloproliferative disorders <sup>^</sup>	110.4	4.1	3.7-4.4	51.8	4.4	3.9-5.0	58.6	3.8	3.3-4.2									
All defined and unspecified sites	229.0	8.4	7.9-8.9	104.4	9.3	8.5-10.1	124.6	7.7	7.1-8.3	243.8	8.9	8.4-9.4	124.8	11.2	10.4-12.2	119.0	7.3	6.7-7.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

<sup>^</sup> Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York (Manhattan)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	8641.2	449.2	444.9-453.6	4126.0	486.1	479.3-492.8	4515.2	430.1	424.4-436.0	2772.8	140.0	137.6-142.3	1351.4	163.1	159.2-167.1	1421.4	124.8	121.8-127.8
Oral cavity and pharynx	222.8	11.5	10.8-12.2	147.2	17.2	15.9-18.5	75.6	7.0	6.3-7.8	45.8	2.3	2.0-2.6	31.4	3.7	3.1-4.3	14.4	1.2	1.0-1.6
Lip	6.2	0.3	0.2-0.5	3.6	0.4	0.3-0.7	2.6	0.2	0.1-0.4	0.8	0.0	0.0-0.1	0.6	0.1	0.0-0.2	0.2	0.0	0.0-0.1
Tongue	72.8	3.7	3.4-4.2	48.6	5.7	5.0-6.4	24.2	2.2	1.8-2.7	12.6	0.6	0.5-0.8	7.8	0.9	0.7-1.3	4.8	0.4	0.3-0.6
Salivary gland	28.6	1.5	1.2-1.8	15.2	1.8	1.4-2.3	13.4	1.3	1.0-1.7	5.2	0.3	0.2-0.4	3.4	0.4	0.2-0.7	1.8	0.1	0.1-0.3
Floor of mouth	7.4	0.4	0.3-0.5	4.8	0.6	0.4-0.9	2.6	0.2	0.1-0.4	0.6	0.0	0.0-0.1	0.2	0.0	0.0-0.1	0.4	0.0	0.0-0.2
Gum & other mouth	29.0	1.5	1.2-1.8	14.0	1.6	1.3-2.1	15.0	1.3	1.0-1.7	4.8	0.2	0.2-0.4	3.0	0.3	0.2-0.6	1.8	0.2	0.1-0.3
Nasopharynx	15.2	0.8	0.6-1.0	9.8	1.1	0.8-1.5	5.4	0.5	0.3-0.8	6.4	0.3	0.2-0.5	5.4	0.6	0.4-0.9	1.0	0.1	0.0-0.3
Tonsil	37.4	1.9	1.7-2.2	30.6	3.5	2.9-4.1	6.8	0.6	0.4-0.9	2.0	0.1	0.0-0.2	1.8	0.2	0.1-0.4	0.2	0.0	0.0-0.1
Oropharynx	11.6	0.6	0.5-0.8	8.6	1.1	0.8-1.4	3.0	0.3	0.2-0.5	5.2	0.3	0.2-0.4	3.2	0.4	0.2-0.6	2.0	0.2	0.1-0.3
Hypopharynx	12.6	0.7	0.5-0.9	10.4	1.2	0.9-1.6	2.2	0.2	0.1-0.4	3.4	0.2	0.1-0.3	2.6	0.3	0.2-0.5	0.8	0.1	0.0-0.2
Other buccal cavity and pharynx	2.0	0.1	0.0-0.2	1.6	0.2	0.1-0.4	0.4	0.0	0.0-0.2	4.8	0.2	0.2-0.4	3.4	0.4	0.2-0.7	1.4	0.1	0.0-0.3
Digestive system	1531.6	78.6	76.8-80.4	828.8	98.0	95.0-101.1	702.8	63.4	61.3-65.6	803.4	40.4	39.2-41.7	437.4	52.2	50.1-54.5	366.0	31.4	30.0-32.9
Esophagus	66.8	3.4	3.0-3.7	44.2	5.2	4.5-5.9	22.6	2.0	1.6-2.4	54.6	2.7	2.4-3.1	37.4	4.5	3.8-5.2	17.2	1.4	1.2-1.8
Stomach	148.8	7.7	7.1-8.3	85.0	10.2	9.2-11.2	63.8	5.8	5.2-6.5	79.6	4.0	3.7-4.5	48.6	5.8	5.1-6.6	31.0	2.7	2.3-3.2
Small intestine	39.8	2.1	1.8-2.4	20.2	2.3	1.9-2.9	19.6	1.9	1.5-2.3	6.4	0.3	0.2-0.5	3.4	0.4	0.2-0.7	3.0	0.3	0.1-0.4
Colorectal	648.0	33.8	32.6-35.0	337.4	40.3	38.4-42.4	310.6	28.7	27.2-30.2	234.6	11.9	11.2-12.6	114.8	13.9	12.8-15.1	119.8	10.3	9.5-11.2
Colon excluding rectum	449.6	23.3	22.3-24.3	223.4	27.0	25.4-28.6	226.2	20.6	19.4-21.9	178.8	9.0	8.4-9.6	84.2	10.2	9.2-11.2	94.6	8.1	7.4-8.9
Cecum	87.8	4.5	4.1-4.9	41.0	4.9	4.3-5.7	46.8	4.2	3.7-4.8									
Appendix	28.0	1.5	1.3-1.8	13.0	1.6	1.2-2.1	15.0	1.5	1.1-1.9									
Ascending colon	87.6	4.4	4.0-4.9	38.0	4.6	3.9-5.3	49.6	4.3	3.8-4.9									
Hepatic flexure	21.8	1.1	0.9-1.3	11.4	1.4	1.0-1.8	10.4	0.9	0.7-1.2									
Transverse colon	39.0	2.0	1.7-2.3	16.8	2.1	1.6-2.6	22.2	2.0	1.6-2.4									
Splenic flexure	12.8	0.7	0.5-0.9	8.2	1.0	0.7-1.4	4.6	0.4	0.3-0.6									
Descending colon	28.4	1.5	1.3-1.8	16.2	2.0	1.6-2.5	12.2	1.1	0.9-1.5									
Sigmoid colon	115.4	6.1	5.6-6.6	65.8	7.9	7.0-8.8	49.6	4.8	4.2-5.5									
Large intestine, NOS	28.8	1.5	1.2-1.7	13.0	1.6	1.2-2.0	15.8	1.4	1.1-1.7									
Rectum & rectosigmoid	198.4	10.5	9.8-11.2	114.0	13.4	12.3-14.5	84.4	8.1	7.3-9.0	55.8	2.9	2.6-3.3	30.6	3.7	3.2-4.4	25.2	2.2	1.8-2.6
Rectosigmoid junction	52.0	2.7	2.4-3.1	29.8	3.5	3.0-4.1	22.2	2.1	1.7-2.6									
Rectum	146.4	7.7	7.2-8.3	84.2	9.9	8.9-10.9	62.2	6.0	5.3-6.7									
Anus, anal canal & anorectum	64.6	3.4	3.0-3.8	32.0	3.8	3.2-4.5	32.6	3.0	2.5-3.5	9.2	0.5	0.4-0.7	5.4	0.7	0.4-1.0	3.8	0.3	0.2-0.5
Liver and intrahepatic bile duct	212.2	10.6	10.0-11.3	142.4	16.2	15.0-17.4	69.8	6.0	5.4-6.7	141.0	7.1	6.5-7.6	95.0	11.0	10.0-12.1	46.0	3.9	3.4-4.5

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York (Manhattan)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	173.4	8.6	8.0-9.2	123.8	14.0	12.9-15.1	49.6	4.2	3.7-4.8	103.4	5.1	4.7-5.6	75.4	8.7	7.8-9.6	28.0	2.3	2.0-2.8
Intrahepatic bile duct	38.8	2.0	1.7-2.3	18.6	2.2	1.8-2.7	20.2	1.8	1.5-2.2	37.6	1.9	1.6-2.2	19.6	2.3	1.9-2.9	18.0	1.6	1.3-2.0
Gallbladder	27.4	1.4	1.1-1.6	9.2	1.1	0.8-1.4	18.2	1.6	1.3-2.0	21.0	1.1	0.9-1.3	7.0	0.9	0.6-1.2	14.0	1.2	0.9-1.5
Other biliary	31.2	1.6	1.3-1.8	17.4	2.1	1.7-2.6	13.8	1.2	0.9-1.5	8.8	0.4	0.3-0.6	4.6	0.6	0.3-0.8	4.2	0.3	0.2-0.6
Pancreas	265.8	13.4	12.7-14.2	133.4	15.9	14.7-17.2	132.4	11.5	10.6-12.4	237.8	11.9	11.2-12.6	116.2	13.9	12.8-15.1	121.6	10.3	9.5-11.2
Retroperitoneum	9.0	0.5	0.4-0.7	3.0	0.4	0.2-0.6	6.0	0.6	0.4-0.9	1.2	0.1	0.0-0.2	0.6	0.1	0.0-0.3	0.6	0.1	0.0-0.2
Peritoneum, omentum & mesentery	9.8	0.5	0.4-0.7	0.4	0.0	0.0-0.2	9.4	0.9	0.6-1.2	4.4	0.2	0.1-0.3	1.0	0.1	0.0-0.3	3.4	0.3	0.2-0.5
Other digestive organs	8.2	0.4	0.3-0.6	4.2	0.5	0.3-0.8	4.0	0.3	0.2-0.5	4.8	0.2	0.1-0.4	3.4	0.4	0.2-0.6	1.4	0.1	0.0-0.3
Respiratory system	974.0	49.2	47.8-50.6	455.2	54.0	51.8-56.3	518.8	45.8	44.0-47.6	545.2	27.2	26.1-28.2	270.2	32.3	30.6-34.1	275.0	23.5	22.2-24.8
Nasal cavity, middle ear & sinuses	14.4	0.7	0.6-0.9	7.0	0.8	0.6-1.2	7.4	0.7	0.5-1.0	2.6	0.1	0.1-0.2	1.4	0.2	0.1-0.3	1.2	0.1	0.0-0.2
Larynx	49.2	2.5	2.2-2.8	38.2	4.4	3.8-5.1	11.0	1.0	0.8-1.3	18.4	0.9	0.7-1.1	15.2	1.8	1.4-2.2	3.2	0.3	0.1-0.5
Lung and bronchus	905.2	45.6	44.3-47.0	407.0	48.4	46.3-50.6	498.2	43.8	42.1-45.6	521.6	26.0	25.0-27.0	252.2	30.3	28.6-32.0	269.4	23.0	21.8-24.3
Pleura	0.8	0.0	0.0-0.1	0.4	0.1	0.0-0.2	0.4	0.0	0.0-0.1	1.6	0.1	0.0-0.2	1.2	0.1	0.1-0.3	0.4	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	4.4	0.3	0.2-0.4	2.6	0.3	0.2-0.5	1.8	0.2	0.1-0.5	1.0	0.1	0.0-0.1	0.2	0.0	0.0-0.1	0.8	0.1	0.0-0.2
Bones & joints	17.6	1.1	0.9-1.4	10.2	1.4	1.0-1.8	7.4	0.9	0.6-1.3	9.0	0.5	0.4-0.7	5.2	0.7	0.4-1.0	3.8	0.4	0.2-0.6
Soft tissue (including heart)	68.2	3.8	3.4-4.2	38.4	4.8	4.1-5.6	29.8	3.0	2.5-3.6	31.0	1.6	1.4-1.9	16.6	2.0	1.6-2.5	14.4	1.4	1.1-1.7
Skin*	365.4	18.8	18.0-19.7	211.6	25.3	23.7-26.8	153.8	14.3	13.2-15.3	41.8	2.1	1.8-2.4	27.6	3.3	2.8-3.9	14.2	1.2	1.0-1.6
Melanoma of the skin	338.8	17.4	16.6-18.3	197.2	23.4	22.0-25.0	141.6	13.1	12.1-14.1	28.8	1.5	1.2-1.7	19.2	2.3	1.9-2.8	9.6	0.8	0.6-1.1
Breast	1427.0	77.0	75.2-78.9	16.4	1.9	1.5-2.4	1410.6	141.0	137.6-144.4	218.2	11.2	10.6-11.9	1.8	0.2	0.1-0.4	216.4	19.8	18.6-21.1
Breast (in situ)#	518.2	29.2	28.1-30.4	2.6	0.3	0.2-0.5	515.6	55.0	52.8-57.2									
Female genital system							549.0	52.6	50.6-54.7							185.0	16.6	15.5-17.7
Cervix uteri							66.2	6.9	6.1-7.7							20.6	2.0	1.6-2.4
Corpus uterus and NOS							318.0	29.9	28.4-31.4							73.4	6.4	5.8-7.1
Ovary							115.8	11.4	10.4-12.4							80.4	7.3	6.6-8.1
Vagina							4.2	0.4	0.2-0.6							1.8	0.1	0.1-0.3
Vulva							21.8	2.1	1.7-2.5							4.8	0.4	0.2-0.6
Other female genital organs							23.0	2.0	1.7-2.5							4.0	0.3	0.2-0.5
Male genital system				1143.6	129.4	126.0-132.9							157.6	19.3	18.0-20.8			
Prostate				1073.4	121.7	118.4-125.0							154.2	19.0	17.7-20.4			
Testis				63.4	6.9	6.2-7.8							1.6	0.2	0.1-0.3			
Penis				5.6	0.7	0.4-1.0							1.6	0.2	0.1-0.4			
Other male genital organs				1.2	0.1	0.1-0.3							0.2	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**New York (Manhattan)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	595.0	30.5	29.4-31.6	413.0	49.6	47.4-51.8	182.0	16.5	15.4-17.7	120.4	5.9	5.4-6.4	81.8	10.0	9.0-11.0	38.6	3.1	2.7-3.6
Urinary bladder (including in situ)	346.2	17.4	16.5-18.2	253.2	30.7	29.0-32.4	93.0	8.0	7.3-8.8	73.6	3.5	3.2-3.9	50.4	6.2	5.5-7.0	23.2	1.8	1.5-2.2
Kidney and renal pelvis	233.6	12.3	11.6-13.1	151.0	17.8	16.5-19.1	82.6	7.9	7.2-8.8	45.0	2.3	2.0-2.6	30.4	3.6	3.1-4.3	14.6	1.2	1.0-1.6
Ureter	6.4	0.3	0.2-0.5	3.4	0.4	0.2-0.7	3.0	0.3	0.1-0.5	0.6	0.0	0.0-0.1	0.2	0.0	0.0-0.1	0.4	0.0	0.0-0.1
Other urinary organs	8.8	0.4	0.3-0.6	5.4	0.7	0.4-1.0	3.4	0.3	0.2-0.5	1.2	0.1	0.0-0.1	0.8	0.1	0.0-0.3	0.4	0.0	0.0-0.1
Eye & orbit	16.6	0.9	0.7-1.2	8.4	1.0	0.7-1.4	8.2	0.9	0.6-1.2	2.4	0.2	0.1-0.3	1.0	0.1	0.0-0.3	1.4	0.2	0.1-0.4
Brain / other central nervous system (all behaviors)	381.6	21.0	20.1-22.1	160.2	19.9	18.5-21.4	221.4	22.0	20.6-23.4	75.8	4.1	3.7-4.5	42.4	5.2	4.5-6.0	33.4	3.2	2.7-3.8
Malignant brain / other central nervous system	120.4	7.0	6.4-7.6	71.6	9.1	8.2-10.2	48.8	5.2	4.5-6.0	64.6	3.5	3.1-3.9	36.2	4.4	3.8-5.2	28.4	2.8	2.3-3.3
Malignant brain	112.2	6.5	5.9-7.0	66.2	8.3	7.4-9.3	46.0	4.9	4.3-5.7									
Malignant other central nervous system	8.2	0.5	0.4-0.7	5.4	0.8	0.5-1.2	2.8	0.3	0.2-0.5									
Benign brain / other central nervous system#	261.2	14.1	13.3-14.9	88.6	10.8	9.8-11.9	172.6	16.8	15.6-18.0	11.2	0.6	0.4-0.8	6.2	0.8	0.5-1.1	5.0	0.4	0.3-0.7
Benign brain	20.4	1.3	1.0-1.6	11.0	1.5	1.1-1.9	9.4	1.1	0.8-1.5									
Benign other central nervous system	240.8	12.8	12.1-13.5	77.6	9.3	8.4-10.3	163.2	15.7	14.6-16.8									
Endocrine system	364.4	20.2	19.2-21.2	104.2	12.3	11.2-13.4	260.2	27.5	26.0-29.2	19.4	1.1	0.9-1.3	7.8	1.0	0.7-1.4	11.6	1.2	0.9-1.6
Thyroid	348.4	19.2	18.3-20.2	97.6	11.4	10.4-12.5	250.8	26.5	25.0-28.1	11.6	0.6	0.4-0.8	5.0	0.6	0.4-0.9	6.6	0.6	0.4-0.8
Other endocrine (including thymus)	16.0	1.0	0.8-1.2	6.6	0.9	0.6-1.3	9.4	1.0	0.7-1.4	7.8	0.5	0.4-0.7	2.8	0.4	0.2-0.7	5.0	0.6	0.4-0.9
Lymphomas	484.0	25.6	24.6-26.7	254.4	30.8	29.1-32.6	229.6	21.6	20.3-23.0	124.8	6.3	5.8-6.9	66.8	8.1	7.3-9.1	58.0	5.0	4.5-5.7
Hodgkin lymphoma	54.0	3.0	2.6-3.4	26.4	3.2	2.6-3.8	27.6	2.9	2.4-3.4	6.0	0.3	0.2-0.4	3.2	0.4	0.2-0.6	2.8	0.3	0.1-0.5
Non-Hodgkin lymphomas	430.0	22.6	21.6-23.6	228.0	27.6	26.0-29.3	202.0	18.7	17.6-20.0	118.8	6.0	5.6-6.6	63.6	7.8	6.9-8.7	55.2	4.8	4.2-5.4
Myeloma	155.0	7.9	7.3-8.5	83.6	10.0	9.0-11.0	71.4	6.3	5.6-7.0	65.2	3.3	2.9-3.7	36.2	4.3	3.7-5.0	29.0	2.5	2.1-3.0
Leukemias	280.2	14.9	14.1-15.7	159.6	19.7	18.3-21.1	120.6	11.2	10.3-12.2	150.2	7.9	7.3-8.5	79.4	9.9	8.9-10.9	70.8	6.5	5.8-7.2
Lymphocytic leukemias	152.8	8.2	7.6-8.8	97.0	12.1	11.0-13.2	55.8	5.3	4.6-6.0	37.0	1.9	1.6-2.2	23.6	2.9	2.4-3.5	13.4	1.2	0.9-1.5
Acute lymphocytic leukemia	21.8	1.6	1.3-1.9	12.4	1.9	1.4-2.5	9.4	1.3	0.9-1.7	11.8	0.6	0.5-0.8	7.4	0.9	0.6-1.3	4.4	0.4	0.3-0.7
Chronic lymphocytic leukemia	123.2	6.2	5.7-6.7	78.2	9.4	8.5-10.4	45.0	3.9	3.4-4.4	22.0	1.1	0.9-1.3	14.4	1.8	1.4-2.2	7.6	0.6	0.4-0.9
Other lymphocytic leukemias	7.8	0.4	0.3-0.6	6.4	0.8	0.5-1.1	1.4	0.1	0.0-0.2	3.2	0.2	0.1-0.3	1.8	0.2	0.1-0.4	1.4	0.1	0.0-0.3
Myeloid and monocytic leukemias	114.4	5.9	5.5-6.5	55.4	6.7	5.9-7.6	59.0	5.4	4.8-6.1	93.0	5.0	4.5-5.4	45.2	5.7	4.9-6.5	47.8	4.5	3.9-5.1
Acute myeloid leukemia	77.0	4.0	3.6-4.5	37.0	4.6	3.9-5.3	40.0	3.7	3.2-4.2	81.6	4.4	3.9-4.8	39.6	5.0	4.3-5.8	42.0	3.9	3.4-4.5
Acute monocytic leukemia	2.4	0.1	0.1-0.2	1.0	0.1	0.0-0.3	1.4	0.1	0.1-0.3	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Chronic myeloid leukemia	33.4	1.7	1.4-2.0	16.6	1.9	1.5-2.4	16.8	1.5	1.2-1.9	6.2	0.3	0.2-0.5	3.0	0.4	0.2-0.6	3.2	0.3	0.2-0.5
Other myeloid/monocytic leukemias	1.6	0.1	0.0-0.2	0.8	0.1	0.0-0.3	0.8	0.1	0.0-0.2	5.2	0.3	0.2-0.4	2.6	0.3	0.2-0.5	2.6	0.2	0.1-0.4
Other leukemias	13.0	0.7	0.5-0.9	7.2	0.9	0.6-1.2	5.8	0.6	0.4-0.8	20.2	1.1	0.9-1.3	10.6	1.3	1.0-1.7	9.6	0.8	0.6-1.1
Other acute leukemias	3.4	0.2	0.1-0.3	1.8	0.2	0.1-0.4	1.6	0.2	0.1-0.4	5.8	0.3	0.2-0.4	2.6	0.3	0.2-0.5	3.2	0.3	0.1-0.5

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018  
New York (Manhattan)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	9.6	0.5	0.4-0.7	5.4	0.7	0.4-1.0	4.2	0.4	0.2-0.6	14.4	0.8	0.6-1.0	8.0	1.0	0.7-1.4	6.4	0.6	0.4-0.8
Mesothelioma	9.0	0.4	0.3-0.6	5.6	0.7	0.4-1.0	3.4	0.3	0.2-0.5									
Kaposi sarcoma	30.4	1.6	1.4-1.9	29.2	3.4	2.8-4.0	1.2	0.1	0.0-0.2									
Myelodysplastic syndromes	69.4	3.5	3.2-3.9	35.2	4.4	3.8-5.1	34.2	2.9	2.5-3.4									
Chronic myeloproliferative disorders <sup>^</sup>	83.8	4.4	4.0-4.9	42.6	5.1	4.4-5.9	41.2	3.8	3.3-4.4									
Ill defined and unspecified sites	133.8	6.7	6.2-7.3	67.2	8.1	7.3-9.1	66.6	5.7	5.1-6.4	188.8	9.4	8.8-10.1	94.4	11.4	10.4-12.5	94.4	8.0	7.2-8.7

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

<sup>^</sup> Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.



**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Queens**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	11343.2	421.3	417.8-424.9	5456.4	453.5	448.0-459.0	5886.8	404.7	400.0-409.5	3122.8	114.3	112.5-116.1	1541.2	134.6	131.5-137.7	1581.6	101.2	98.9-103.5
Oral cavity and pharynx	250.6	9.2	8.7-9.8	157.8	12.8	11.9-13.7	92.8	6.3	5.7-6.9	49.8	1.8	1.6-2.1	34.0	2.8	2.4-3.3	15.8	1.0	0.8-1.3
Lip	5.0	0.2	0.1-0.3	3.2	0.3	0.1-0.4	1.8	0.1	0.0-0.2	0.2	0.0	0.0-0.0	0.0	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Tongue	66.8	2.4	2.2-2.7	42.2	3.4	2.9-3.9	24.6	1.6	1.4-2.0	12.4	0.4	0.3-0.6	7.6	0.6	0.4-0.9	4.8	0.3	0.2-0.4
Salivary gland	36.6	1.4	1.2-1.6	19.6	1.6	1.3-2.0	17.0	1.3	1.0-1.6	5.0	0.2	0.1-0.3	3.6	0.3	0.2-0.5	1.4	0.1	0.0-0.2
Floor of mouth	9.0	0.3	0.2-0.4	5.8	0.4	0.3-0.6	3.2	0.2	0.1-0.4	0.4	0.0	0.0-0.1	0.4	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Gum & other mouth	44.2	1.6	1.4-1.9	21.4	1.8	1.5-2.2	22.8	1.5	1.2-1.8	5.4	0.2	0.1-0.3	4.2	0.3	0.2-0.5	1.2	0.1	0.0-0.2
Nasopharynx	34.8	1.3	1.1-1.6	24.6	2.0	1.7-2.4	10.2	0.7	0.5-1.0	8.4	0.3	0.2-0.4	5.4	0.4	0.3-0.6	3.0	0.2	0.1-0.3
Tonsil	26.8	1.0	0.8-1.1	21.8	1.7	1.4-2.0	5.0	0.3	0.2-0.5	2.2	0.1	0.0-0.1	1.8	0.1	0.1-0.3	0.4	0.0	0.0-0.1
Oropharynx	11.2	0.4	0.3-0.5	7.4	0.6	0.4-0.8	3.8	0.3	0.2-0.4	7.8	0.3	0.2-0.4	5.4	0.4	0.3-0.6	2.4	0.1	0.1-0.3
Hypopharynx	13.0	0.5	0.4-0.6	9.8	0.8	0.6-1.0	3.2	0.2	0.1-0.4	2.2	0.1	0.0-0.1	1.8	0.1	0.1-0.3	0.4	0.0	0.0-0.1
Other buccal cavity and pharynx	3.2	0.1	0.1-0.2	2.0	0.2	0.1-0.3	1.2	0.1	0.0-0.2	5.8	0.2	0.1-0.3	3.8	0.3	0.2-0.5	2.0	0.1	0.1-0.2
Digestive system	2356.0	86.7	85.2-88.4	1280.4	106.7	104.0-109.4	1075.6	71.1	69.2-73.1	976.4	35.5	34.5-36.5	528.6	45.2	43.4-47.0	447.8	28.2	27.1-29.5
Esophagus	93.4	3.3	3.0-3.6	70.2	5.7	5.1-6.4	23.2	1.4	1.2-1.7	61.8	2.2	2.0-2.5	45.6	3.8	3.3-4.4	16.2	1.0	0.8-1.2
Stomach	331.6	12.3	11.7-12.9	193.2	16.2	15.2-17.3	138.4	9.2	8.5-10.0	129.4	4.8	4.4-5.2	78.0	6.8	6.1-7.5	51.4	3.3	2.9-3.7
Small intestine	63.0	2.4	2.1-2.7	34.4	2.9	2.5-3.4	28.6	2.0	1.7-2.4	7.2	0.3	0.2-0.4	3.4	0.3	0.2-0.4	3.8	0.2	0.1-0.4
Colorectal	1031.0	38.3	37.3-39.4	535.8	44.9	43.1-46.6	495.2	33.2	31.9-34.6	311.0	11.3	10.8-11.9	155.0	13.5	12.5-14.5	156.0	9.8	9.1-10.6
Colon excluding rectum	723.4	26.9	26.0-27.8	365.2	30.9	29.5-32.4	358.2	23.8	22.7-25.0	262.0	9.5	9.0-10.1	129.4	11.3	10.4-12.2	132.6	8.3	7.7-9.0
Cecum	134.6	4.9	4.6-5.3	60.2	5.2	4.6-5.8	74.4	4.7	4.3-5.3									
Appendix	33.2	1.3	1.1-1.6	13.6	1.1	0.9-1.5	19.6	1.5	1.2-1.8									
Ascending colon	136.8	5.1	4.7-5.5	65.0	5.6	5.0-6.3	71.8	4.6	4.2-5.1									
Hepatic flexure	30.2	1.1	0.9-1.3	17.8	1.5	1.2-1.8	12.4	0.8	0.6-1.0									
Transverse colon	59.0	2.2	2.0-2.5	28.6	2.5	2.1-3.0	30.4	2.0	1.7-2.3									
Splenic flexure	21.6	0.8	0.7-1.0	12.8	1.1	0.8-1.4	8.8	0.6	0.4-0.8									
Descending colon	57.6	2.2	1.9-2.4	32.2	2.7	2.3-3.2	25.4	1.7	1.5-2.1									
Sigmoid colon	203.4	7.5	7.1-8.0	110.0	9.0	8.2-9.8	93.4	6.4	5.8-7.1									
Large intestine, NOS	47.0	1.7	1.5-2.0	25.0	2.2	1.8-2.6	22.0	1.4	1.2-1.7									
Rectum & rectosigmoid	307.6	11.4	10.9-12.0	170.6	14.0	13.0-15.0	137.0	9.4	8.7-10.1	49.0	1.8	1.6-2.1	25.6	2.2	1.8-2.6	23.4	1.5	1.3-1.8
Rectosigmoid junction	81.0	3.0	2.7-3.3	43.4	3.6	3.1-4.1	37.6	2.6	2.2-3.0									
Rectum	226.6	8.4	7.9-8.9	127.2	10.4	9.6-11.3	99.4	6.8	6.2-7.5									
Anus, anal canal & anorectum	42.0	1.5	1.3-1.7	17.0	1.4	1.1-1.7	25.0	1.6	1.3-1.9	3.8	0.1	0.1-0.2	2.0	0.2	0.1-0.3	1.8	0.1	0.1-0.2
Liver and intrahepatic bile duct	282.6	10.1	9.6-10.7	199.2	15.8	14.8-16.9	83.4	5.5	4.9-6.0	164.4	5.9	5.5-6.3	106.2	8.7	7.9-9.5	58.2	3.8	3.3-4.2

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Queens**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	233.8	8.3	7.9-8.8	172.8	13.7	12.7-14.6	61.0	4.0	3.5-4.5	113.0	4.0	3.7-4.4	83.2	6.7	6.1-7.4	29.8	1.9	1.6-2.2
Intrahepatic bile duct	48.8	1.8	1.6-2.0	26.4	2.2	1.8-2.6	22.4	1.5	1.2-1.8	51.4	1.9	1.7-2.1	23.0	1.9	1.6-2.3	28.4	1.9	1.6-2.2
Gallbladder	58.0	2.1	1.9-2.4	15.6	1.3	1.1-1.7	42.4	2.8	2.4-3.2	30.8	1.1	1.0-1.3	11.6	1.0	0.7-1.3	19.2	1.2	1.0-1.5
Other biliary	66.0	2.5	2.2-2.8	34.8	3.0	2.6-3.5	31.2	2.1	1.8-2.4	10.8	0.4	0.3-0.5	6.0	0.5	0.3-0.7	4.8	0.3	0.2-0.4
Pancreas	353.0	12.9	12.3-13.5	166.0	14.2	13.2-15.2	187.0	11.9	11.1-12.7	246.0	9.0	8.5-9.5	116.0	10.0	9.2-10.9	130.0	8.1	7.5-8.8
Retroperitoneum	10.4	0.4	0.3-0.5	5.8	0.5	0.3-0.7	4.6	0.3	0.2-0.5	1.8	0.1	0.0-0.1	1.4	0.1	0.1-0.3	0.4	0.0	0.0-0.1
Peritoneum, omentum & mesentery	8.2	0.3	0.2-0.4	0.0	0.0	0.0-0.1	8.2	0.5	0.4-0.7	5.6	0.2	0.1-0.3	1.4	0.1	0.0-0.2	4.2	0.2	0.2-0.4
Other digestive organs	16.8	0.6	0.5-0.8	8.4	0.7	0.5-1.0	8.4	0.6	0.4-0.8	3.8	0.1	0.1-0.2	2.0	0.2	0.1-0.4	1.8	0.1	0.1-0.2
Respiratory system	1266.0	46.3	45.1-47.4	679.4	57.6	55.6-59.6	586.6	38.0	36.6-39.4	623.4	22.6	21.8-23.4	344.6	29.7	28.3-31.2	278.8	17.6	16.6-18.5
Nasal cavity, middle ear & sinuses	14.2	0.5	0.4-0.7	6.4	0.5	0.4-0.8	7.8	0.6	0.4-0.8	1.8	0.1	0.0-0.1	0.6	0.1	0.0-0.2	1.2	0.1	0.0-0.2
Larynx	65.0	2.4	2.1-2.6	53.8	4.5	3.9-5.0	11.2	0.7	0.5-0.9	18.0	0.6	0.5-0.8	14.0	1.2	0.9-1.5	4.0	0.2	0.1-0.4
Lung and bronchus	1182.2	43.2	42.1-44.3	616.0	52.4	50.5-54.3	566.2	36.6	35.3-38.0	600.4	21.8	21.0-22.6	328.6	28.4	27.0-29.8	271.8	17.1	16.2-18.1
Pleura	0.0	0.0	0.0-0.0	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	1.6	0.1	0.0-0.1	1.0	0.1	0.0-0.2	0.6	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	4.6	0.2	0.1-0.3	3.2	0.2	0.1-0.4	1.4	0.1	0.0-0.2	1.6	0.1	0.0-0.1	0.4	0.0	0.0-0.1	1.2	0.1	0.0-0.2
Bones & joints	23.6	1.0	0.8-1.2	13.4	1.2	1.0-1.6	10.2	0.8	0.6-1.1	6.4	0.3	0.2-0.4	3.8	0.3	0.2-0.5	2.6	0.2	0.1-0.3
Soft tissue (including heart)	94.6	3.6	3.3-4.0	52.2	4.4	3.9-5.0	42.4	3.1	2.7-3.5	26.4	1.0	0.8-1.2	14.2	1.2	0.9-1.5	12.2	0.9	0.7-1.2
Skin*	235.6	8.9	8.4-9.4	128.4	11.2	10.3-12.1	107.2	7.3	6.7-8.0	40.4	1.5	1.3-1.7	24.6	2.2	1.8-2.6	15.8	1.0	0.8-1.3
Melanoma of the skin	203.6	7.7	7.2-8.2	111.2	9.7	8.9-10.6	92.4	6.3	5.7-6.9	26.2	1.0	0.8-1.2	14.6	1.3	1.0-1.6	11.6	0.7	0.6-1.0
Breast	1751.6	66.2	64.8-67.6	15.0	1.3	1.0-1.6	1736.6	121.9	119.3-124.6	251.8	9.2	8.7-9.8	2.6	0.2	0.1-0.4	249.2	16.3	15.3-17.2
Breast (in situ)#	589.2	22.6	21.8-23.5	2.4	0.2	0.1-0.4	586.8	42.4	40.8-44.0									
Female genital system							793.4	54.5	52.8-56.3							212.2	13.9	13.1-14.8
Cervix uteri							125.0	9.4	8.7-10.2							33.8	2.3	2.0-2.7
Corpus uteri and NOS							441.2	29.3	28.1-30.6							88.8	5.7	5.2-6.3
Ovary							164.2	11.6	10.8-12.5							80.2	5.3	4.8-5.8
Vagina							8.6	0.6	0.4-0.8							2.8	0.2	0.1-0.3
Vulva							28.8	1.9	1.6-2.2							4.4	0.3	0.2-0.4
Other female genital organs							25.6	1.7	1.4-2.0							2.2	0.1	0.1-0.3
Male genital system				1512.2	119.7	116.9-122.5							169.2	15.7	14.7-16.8			
Prostate				1451.6	114.6	111.9-117.3							165.4	15.4	14.3-16.5			
Testis				47.6	4.0	3.5-4.6							1.2	0.1	0.0-0.2			
Penis				10.4	0.9	0.7-1.2							2.4	0.2	0.1-0.4			
Other male genital organs				2.6	0.2	0.1-0.4							0.2	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Queens**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	826.4	30.5	29.5-31.4	572.4	48.8	47.0-50.7	254.0	16.7	15.8-17.7	148.4	5.5	5.1-5.9	98.2	9.0	8.2-9.8	50.2	3.1	2.7-3.5
Urinary bladder (including in situ)	443.4	16.3	15.6-17.0	327.8	28.7	27.3-30.2	115.6	7.4	6.8-8.0	81.4	3.0	2.7-3.3	56.0	5.2	4.6-5.9	25.4	1.6	1.3-1.9
Kidney and renal pelvis	365.0	13.5	12.9-14.2	234.4	19.1	18.0-20.3	130.6	8.9	8.2-9.6	61.8	2.3	2.0-2.5	39.6	3.4	3.0-4.0	22.2	1.4	1.1-1.7
Ureter	10.8	0.4	0.3-0.5	5.6	0.5	0.3-0.7	5.2	0.3	0.2-0.5	2.8	0.1	0.1-0.2	1.4	0.1	0.1-0.3	1.4	0.1	0.0-0.2
Other urinary organs	7.2	0.3	0.2-0.4	4.6	0.4	0.3-0.6	2.6	0.2	0.1-0.3	2.4	0.1	0.0-0.2	1.2	0.1	0.0-0.3	1.2	0.1	0.0-0.2
Eye & orbit	20.6	0.8	0.6-1.0	12.4	1.1	0.8-1.4	8.2	0.6	0.4-0.8	1.0	0.0	0.0-0.1	0.4	0.0	0.0-0.1	0.6	0.0	0.0-0.1
Brain / other central nervous system (all behaviors)	487.4	18.8	18.1-19.6	185.8	16.0	14.9-17.1	301.6	21.2	20.1-22.3	86.2	3.3	3.0-3.7	43.4	3.8	3.3-4.3	42.8	3.0	2.6-3.4
Malignant brain / other central nervous system	131.8	5.3	4.9-5.7	73.8	6.3	5.7-7.0	58.0	4.3	3.8-4.8	73.6	2.8	2.6-3.2	37.6	3.3	2.8-3.8	36.0	2.5	2.1-2.9
Malignant brain	125.6	5.0	4.6-5.4	71.0	6.1	5.4-6.7	54.6	4.0	3.5-4.6									
Malignant other central nervous system	6.2	0.3	0.2-0.4	2.8	0.3	0.1-0.5	3.4	0.3	0.1-0.4									
Benign brain / other central nervous system#	355.6	13.6	12.9-14.2	112.0	9.6	8.8-10.5	243.6	16.9	15.9-17.9	12.6	0.5	0.4-0.6	5.8	0.5	0.3-0.7	6.8	0.5	0.3-0.7
Benign brain	28.8	1.2	1.0-1.4	13.2	1.2	0.9-1.5	15.6	1.2	0.9-1.5									
Benign other central nervous system	326.8	12.4	11.8-13.0	98.8	8.5	7.7-9.3	228.0	15.7	14.8-16.7									
Endocrine system	542.4	21.8	21.0-22.6	134.2	11.1	10.3-12.0	408.2	31.9	30.5-33.3	18.8	0.7	0.6-0.9	6.8	0.6	0.4-0.8	12.0	0.8	0.6-1.1
Thyroid	507.2	20.4	19.6-21.2	116.4	9.7	8.9-10.5	390.8	30.6	29.2-32.0	13.0	0.5	0.4-0.6	4.2	0.3	0.2-0.5	8.8	0.6	0.4-0.8
Other endocrine (including thymus)	35.2	1.4	1.2-1.6	17.8	1.5	1.2-1.8	17.4	1.3	1.0-1.6	5.8	0.2	0.2-0.3	2.6	0.2	0.1-0.4	3.2	0.3	0.1-0.4
Lymphomas	542.6	20.7	20.0-21.6	292.8	25.1	23.8-26.4	249.8	17.4	16.4-18.4	121.8	4.5	4.1-4.9	71.2	6.2	5.6-6.9	50.6	3.2	2.8-3.6
Hodgkin lymphoma	64.2	2.7	2.4-3.0	38.2	3.3	2.9-3.8	26.0	2.2	1.8-2.6	6.6	0.3	0.2-0.4	3.8	0.3	0.2-0.5	2.8	0.2	0.1-0.3
Non-Hodgkin lymphomas	478.4	18.0	17.3-18.8	254.6	21.7	20.5-23.0	223.8	15.2	14.3-16.2	115.2	4.2	3.9-4.6	67.4	5.9	5.3-6.6	47.8	3.0	2.6-3.4
Myeloma	213.8	7.9	7.4-8.4	106.8	8.9	8.1-9.7	107.0	7.1	6.5-7.7	72.6	2.6	2.4-2.9	35.0	3.0	2.6-3.5	37.6	2.4	2.0-2.8
Leukemias	353.0	13.6	13.0-14.3	195.4	17.1	16.0-18.2	157.6	11.0	10.2-11.8	119.6	4.5	4.1-4.9	66.4	6.0	5.3-6.7	53.2	3.5	3.0-3.9
Lymphocytic leukemias	162.6	6.3	5.9-6.8	93.2	8.1	7.4-8.9	69.4	4.9	4.3-5.4	31.0	1.2	1.0-1.4	17.0	1.5	1.2-1.9	14.0	0.9	0.7-1.2
Acute lymphocytic leukemia	41.4	1.9	1.6-2.2	24.0	2.3	1.9-2.7	17.4	1.5	1.2-1.9	9.4	0.4	0.3-0.5	5.4	0.5	0.3-0.7	4.0	0.3	0.2-0.5
Chronic lymphocytic leukemia	112.8	4.1	3.8-4.5	63.0	5.3	4.8-6.0	49.8	3.2	2.8-3.6	20.6	0.7	0.6-0.9	11.2	1.0	0.8-1.3	9.4	0.6	0.4-0.8
Other lymphocytic leukemias	8.4	0.3	0.2-0.4	6.2	0.5	0.3-0.7	2.2	0.1	0.1-0.3	1.0	0.0	0.0-0.1	0.4	0.0	0.0-0.1	0.6	0.0	0.0-0.1
Myeloid and monocytic leukemias	169.8	6.5	6.1-7.0	90.6	7.9	7.2-8.7	79.2	5.5	4.9-6.1	65.8	2.5	2.2-2.8	36.4	3.3	2.8-3.8	29.4	1.9	1.6-2.3
Acute myeloid leukemia	110.4	4.2	3.9-4.6	58.2	5.1	4.5-5.7	52.2	3.6	3.2-4.1	57.4	2.2	1.9-2.4	31.6	2.8	2.4-3.3	25.8	1.7	1.4-2.0
Acute monocytic leukemia	4.6	0.2	0.1-0.3	2.2	0.2	0.1-0.4	2.4	0.2	0.1-0.3	0.4	0.0	0.0-0.1	0.4	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Chronic myeloid leukemia	50.0	1.9	1.7-2.2	27.2	2.4	2.0-2.8	22.8	1.5	1.3-1.9	4.8	0.2	0.1-0.3	2.6	0.2	0.1-0.4	2.2	0.1	0.1-0.3
Other myeloid/monocytic leukemias	4.8	0.2	0.1-0.3	3.0	0.3	0.2-0.5	1.8	0.1	0.1-0.3	3.2	0.1	0.1-0.2	1.8	0.2	0.1-0.3	1.4	0.1	0.0-0.2
Other leukemias	20.6	0.8	0.6-1.0	11.6	1.0	0.8-1.3	9.0	0.6	0.5-0.9	22.8	0.8	0.7-1.0	13.0	1.2	0.9-1.5	9.8	0.6	0.4-0.8
Other acute leukemias	6.6	0.3	0.2-0.4	4.4	0.4	0.2-0.6	2.2	0.2	0.1-0.3	6.2	0.2	0.2-0.3	4.0	0.3	0.2-0.5	2.2	0.1	0.1-0.2

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Queens**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	14.0	0.5	0.4-0.7	7.2	0.6	0.5-0.9	6.8	0.5	0.3-0.7	16.6	0.6	0.5-0.8	9.0	0.8	0.6-1.1	7.6	0.5	0.3-0.7
Mesothelioma	13.8	0.5	0.4-0.7	9.2	0.8	0.6-1.1	4.6	0.3	0.2-0.5									
Kaposi sarcoma	25.6	1.0	0.8-1.2	22.6	2.0	1.6-2.4	3.0	0.2	0.1-0.3									
Myelodysplastic syndromes	106.6	4.0	3.7-4.4	62.8	5.9	5.3-6.6	43.8	2.7	2.3-3.1									
Chronic myeloproliferative disorders <sup>^</sup>	87.0	3.3	3.0-3.6	42.4	3.5	3.0-4.0	44.6	3.1	2.7-3.5									
All defined and unspecified sites	196.0	7.2	6.7-7.7	92.8	8.1	7.4-8.9	103.2	6.5	6.0-7.1	211.0	7.7	7.3-8.2	104.0	9.1	8.3-10.0	107.0	6.7	6.1-7.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

<sup>^</sup> Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**Richmond (Staten Island)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	2999.2	526.2	517.6-535.0	1463.0	565.0	551.7-578.5	1536.2	501.8	490.3-513.6	834.2	145.0	140.5-149.6	415.2	170.8	163.3-178.6	419.0	127.5	122.0-133.2
Oral cavity and pharynx	59.6	10.1	8.9-11.3	40.8	15.1	13.0-17.4	18.8	5.8	4.7-7.2	11.2	1.8	1.4-2.4	7.8	2.7	1.9-3.8	3.4	1.0	0.6-1.6
Lip	1.0	0.2	0.1-0.4	0.6	0.2	0.0-0.7	0.4	0.1	0.0-0.5	0.2	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.2	0.1	0.0-0.4
Tongue	18.8	3.2	2.6-3.9	13.4	4.9	3.7-6.2	5.4	1.7	1.1-2.6	1.8	0.3	0.1-0.6	1.2	0.4	0.1-0.9	0.6	0.2	0.0-0.6
Salivary gland	7.8	1.4	1.0-2.0	4.4	1.8	1.1-2.8	3.4	1.2	0.7-1.9	1.0	0.2	0.1-0.4	0.8	0.3	0.1-0.9	0.2	0.1	0.0-0.4
Floor of mouth	1.4	0.2	0.1-0.5	1.2	0.4	0.1-1.0	0.2	0.0	0.0-0.4	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Gum & other mouth	10.8	1.8	1.4-2.4	5.8	2.3	1.5-3.3	5.0	1.5	0.9-2.2	2.2	0.3	0.2-0.6	1.6	0.6	0.2-1.2	0.6	0.2	0.0-0.5
Nasopharynx	3.2	0.5	0.3-0.9	2.2	0.8	0.4-1.5	1.0	0.3	0.1-0.7	2.2	0.4	0.2-0.7	1.2	0.4	0.1-0.9	1.0	0.3	0.1-0.7
Tonsil	9.8	1.6	1.2-2.2	8.0	2.9	2.0-4.0	1.8	0.5	0.2-1.1	0.6	0.1	0.0-0.3	0.6	0.2	0.0-0.6	0.0	0.0	0.0-0.3
Oropharynx	3.0	0.5	0.3-0.8	2.0	0.7	0.3-1.3	1.0	0.3	0.1-0.8	0.6	0.1	0.0-0.3	0.2	0.1	0.0-0.4	0.4	0.1	0.0-0.5
Hypopharynx	2.2	0.4	0.2-0.7	2.0	0.8	0.4-1.5	0.2	0.1	0.0-0.4	0.4	0.1	0.0-0.3	0.2	0.1	0.0-0.4	0.2	0.1	0.0-0.4
Other buccal cavity and pharynx	1.6	0.2	0.1-0.5	1.2	0.4	0.1-0.9	0.4	0.1	0.0-0.5	2.2	0.4	0.2-0.7	2.0	0.8	0.4-1.4	0.2	0.1	0.0-0.4
Digestive system	513.6	88.9	85.5-92.5	286.4	110.4	104.6-116.5	227.2	70.9	66.7-75.3	243.8	41.6	39.3-44.1	132.2	51.9	47.9-56.1	111.6	33.6	30.8-36.6
Esophagus	25.8	4.3	3.6-5.1	19.4	7.1	5.7-8.8	6.4	2.0	1.4-2.9	20.4	3.5	2.8-4.2	15.4	5.7	4.5-7.3	5.0	1.6	1.0-2.4
Stomach	50.8	8.8	7.7-10.0	30.8	12.2	10.2-14.3	20.0	6.2	5.0-7.6	22.6	3.8	3.2-4.6	11.6	4.7	3.6-6.2	11.0	3.2	2.4-4.3
Small intestine	14.2	2.6	2.0-3.3	6.8	2.7	1.9-3.9	7.4	2.4	1.7-3.4	1.8	0.3	0.1-0.6	1.0	0.3	0.1-0.8	0.8	0.2	0.1-0.7
Colorectal	230.6	40.5	38.2-43.0	122.0	48.1	44.2-52.2	108.6	34.0	31.1-37.1	85.8	14.9	13.5-16.4	43.6	18.2	15.8-20.8	42.2	12.4	10.8-14.3
Colon excluding rectum	165.6	29.1	27.2-31.2	83.6	33.4	30.1-36.8	82.0	25.5	23.0-28.2	70.0	12.2	10.9-13.6	34.2	14.3	12.2-16.7	35.8	10.6	9.1-12.4
Cecum	27.6	4.9	4.1-5.9	10.2	4.1	3.1-5.5	17.4	5.4	4.3-6.7									
Appendix	7.6	1.5	1.0-2.0	4.0	1.7	1.0-2.7	3.6	1.3	0.7-2.0									
Ascending colon	35.8	6.3	5.4-7.3	20.4	8.4	6.8-10.2	15.4	4.7	3.7-5.9									
Hepatic flexure	6.4	1.2	0.8-1.7	3.2	1.3	0.7-2.2	3.2	1.1	0.6-1.8									
Transverse colon	15.0	2.6	2.0-3.2	7.6	3.1	2.1-4.2	7.4	2.2	1.5-3.1									
Splenic flexure	3.6	0.7	0.4-1.1	1.8	0.8	0.4-1.5	1.8	0.6	0.3-1.3									
Descending colon	11.8	2.1	1.6-2.7	6.2	2.4	1.6-3.5	5.6	1.8	1.2-2.6									
Sigmoid colon	46.6	8.0	7.0-9.1	26.2	10.0	8.3-11.9	20.4	6.4	5.2-7.8									
Large intestine, NOS	11.2	1.9	1.4-2.5	4.0	1.5	0.9-2.4	7.2	2.1	1.5-3.0									
Rectum & rectosigmoid	65.0	11.4	10.1-12.7	38.4	14.7	12.7-17.1	26.6	8.5	7.1-10.1	15.8	2.7	2.1-3.4	9.4	3.9	2.8-5.2	6.4	1.8	1.2-2.6
Rectosigmoid junction	19.6	3.6	2.9-4.4	9.2	3.6	2.6-4.9	10.4	3.5	2.6-4.6									
Rectum	45.4	7.8	6.8-8.9	29.2	11.1	9.3-13.1	16.2	5.0	4.0-6.3									
Anus, anal canal & anorectum	10.8	1.8	1.3-2.4	5.4	2.1	1.3-3.0	5.4	1.6	1.0-2.4	0.6	0.1	0.0-0.3	0.2	0.1	0.0-0.4	0.4	0.1	0.0-0.5
Liver and intrahepatic bile duct	65.4	10.9	9.7-12.2	46.8	17.0	14.8-19.4	18.6	5.7	4.6-7.1	41.2	6.9	5.9-7.9	27.6	10.0	8.3-11.9	13.6	4.2	3.2-5.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**Richmond (Staten Island)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	52.4	8.7	7.7-9.9	40.4	14.7	12.7-17.0	12.0	3.8	2.9-4.9	31.8	5.3	4.5-6.2	23.0	8.3	6.8-10.0	8.8	2.7	2.0-3.7
Intrahepatic bile duct	13.0	2.1	1.6-2.8	6.4	2.3	1.6-3.3	6.6	2.0	1.3-2.8	9.4	1.6	1.2-2.1	4.6	1.7	1.1-2.6	4.8	1.4	0.9-2.2
Gallbladder	8.2	1.5	1.0-2.0	2.2	0.9	0.4-1.6	6.0	1.9	1.3-2.8	4.6	0.8	0.5-1.3	2.0	0.8	0.4-1.5	2.6	0.9	0.5-1.5
Other biliary	9.2	1.7	1.2-2.2	4.2	1.6	1.0-2.5	5.0	1.7	1.1-2.5	1.2	0.2	0.1-0.4	0.4	0.2	0.0-0.6	0.8	0.2	0.1-0.7
Pancreas	89.8	15.3	13.9-16.9	45.0	17.2	15.0-19.7	44.8	13.7	11.9-15.6	64.2	10.9	9.7-12.2	30.0	11.7	9.8-13.8	34.2	10.4	8.8-12.1
Retroperitoneum	4.6	0.9	0.5-1.3	2.6	1.0	0.5-1.8	2.0	0.7	0.3-1.4	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Peritoneum, omentum & mesentery	1.6	0.3	0.1-0.6	0.0	0.0	0.0-0.3	1.6	0.6	0.2-1.1	0.8	0.2	0.0-0.4	0.2	0.1	0.0-0.5	0.6	0.2	0.0-0.6
Other digestive organs	2.6	0.4	0.2-0.8	1.2	0.5	0.2-1.1	1.4	0.4	0.2-0.9	0.6	0.1	0.0-0.3	0.2	0.1	0.0-0.5	0.4	0.1	0.0-0.5
Respiratory system	409.6	70.5	67.4-73.7	203.0	80.0	75.0-85.3	206.6	63.9	60.0-68.0	209.4	36.5	34.2-38.8	106.6	43.5	39.8-47.5	102.8	31.4	28.7-34.3
Nasal cavity, middle ear & sinuses	5.8	1.0	0.7-1.5	2.8	1.1	0.6-1.8	3.0	1.0	0.5-1.7	0.4	0.1	0.0-0.3	0.2	0.1	0.0-0.4	0.2	0.1	0.0-0.5
Larynx	20.8	3.5	2.8-4.2	16.4	6.3	5.0-7.9	4.4	1.4	0.9-2.1	4.4	0.7	0.5-1.1	3.2	1.3	0.7-2.1	1.2	0.3	0.1-0.8
Lung and bronchus	382.6	65.9	63.0-69.0	183.4	72.5	67.7-77.5	199.2	61.5	57.7-65.6	204.2	35.6	33.4-37.9	103.2	42.2	38.5-46.1	101.0	30.8	28.1-33.7
Pleura	0.2	0.0	0.0-0.2	0.2	0.1	0.0-0.5	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Trachea, mediastinum, other respiratory	0.2	0.0	0.0-0.2	0.2	0.1	0.0-0.5	0.0	0.0	0.0-0.3	0.4	0.1	0.0-0.3	0.0	0.0	0.0-0.3	0.4	0.2	0.0-0.6
Bones & joints	6.2	1.2	0.8-1.8	3.2	1.4	0.8-2.3	3.0	1.1	0.6-1.9	2.2	0.5	0.2-0.8	1.4	0.7	0.3-1.4	0.8	0.3	0.1-0.7
Soft tissue (including heart)	20.4	3.8	3.1-4.7	10.2	4.2	3.1-5.6	10.2	3.6	2.7-4.8	6.8	1.2	0.8-1.7	3.8	1.6	0.9-2.5	3.0	1.0	0.5-1.7
Skin*	101.0	18.0	16.4-19.7	56.6	22.4	19.8-25.3	44.4	14.8	12.9-17.0	13.4	2.3	1.8-3.0	8.4	3.7	2.6-5.0	5.0	1.5	1.0-2.3
Melanoma of the skin	88.4	15.6	14.2-17.2	49.4	19.4	17.0-22.1	39.0	12.9	11.1-15.0	9.8	1.7	1.3-2.3	5.8	2.6	1.7-3.7	4.0	1.2	0.7-1.9
Breast	410.6	73.1	69.9-76.4	2.8	1.0	0.6-1.8	407.8	134.4	128.4-140.5	57.8	9.8	8.7-11.0	1.0	0.5	0.1-1.1	56.8	16.8	14.8-18.9
Breast (in situ)#	132.8	24.3	22.4-26.3	0.4	0.2	0.0-0.7	132.4	45.6	42.1-49.4									
Female genital system							193.6	62.1	58.1-66.3							50.4	15.3	13.5-17.4
Cervix uteri							22.4	8.2	6.7-10.0							6.8	2.2	1.5-3.1
Corpus uteri and NOS							115.8	35.9	32.9-39.0							20.6	6.3	5.1-7.6
Ovary							41.6	13.6	11.8-15.7							20.0	6.0	4.8-7.3
Vagina							3.2	1.1	0.6-1.8							0.4	0.1	0.0-0.5
Vulva							6.6	2.0	1.3-2.8							2.0	0.6	0.3-1.1
Other female genital organs							4.0	1.3	0.8-2.1							0.6	0.2	0.0-0.6
Male genital system				345.2	124.9	118.9-131.1							38.4	17.6	15.1-20.3			
Prostate				328.8	117.6	111.8-123.6							37.0	17.0	14.6-19.6			
Testis				13.2	6.0	4.6-7.6							0.6	0.3	0.1-0.8			
Penis				2.4	1.0	0.5-1.7							0.4	0.1	0.0-0.6			
Other male genital organs				0.8	0.3	0.1-0.9							0.4	0.2	0.0-0.7			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**Richmond (Staten Island)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	278.4	48.2	45.7-50.9	200.2	78.4	73.5-83.6	78.2	24.6	22.1-27.2	52.0	9.3	8.2-10.5	35.8	15.5	13.3-18.0	16.2	5.0	3.9-6.3
Urinary bladder (including in situ)	147.8	25.6	23.7-27.5	113.8	45.7	42.0-49.8	34.0	10.3	8.7-12.0	29.6	5.3	4.5-6.3	20.8	9.5	7.7-11.5	8.8	2.6	1.9-3.6
Kidney and renal pelvis	123.0	21.4	19.7-23.2	81.4	30.7	27.7-33.9	41.6	13.5	11.7-15.5	20.8	3.7	3.0-4.5	13.8	5.6	4.3-7.1	7.0	2.2	1.5-3.1
Ureter	5.2	0.9	0.6-1.3	3.4	1.4	0.8-2.2	1.8	0.5	0.2-1.1	1.0	0.2	0.1-0.4	0.8	0.3	0.1-0.9	0.2	0.1	0.0-0.4
Other urinary organs	2.4	0.4	0.2-0.8	1.6	0.6	0.3-1.3	0.8	0.3	0.1-0.8	0.6	0.1	0.0-0.3	0.4	0.1	0.0-0.5	0.2	0.1	0.0-0.4
Eye & orbit	4.4	0.8	0.5-1.2	1.4	0.6	0.2-1.2	3.0	1.0	0.5-1.7	0.6	0.1	0.0-0.3	0.0	0.0	0.0-0.3	0.6	0.2	0.0-0.6
Brain / other central nervous system (all behaviors)	118.2	21.6	19.8-23.5	48.4	19.2	16.8-21.9	69.8	23.3	20.8-26.0	24.8	4.4	3.7-5.3	14.0	5.5	4.2-6.9	10.8	3.4	2.6-4.5
Malignant brain / other central nervous system	38.2	7.0	6.0-8.1	20.0	7.9	6.4-9.7	18.2	6.2	4.9-7.6	22.6	4.0	3.3-4.8	13.2	5.1	3.9-6.6	9.4	3.0	2.2-4.0
Malignant brain	36.0	6.6	5.6-7.7	19.2	7.6	6.1-9.4	16.8	5.6	4.5-7.1									
Malignant other central nervous system	2.2	0.4	0.2-0.7	0.8	0.3	0.1-0.8	1.4	0.5	0.2-1.1									
Benign brain / other central nervous system#	80.0	14.6	13.2-16.1	28.4	11.3	9.5-13.4	51.6	17.1	15.0-19.4	2.2	0.4	0.2-0.8	0.8	0.3	0.1-0.8	1.4	0.4	0.2-1.0
Benign brain	6.8	1.4	1.0-2.0	4.8	2.0	1.3-3.1	2.0	0.8	0.4-1.5									
Benign other central nervous system	73.2	13.2	11.8-14.6	23.6	9.3	7.7-11.2	49.6	16.3	14.3-18.6									
Endocrine system	177.4	34.4	32.1-36.9	49.4	19.4	17.0-22.1	128.0	48.5	44.7-52.6	4.2	0.7	0.5-1.2	1.2	0.5	0.2-1.1	3.0	1.0	0.5-1.6
Thyroid	173.0	33.7	31.4-36.1	46.4	18.3	15.9-20.9	126.6	48.1	44.3-52.1	3.4	0.6	0.3-1.0	1.0	0.4	0.1-0.9	2.4	0.7	0.4-1.3
Other endocrine (including thymus)	4.4	0.8	0.5-1.2	3.0	1.2	0.6-2.0	1.4	0.4	0.2-1.0	0.8	0.2	0.0-0.4	0.2	0.1	0.0-0.5	0.6	0.2	0.0-0.7
Lymphomas	160.0	29.3	27.3-31.5	87.4	35.5	32.2-39.1	72.6	24.2	21.7-26.9	25.0	4.5	3.7-5.3	15.2	6.5	5.1-8.1	9.8	3.0	2.2-4.0
Hodgkin lymphoma	18.4	3.8	3.0-4.7	11.6	4.8	3.6-6.3	6.8	2.8	1.9-4.0	2.4	0.4	0.2-0.7	1.6	0.6	0.3-1.3	0.8	0.2	0.1-0.7
Non-Hodgkin lymphomas	141.6	25.5	23.6-27.5	75.8	30.7	27.6-34.1	65.8	21.3	19.0-23.9	22.6	4.1	3.3-4.9	13.6	5.8	4.5-7.4	9.0	2.7	2.0-3.7
Myeloma	53.2	9.2	8.1-10.4	30.6	12.0	10.1-14.2	22.6	6.9	5.7-8.3	15.2	2.7	2.1-3.4	9.0	3.7	2.6-4.9	6.2	2.0	1.3-2.8
Leukemias	102.0	18.6	17.0-20.4	60.2	24.3	21.6-27.3	41.8	14.3	12.4-16.4	32.0	5.8	4.9-6.8	16.0	7.0	5.5-8.7	16.0	5.1	4.0-6.4
Lymphocytic leukemias	54.6	9.9	8.7-11.2	33.0	13.2	11.2-15.4	21.6	7.3	6.0-8.9	7.8	1.4	1.0-1.9	3.2	1.3	0.8-2.2	4.6	1.4	0.9-2.2
Acute lymphocytic leukemia	7.4	1.7	1.2-2.3	3.6	1.6	1.0-2.6	3.8	1.7	1.0-2.7	1.4	0.3	0.1-0.5	0.4	0.2	0.0-0.6	1.0	0.3	0.1-0.8
Chronic lymphocytic leukemia	43.4	7.5	6.5-8.6	26.0	10.3	8.5-12.2	17.4	5.5	4.4-6.8	6.4	1.1	0.8-1.6	2.8	1.2	0.6-2.0	3.6	1.1	0.7-1.8
Other lymphocytic leukemias	3.8	0.7	0.4-1.1	3.4	1.3	0.7-2.1	0.4	0.1	0.0-0.6	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Myeloid and monocytic leukemias	42.4	7.9	6.8-9.0	24.4	10.1	8.3-12.1	18.0	6.3	5.0-7.8	18.8	3.4	2.8-4.2	10.4	4.6	3.4-6.0	8.4	2.8	2.0-3.8
Acute myeloid leukemia	28.4	5.3	4.4-6.3	14.6	6.1	4.7-7.7	13.8	4.9	3.7-6.2	16.8	3.1	2.5-3.9	9.2	4.0	2.9-5.4	7.6	2.6	1.8-3.6
Acute monocytic leukemia	1.2	0.2	0.1-0.5	0.8	0.3	0.1-0.8	0.4	0.1	0.0-0.6	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Chronic myeloid leukemia	11.6	2.2	1.6-2.8	8.4	3.4	2.4-4.6	3.2	1.1	0.6-1.8	1.4	0.3	0.1-0.6	1.0	0.5	0.2-1.1	0.4	0.1	0.0-0.5
Other myeloid/monocytic leukemias	1.2	0.2	0.1-0.5	0.6	0.3	0.1-0.8	0.6	0.2	0.0-0.6	0.6	0.1	0.0-0.3	0.2	0.1	0.0-0.4	0.4	0.1	0.0-0.5
Other leukemias	5.0	0.9	0.6-1.3	2.8	1.1	0.6-1.8	2.2	0.7	0.3-1.2	5.4	1.0	0.6-1.4	2.4	1.1	0.5-1.9	3.0	0.9	0.5-1.5
Other acute leukemias	1.4	0.3	0.1-0.6	0.8	0.3	0.1-0.8	0.6	0.2	0.0-0.6	2.0	0.3	0.2-0.6	0.6	0.3	0.1-0.8	1.4	0.4	0.1-0.8

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018  
Richmond (Staten Island)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	3.6	0.6	0.4-1.0	2.0	0.7	0.3-1.4	1.6	0.5	0.2-1.0	3.4	0.6	0.4-1.0	1.8	0.8	0.4-1.5	1.6	0.5	0.2-1.0
Mesothelioma	7.0	1.3	0.9-1.8	4.8	2.3	1.4-3.4	2.2	0.7	0.3-1.3									
Kaposi sarcoma	4.2	0.8	0.5-1.2	3.0	1.3	0.7-2.1	1.2	0.4	0.1-0.9									
Myelodysplastic syndromes	24.4	4.5	3.7-5.4	15.0	6.6	5.1-8.3	9.4	2.9	2.1-3.9									
Chronic myeloproliferative disorders <sup>^</sup>	39.0	7.4	6.4-8.6	17.4	7.2	5.7-8.9	21.6	7.4	6.0-9.0									
All defined and unspecified sites	51.2	9.1	8.0-10.4	25.4	10.1	8.4-12.1	25.8	8.2	6.8-9.8	49.2	8.8	7.7-10.0	25.2	10.5	8.7-12.6	24.0	7.5	6.2-9.0

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

<sup>^</sup> Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.



**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Erie**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	6458.2	541.5	535.4-547.6	3225.6	597.3	587.9-606.9	3232.6	506.4	498.2-514.7	2109.0	168.6	165.3-172.0	1064.8	201.7	196.2-207.3	1044.2	146.3	142.2-150.5
Oral cavity and pharynx	159.2	12.9	12.0-13.9	111.4	19.8	18.2-21.6	47.8	7.1	6.2-8.1	36.0	2.8	2.4-3.3	27.2	4.9	4.1-5.8	8.8	1.2	0.9-1.6
Lip	7.4	0.6	0.4-0.9	5.4	1.0	0.7-1.5	2.0	0.3	0.1-0.6	0.6	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.0	0.0	0.0-0.2
Tongue	50.2	4.0	3.5-4.6	35.6	6.2	5.3-7.2	14.6	2.2	1.7-2.8	8.2	0.6	0.5-0.9	5.4	1.0	0.6-1.5	2.8	0.4	0.2-0.7
Salivary gland	17.4	1.6	1.3-2.0	10.4	2.2	1.6-2.9	7.0	1.1	0.8-1.6	3.0	0.3	0.1-0.4	2.0	0.4	0.2-0.8	1.0	0.1	0.0-0.3
Floor of mouth	7.0	0.5	0.4-0.7	3.6	0.6	0.3-0.9	3.4	0.5	0.3-0.8	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Gum & other mouth	18.2	1.5	1.2-1.9	10.0	1.8	1.4-2.5	8.2	1.2	0.9-1.7	5.2	0.4	0.3-0.6	3.8	0.7	0.4-1.1	1.4	0.2	0.1-0.4
Nasopharynx	5.0	0.4	0.3-0.6	4.4	0.8	0.5-1.3	0.6	0.1	0.0-0.3	1.8	0.1	0.1-0.3	1.2	0.2	0.1-0.5	0.6	0.1	0.0-0.3
Tonsil	29.4	2.3	1.9-2.7	23.6	4.0	3.3-4.8	5.8	0.8	0.5-1.2	4.2	0.3	0.2-0.5	4.0	0.7	0.4-1.0	0.2	0.0	0.0-0.2
Oropharynx	8.8	0.7	0.5-1.0	6.8	1.2	0.8-1.7	2.0	0.3	0.1-0.6	6.2	0.5	0.3-0.7	5.2	0.8	0.5-1.2	1.0	0.2	0.0-0.4
Hypopharynx	12.4	1.0	0.7-1.3	9.0	1.6	1.2-2.2	3.4	0.5	0.3-0.8	3.2	0.3	0.1-0.4	2.2	0.4	0.2-0.8	1.0	0.1	0.0-0.4
Other buccal cavity and pharynx	3.4	0.3	0.2-0.4	2.6	0.4	0.2-0.8	0.8	0.1	0.0-0.4	3.6	0.3	0.2-0.5	2.8	0.5	0.3-0.9	0.8	0.1	0.0-0.3
Digestive system	1051.0	86.8	84.4-89.3	573.6	107.1	103.1-111.2	477.4	70.7	67.7-73.7	509.6	40.6	39.0-42.2	296.6	54.9	52.1-57.9	213.0	29.4	27.6-31.3
Esophagus	73.8	5.9	5.3-6.5	56.4	10.1	9.0-11.4	17.4	2.5	2.0-3.1	62.6	5.0	4.4-5.6	50.2	9.1	8.0-10.4	12.4	1.7	1.3-2.2
Stomach	97.6	8.2	7.5-9.0	61.2	11.7	10.4-13.1	36.4	5.5	4.7-6.4	36.2	2.9	2.5-3.4	24.2	4.7	3.9-5.6	12.0	1.6	1.2-2.1
Small intestine	43.6	3.6	3.1-4.1	23.4	4.3	3.5-5.2	20.2	3.0	2.4-3.7	7.4	0.6	0.4-0.8	4.0	0.7	0.4-1.1	3.4	0.4	0.3-0.7
Colorectal	459.0	38.7	37.1-40.4	227.2	43.5	40.9-46.2	231.8	34.8	32.7-37.0	160.0	12.9	12.0-13.8	83.6	15.9	14.4-17.5	76.4	10.5	9.4-11.7
Colon excluding rectum	316.8	26.5	25.2-27.9	146.8	28.1	26.1-30.3	170.0	25.3	23.5-27.2	123.0	9.8	9.0-10.7	62.8	12.0	10.6-13.4	60.2	8.2	7.2-9.2
Cecum	75.0	6.1	5.5-6.8	27.6	5.3	4.5-6.3	47.4	6.7	5.8-7.6									
Appendix	18.8	1.8	1.4-2.2	8.2	1.6	1.1-2.2	10.6	1.9	1.4-2.6									
Ascending colon	56.2	4.6	4.0-5.1	22.8	4.3	3.6-5.2	33.4	4.7	4.0-5.5									
Hepatic flexure	12.8	1.1	0.8-1.4	6.0	1.2	0.8-1.7	6.8	1.0	0.7-1.4									
Transverse colon	28.6	2.4	2.0-2.8	15.2	2.9	2.3-3.7	13.4	1.8	1.4-2.4									
Splenic flexure	9.4	0.7	0.5-1.0	4.4	0.8	0.5-1.2	5.0	0.7	0.4-1.0									
Descending colon	15.2	1.3	1.0-1.6	8.4	1.6	1.2-2.3	6.8	1.0	0.7-1.5									
Sigmoid colon	78.0	6.8	6.1-7.5	43.6	8.3	7.2-9.5	34.4	5.8	4.9-6.8									
Large intestine, NOS	22.8	1.8	1.5-2.2	10.6	2.0	1.5-2.7	12.2	1.7	1.3-2.2									
Rectum & rectosigmoid	142.2	12.2	11.2-13.1	80.4	15.4	13.8-17.0	61.8	9.5	8.4-10.7	37.0	3.0	2.6-3.5	20.8	3.9	3.2-4.8	16.2	2.3	1.8-2.9
Rectosigmoid junction	33.6	2.8	2.4-3.3	18.0	3.4	2.7-4.2	15.6	2.2	1.8-2.8									
Rectum	108.6	9.4	8.6-10.2	62.4	11.9	10.6-13.4	46.2	7.3	6.3-8.3									
Anus, anal canal & anorectum	25.6	2.3	1.9-2.7	9.8	2.0	1.4-2.6	15.8	2.5	2.0-3.2	4.2	0.4	0.2-0.6	2.6	0.5	0.3-1.0	1.6	0.2	0.1-0.4
Liver and intrahepatic bile duct	107.8	8.4	7.7-9.2	81.4	14.1	12.7-15.6	26.4	3.8	3.1-4.5	74.8	5.8	5.2-6.5	54.0	9.5	8.3-10.7	20.8	3.0	2.4-3.6

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Erie**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	85.4	6.6	6.0-7.2	68.2	11.8	10.6-13.2	17.2	2.4	1.9-3.0	50.8	3.9	3.4-4.4	40.0	7.0	6.0-8.1	10.8	1.5	1.1-2.0
Intrahepatic bile duct	22.4	1.8	1.5-2.2	13.2	2.3	1.8-3.0	9.2	1.4	1.0-1.9	24.0	1.9	1.6-2.3	14.0	2.5	1.9-3.1	10.0	1.5	1.1-2.0
Gallbladder	12.2	1.0	0.8-1.3	2.6	0.5	0.3-0.9	9.6	1.4	1.0-1.9	6.0	0.5	0.3-0.7	1.4	0.3	0.1-0.6	4.6	0.7	0.4-1.1
Other biliary	18.6	1.5	1.2-1.8	10.2	1.8	1.3-2.4	8.4	1.2	0.8-1.6	4.8	0.3	0.2-0.5	2.4	0.4	0.2-0.7	2.4	0.3	0.1-0.5
Pancreas	188.0	15.3	14.3-16.3	93.0	17.4	15.8-19.1	95.0	13.7	12.4-15.0	144.4	11.5	10.7-12.4	70.8	13.2	11.9-14.7	73.6	10.2	9.2-11.4
Retroperitoneum	4.4	0.4	0.2-0.6	2.4	0.5	0.2-0.9	2.0	0.3	0.1-0.6	0.4	0.0	0.0-0.2	0.2	0.1	0.0-0.3	0.2	0.0	0.0-0.2
Peritoneum, omentum & mesentery	6.6	0.5	0.4-0.8	0.4	0.1	0.0-0.3	6.2	0.9	0.6-1.3	2.6	0.2	0.1-0.4	0.4	0.1	0.0-0.3	2.2	0.3	0.2-0.6
Other digestive organs	13.8	1.1	0.9-1.4	5.6	1.1	0.7-1.6	8.2	1.1	0.8-1.5	6.2	0.5	0.3-0.7	2.8	0.5	0.3-0.9	3.4	0.5	0.3-0.8
Respiratory system	941.6	75.8	73.6-78.1	456.2	84.7	81.1-88.3	485.4	70.0	67.2-73.0	559.8	44.8	43.1-46.5	281.8	52.8	50.1-55.7	278.0	39.0	36.9-41.2
Nasal cavity, middle ear & sinuses	8.4	0.7	0.5-1.0	4.0	0.7	0.4-1.2	4.4	0.7	0.4-1.1	1.6	0.1	0.1-0.3	0.8	0.1	0.0-0.4	0.8	0.1	0.0-0.4
Larynx	44.0	3.6	3.2-4.2	32.6	5.9	5.0-6.9	11.4	1.9	1.4-2.5	14.0	1.1	0.9-1.4	10.2	1.8	1.4-2.4	3.8	0.6	0.3-0.9
Lung and bronchus	886.4	71.2	69.1-73.4	417.8	77.7	74.3-81.2	468.6	67.3	64.5-70.1	542.4	43.4	41.7-45.1	269.8	50.7	47.9-53.5	272.6	38.2	36.1-40.4
Pleura	0.8	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.2	0.0	0.0-0.2	0.6	0.0	0.0-0.2	0.4	0.1	0.0-0.3	0.2	0.0	0.0-0.2
Trachea, mediastinum, other respiratory	2.0	0.2	0.1-0.4	1.2	0.2	0.1-0.5	0.8	0.2	0.0-0.4	1.2	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.6	0.1	0.0-0.3
Bones & joints	10.6	1.1	0.8-1.4	5.6	1.2	0.8-1.8	5.0	1.0	0.6-1.5	3.4	0.3	0.2-0.6	1.8	0.4	0.2-0.8	1.6	0.3	0.1-0.6
Soft tissue (including heart)	41.0	3.7	3.2-4.3	24.6	4.9	4.1-5.9	16.4	2.9	2.2-3.6	17.8	1.5	1.2-1.9	10.6	2.0	1.5-2.7	7.2	1.1	0.8-1.6
Skin*	365.8	31.6	30.1-33.1	215.4	40.9	38.4-43.5	150.4	25.1	23.3-27.1	38.2	3.0	2.6-3.5	23.0	4.4	3.6-5.4	15.2	2.1	1.6-2.7
Melanoma of the skin	335.8	29.0	27.6-30.5	197.4	37.3	34.9-39.8	138.4	23.2	21.4-25.1	25.8	2.1	1.7-2.5	14.4	2.8	2.2-3.6	11.4	1.6	1.2-2.1
Breast	921.6	80.4	78.0-82.9	8.6	1.5	1.1-2.1	913.0	147.8	143.3-152.4	161.8	13.1	12.2-14.1	2.4	0.4	0.2-0.8	159.4	23.0	21.3-24.7
Breast (in situ)#	245.6	22.6	21.3-24.0	0.8	0.1	0.0-0.4	244.8	42.6	40.1-45.2									
Female genital system							372.6	58.9	56.1-61.8							113.2	16.6	15.2-18.1
Cervix uteri							35.8	7.3	6.2-8.5							11.2	1.9	1.4-2.5
Corpus uteri and NOS							216.8	32.9	30.9-35.0							37.2	5.3	4.5-6.1
Ovary							75.6	12.1	10.8-13.4							53.6	7.9	7.0-9.0
Vagina							4.8	0.7	0.5-1.1							1.2	0.2	0.1-0.4
Vulva							27.0	4.0	3.3-4.8							6.0	0.7	0.5-1.1
Other female genital organs							12.6	1.9	1.4-2.5							4.0	0.6	0.3-0.9
Male genital system				862.6	150.7	146.1-155.4							97.0	19.2	17.5-21.0			
Prostate				825.2	142.1	137.7-146.6							94.8	18.8	17.1-20.6			
Testis				31.8	7.4	6.3-8.7							1.0	0.2	0.1-0.5			
Penis				5.0	1.0	0.6-1.5							0.8	0.2	0.0-0.4			
Other male genital organs				0.6	0.1	0.0-0.4							0.4	0.1	0.0-0.3			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Erie**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	586.4	48.1	46.3-49.9	397.2	74.8	71.4-78.2	189.2	27.7	25.9-29.6	110.8	8.6	7.9-9.4	71.0	13.6	12.2-15.1	39.8	5.2	4.5-6.0
Urinary bladder (including in situ)	353.0	28.5	27.1-29.9	247.2	46.7	44.1-49.5	105.8	15.0	13.7-16.4	65.8	5.1	4.5-5.7	43.0	8.3	7.2-9.6	22.8	2.9	2.4-3.5
Kidney and renal pelvis	220.2	18.6	17.5-19.7	141.0	26.3	24.3-28.4	79.2	12.2	10.9-13.5	41.6	3.3	2.8-3.8	25.8	4.8	4.0-5.7	15.8	2.2	1.7-2.7
Ureter	8.0	0.6	0.4-0.9	5.0	1.0	0.6-1.5	3.0	0.4	0.2-0.7	1.4	0.1	0.0-0.2	1.2	0.2	0.1-0.5	0.2	0.0	0.0-0.2
Other urinary organs	5.2	0.4	0.3-0.6	4.0	0.8	0.5-1.2	1.2	0.2	0.1-0.4	2.0	0.2	0.1-0.3	1.0	0.2	0.1-0.5	1.0	0.1	0.0-0.3
Eye & orbit	10.6	0.9	0.7-1.2	5.0	0.9	0.6-1.4	5.6	0.9	0.6-1.4	1.0	0.1	0.0-0.2	0.6	0.1	0.0-0.3	0.4	0.1	0.0-0.3
Brain / other central nervous system (all behaviors)	257.6	23.5	22.2-24.9	105.8	20.8	19.0-22.8	151.8	25.9	23.9-27.9	61.4	5.2	4.6-5.8	33.0	6.2	5.3-7.3	28.4	4.2	3.5-5.1
Malignant brain / other central nervous system	75.0	7.3	6.6-8.1	43.2	8.8	7.6-10.1	31.8	6.0	5.1-7.1	48.4	4.2	3.7-4.8	27.6	5.2	4.4-6.2	20.8	3.2	2.6-4.0
Malignant brain	67.0	6.4	5.7-7.1	38.8	7.8	6.7-9.0	28.2	5.2	4.3-6.2									
Malignant other central nervous system	8.0	0.9	0.7-1.3	4.4	1.0	0.6-1.5	3.6	0.8	0.5-1.4									
Benign brain / other central nervous system#	182.6	16.2	15.1-17.4	62.6	12.0	10.7-13.5	120.0	19.8	18.2-21.6	13.0	1.0	0.8-1.3	5.4	1.0	0.6-1.4	7.6	1.0	0.7-1.4
Benign brain	21.0	2.1	1.7-2.6	9.0	1.9	1.3-2.5	12.0	2.3	1.8-3.1									
Benign other central nervous system	161.6	14.1	13.1-15.2	53.6	10.2	9.0-11.5	108.0	17.5	16.0-19.1									
Endocrine system	179.2	18.4	17.2-19.7	45.4	9.4	8.1-10.7	133.8	27.1	25.0-29.3	7.4	0.6	0.4-0.8	2.8	0.6	0.3-1.0	4.6	0.7	0.4-1.0
Thyroid	172.0	17.7	16.5-19.0	42.8	8.8	7.6-10.1	129.2	26.3	24.2-28.5	4.4	0.3	0.2-0.5	1.6	0.3	0.1-0.7	2.8	0.3	0.2-0.6
Other endocrine (including thymus)	7.2	0.7	0.5-1.0	2.6	0.6	0.3-1.0	4.6	0.8	0.5-1.2	3.0	0.3	0.1-0.4	1.2	0.2	0.1-0.6	1.8	0.3	0.1-0.6
Lymphomas	304.0	26.5	25.1-27.9	161.0	31.4	29.2-33.8	143.0	22.9	21.1-24.7	76.2	6.1	5.5-6.8	49.0	9.6	8.4-10.9	27.2	3.7	3.1-4.5
Hodgkin lymphoma	29.4	3.1	2.6-3.7	15.4	3.4	2.7-4.3	14.0	2.8	2.2-3.6	2.2	0.2	0.1-0.4	1.2	0.2	0.1-0.5	1.0	0.2	0.0-0.4
Non-Hodgkin lymphomas	274.6	23.4	22.1-24.7	145.6	28.0	25.9-30.2	129.0	20.0	18.4-21.7	74.0	5.9	5.3-6.6	47.8	9.4	8.2-10.6	26.2	3.6	3.0-4.3
Myeloma	91.0	7.6	6.9-8.3	47.6	9.2	8.1-10.5	43.4	6.4	5.6-7.4	44.0	3.5	3.0-4.0	23.6	4.6	3.8-5.5	20.4	2.8	2.3-3.5
Leukemias	197.6	16.9	15.9-18.1	121.8	23.6	21.7-25.6	75.8	11.7	10.5-13.1	86.0	7.0	6.3-7.7	51.0	10.0	8.8-11.4	35.0	4.7	4.0-5.5
Lymphocytic leukemias	94.6	8.1	7.4-9.0	61.6	11.8	10.4-13.2	33.0	5.3	4.5-6.3	25.6	2.0	1.7-2.4	15.4	3.0	2.4-3.8	10.2	1.3	0.9-1.7
Acute lymphocytic leukemia	12.2	1.5	1.1-1.9	6.0	1.4	0.9-2.0	6.2	1.5	1.0-2.2	5.0	0.5	0.3-0.8	3.2	0.7	0.4-1.2	1.8	0.3	0.1-0.7
Chronic lymphocytic leukemia	75.4	6.1	5.4-6.7	50.4	9.3	8.2-10.6	25.0	3.5	2.9-4.3	19.2	1.4	1.1-1.7	11.4	2.1	1.6-2.8	7.8	0.9	0.6-1.2
Other lymphocytic leukemias	7.0	0.6	0.4-0.9	5.2	1.0	0.7-1.5	1.8	0.2	0.1-0.5	1.4	0.1	0.0-0.2	0.8	0.2	0.0-0.4	0.6	0.1	0.0-0.3
Myeloid and monocytic leukemias	93.8	8.0	7.3-8.8	55.2	10.8	9.5-12.2	38.6	5.9	5.0-6.8	45.8	3.8	3.3-4.3	28.4	5.5	4.6-6.5	17.4	2.5	2.0-3.2
Acute myeloid leukemia	65.4	5.5	4.9-6.2	37.4	7.3	6.2-8.4	28.0	4.2	3.5-5.0	41.0	3.4	2.9-3.9	25.6	4.9	4.1-5.9	15.4	2.3	1.8-2.9
Acute monocytic leukemia	3.2	0.3	0.2-0.5	2.0	0.4	0.2-0.8	1.2	0.2	0.1-0.5	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Chronic myeloid leukemia	24.8	2.2	1.8-2.6	15.6	3.1	2.4-3.9	9.2	1.5	1.1-2.0	3.2	0.3	0.1-0.4	1.6	0.3	0.1-0.6	1.6	0.2	0.1-0.5
Other myeloid/monocytic leukemias	0.4	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.2	0.0	0.0-0.2	1.6	0.1	0.1-0.3	1.2	0.2	0.1-0.5	0.4	0.0	0.0-0.2
Other leukemias	9.2	0.8	0.6-1.1	5.0	1.1	0.7-1.6	4.2	0.6	0.3-0.9	14.6	1.2	0.9-1.5	7.2	1.5	1.1-2.2	7.4	0.9	0.6-1.3
Other acute leukemias	3.4	0.3	0.2-0.5	1.8	0.4	0.2-0.8	1.6	0.2	0.1-0.4	4.8	0.4	0.2-0.6	2.4	0.5	0.3-0.9	2.4	0.3	0.1-0.5

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Erie**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	5.8	0.5	0.3-0.7	3.2	0.6	0.4-1.1	2.6	0.4	0.2-0.7	9.8	0.8	0.6-1.1	4.8	1.0	0.6-1.5	5.0	0.6	0.4-1.0
Mesothelioma	12.4	1.0	0.8-1.3	9.2	1.9	1.4-2.5	3.2	0.5	0.3-0.9									
Kaposi sarcoma	1.4	0.1	0.0-0.2	1.2	0.2	0.1-0.5	0.2	0.0	0.0-0.2									
Myelodysplastic syndromes	73.6	5.9	5.3-6.6	41.0	8.0	7.0-9.2	32.6	4.4	3.8-5.2									
Chronic myeloproliferative disorders^	58.8	5.1	4.5-5.7	27.4	5.3	4.4-6.3	31.4	4.9	4.1-5.8									
All defined and unspecified sites	142.2	11.4	10.6-12.3	67.6	13.0	11.6-14.5	74.6	10.2	9.2-11.4	198.4	15.5	14.6-16.6	98.8	18.8	17.1-20.6	99.6	13.3	12.1-14.5

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Monroe**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	4669.8	504.9	498.2-511.6	2320.2	551.7	541.4-562.1	2349.6	475.1	466.2-484.2	1488.2	156.3	152.7-160.0	754.6	185.7	179.7-191.9	733.6	136.5	132.0-141.2
Oral cavity and pharynx	114.2	12.2	11.2-13.3	77.0	18.1	16.2-20.0	37.2	7.2	6.1-8.3	24.0	2.6	2.1-3.1	15.2	3.7	2.9-4.7	8.8	1.6	1.2-2.2
Lip	3.6	0.4	0.2-0.6	2.2	0.5	0.3-1.0	1.4	0.3	0.1-0.6	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Tongue	34.2	3.7	3.1-4.3	21.6	5.2	4.2-6.3	12.6	2.4	1.8-3.1	5.4	0.6	0.4-0.9	3.4	0.9	0.5-1.4	2.0	0.4	0.2-0.8
Salivary gland	13.8	1.5	1.2-2.0	9.4	2.4	1.7-3.2	4.4	0.9	0.6-1.5	2.0	0.2	0.1-0.4	1.0	0.3	0.1-0.6	1.0	0.2	0.0-0.4
Floor of mouth	4.8	0.5	0.3-0.8	3.0	0.7	0.4-1.2	1.8	0.3	0.2-0.7	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Gum & other mouth	18.6	2.0	1.6-2.5	8.2	1.9	1.3-2.5	10.4	2.1	1.5-2.8	4.2	0.5	0.3-0.7	1.8	0.5	0.2-1.0	2.4	0.4	0.2-0.8
Nasopharynx	4.4	0.5	0.3-0.7	3.4	0.8	0.4-1.2	1.0	0.2	0.1-0.4	2.0	0.2	0.1-0.4	1.2	0.3	0.1-0.6	0.8	0.2	0.0-0.4
Tonsil	21.6	2.3	1.9-2.8	18.2	4.1	3.3-5.1	3.4	0.6	0.4-1.0	3.0	0.3	0.2-0.5	2.8	0.6	0.3-1.1	0.2	0.0	0.0-0.2
Oropharynx	5.2	0.5	0.3-0.8	4.2	1.0	0.6-1.5	1.0	0.2	0.0-0.4	2.6	0.3	0.2-0.5	1.2	0.3	0.1-0.7	1.4	0.3	0.1-0.6
Hypopharynx	6.6	0.7	0.5-1.0	5.6	1.3	0.8-1.9	1.0	0.2	0.1-0.5	1.2	0.1	0.0-0.3	1.0	0.2	0.1-0.6	0.2	0.0	0.0-0.3
Other buccal cavity and pharynx	1.4	0.1	0.1-0.3	1.2	0.3	0.1-0.6	0.2	0.0	0.0-0.2	3.6	0.4	0.2-0.6	2.8	0.6	0.3-1.1	0.8	0.2	0.0-0.4
Digestive system	749.8	80.0	77.4-82.7	400.4	95.3	91.0-99.7	349.4	67.8	64.6-71.2	384.0	40.2	38.4-42.1	217.8	52.4	49.3-55.7	166.2	30.6	28.5-32.8
Esophagus	43.6	4.6	4.0-5.3	31.6	7.5	6.4-8.9	12.0	2.2	1.7-2.9	43.2	4.5	3.9-5.2	31.4	7.4	6.2-8.6	11.8	2.2	1.7-2.9
Stomach	62.6	6.7	6.0-7.5	39.6	9.6	8.3-11.1	23.0	4.5	3.7-5.4	25.4	2.7	2.2-3.2	16.0	3.8	3.0-4.8	9.4	1.8	1.3-2.4
Small intestine	28.8	3.2	2.7-3.8	16.2	4.0	3.1-5.0	12.6	2.6	2.0-3.4	4.6	0.5	0.3-0.7	2.8	0.7	0.4-1.2	1.8	0.3	0.2-0.7
Colorectal	344.4	37.1	35.3-39.0	172.4	41.2	38.4-44.1	172.0	33.8	31.5-36.2	119.8	12.6	11.5-13.6	64.4	15.8	14.1-17.7	55.4	10.0	8.8-11.3
Colon excluding rectum	247.4	26.6	25.1-28.2	118.0	28.4	26.1-30.9	129.4	25.2	23.2-27.3	93.8	9.8	8.9-10.8	48.4	11.9	10.5-13.6	45.4	8.0	7.0-9.2
Cecum	48.6	5.1	4.4-5.8	22.2	5.4	4.5-6.6	26.4	4.9	4.0-5.8									
Appendix	20.2	2.5	2.0-3.1	9.4	2.4	1.7-3.2	10.8	2.7	2.0-3.6									
Ascending colon	48.6	5.0	4.4-5.7	22.6	5.3	4.3-6.4	26.0	4.9	4.1-5.9									
Hepatic flexure	12.4	1.3	1.0-1.7	5.2	1.3	0.9-1.9	7.2	1.4	0.9-1.9									
Transverse colon	21.6	2.3	1.9-2.8	9.6	2.3	1.7-3.1	12.0	2.3	1.7-3.0									
Splenic flexure	7.0	0.8	0.6-1.1	3.6	0.9	0.5-1.5	3.4	0.7	0.4-1.1									
Descending colon	13.8	1.6	1.2-2.0	7.4	1.8	1.3-2.6	6.4	1.4	0.9-2.0									
Sigmoid colon	62.6	6.7	5.9-7.5	32.6	7.5	6.4-8.9	30.0	5.8	4.9-6.9									
Large intestine, NOS	12.6	1.3	1.0-1.7	5.4	1.4	0.9-2.0	7.2	1.2	0.9-1.8									
Rectum & rectosigmoid	97.0	10.5	9.6-11.6	54.4	12.8	11.3-14.5	42.6	8.6	7.4-9.9	26.0	2.8	2.3-3.3	16.0	3.8	3.0-4.8	10.0	1.9	1.4-2.6
Rectosigmoid junction	17.6	2.0	1.6-2.4	10.0	2.4	1.7-3.2	7.6	1.6	1.1-2.2									
Rectum	79.4	8.6	7.7-9.5	44.4	10.4	9.1-11.9	35.0	7.0	6.0-8.2									
Anus, anal canal & anorectum	17.6	1.8	1.5-2.3	5.4	1.2	0.8-1.7	12.2	2.4	1.9-3.2	3.4	0.3	0.2-0.5	1.0	0.2	0.1-0.5	2.4	0.4	0.2-0.8
Liver and intrahepatic bile duct	71.2	7.3	6.6-8.2	47.4	10.7	9.3-12.2	23.8	4.6	3.8-5.6	52.0	5.4	4.8-6.2	34.4	8.1	6.9-9.4	17.6	3.5	2.8-4.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Monroe**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	53.2	5.4	4.7-6.1	39.4	8.6	7.4-9.9	13.8	2.7	2.0-3.4	33.4	3.5	2.9-4.0	25.0	5.7	4.7-6.8	8.4	1.7	1.2-2.3
Intrahepatic bile duct	18.0	2.0	1.6-2.4	8.0	2.1	1.5-2.8	10.0	2.0	1.4-2.6	18.6	2.0	1.6-2.4	9.4	2.4	1.7-3.2	9.2	1.8	1.3-2.4
Gallbladder	9.0	0.9	0.7-1.2	4.0	0.9	0.5-1.4	5.0	1.0	0.6-1.4	3.0	0.3	0.2-0.5	0.8	0.2	0.0-0.5	2.2	0.4	0.2-0.8
Other biliary	16.2	1.7	1.3-2.1	7.6	1.8	1.3-2.5	8.6	1.6	1.1-2.2	4.6	0.5	0.3-0.7	2.0	0.5	0.2-0.9	2.6	0.4	0.2-0.8
Pancreas	138.0	14.6	13.5-15.8	69.2	16.8	15.0-18.7	68.8	12.9	11.6-14.4	121.2	12.8	11.7-13.8	62.4	15.3	13.6-17.1	58.8	10.8	9.5-12.1
Retroperitoneum	3.8	0.4	0.3-0.7	2.0	0.5	0.2-0.9	1.8	0.4	0.2-0.8	1.0	0.1	0.0-0.3	0.4	0.1	0.0-0.3	0.6	0.1	0.0-0.4
Peritoneum, omentum & mesentery	5.0	0.5	0.3-0.7	0.2	0.0	0.0-0.3	4.8	0.8	0.5-1.3	3.0	0.3	0.2-0.5	0.4	0.1	0.0-0.3	2.6	0.5	0.2-0.8
Other digestive organs	9.6	1.0	0.8-1.4	4.8	1.1	0.7-1.7	4.8	0.9	0.6-1.4	2.8	0.3	0.2-0.5	1.8	0.4	0.2-0.8	1.0	0.2	0.1-0.5
Respiratory system	638.4	66.8	64.5-69.2	322.4	76.5	72.7-80.4	316.0	59.9	56.9-63.0	378.8	39.8	38.0-41.7	199.0	48.5	45.5-51.7	179.8	33.7	31.4-36.0
Nasal cavity, middle ear & sinuses	8.4	0.9	0.7-1.2	4.2	1.0	0.6-1.6	4.2	0.8	0.5-1.3	1.2	0.1	0.0-0.3	0.6	0.1	0.0-0.4	0.6	0.1	0.0-0.4
Larynx	30.2	3.1	2.6-3.7	24.2	5.5	4.5-6.6	6.0	1.2	0.8-1.7	10.4	1.1	0.8-1.4	8.0	1.9	1.3-2.6	2.4	0.5	0.2-0.8
Lung and bronchus	599.4	62.7	60.4-65.1	293.8	69.9	66.3-73.6	305.6	57.8	54.9-60.9	367.0	38.6	36.8-40.4	190.2	46.4	43.4-49.5	176.8	33.1	30.9-35.4
Pleura	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.2	0.0	0.0-0.3	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Trachea, mediastinum, other respiratory	0.2	0.0	0.0-0.2	0.2	0.1	0.0-0.4	0.0	0.0	0.0-0.2	0.2	0.0	0.0-0.2	0.2	0.1	0.0-0.4	0.0	0.0	0.0-0.2
Bones & joints	7.8	1.0	0.7-1.4	3.6	0.9	0.6-1.5	4.2	1.1	0.7-1.7	4.0	0.4	0.3-0.7	2.6	0.6	0.3-1.1	1.4	0.3	0.1-0.6
Soft tissue (including heart)	31.0	3.5	3.0-4.2	19.2	4.7	3.8-5.8	11.8	2.5	1.9-3.2	11.8	1.3	1.0-1.7	7.2	1.9	1.3-2.6	4.6	0.9	0.5-1.4
Skin*	267.4	30.4	28.7-32.1	144.2	36.0	33.3-38.8	123.2	26.9	24.7-29.2	27.6	2.9	2.4-3.4	16.8	4.3	3.4-5.3	10.8	1.9	1.4-2.6
Melanoma of the skin	243.2	27.7	26.1-29.4	129.6	32.4	29.9-35.1	113.6	24.9	22.8-27.1	18.0	1.9	1.5-2.3	10.8	2.7	2.0-3.6	7.2	1.3	0.9-1.8
Breast	713.8	79.6	77.0-82.4	7.0	1.7	1.2-2.4	706.8	146.0	141.0-151.2	93.8	10.0	9.1-11.0	1.4	0.4	0.1-0.8	92.4	17.7	16.0-19.4
Breast (in situ)#	164.0	18.5	17.2-19.9	1.2	0.3	0.1-0.7	162.8	34.5	32.1-37.1									
Female genital system							279.2	56.3	53.3-59.5							87.0	16.3	14.7-17.9
Cervix uteri							26.8	6.3	5.2-7.5							10.8	2.4	1.7-3.1
Corpus uterus and NOS							164.6	32.2	29.9-34.6							31.6	5.8	4.9-6.8
Ovary							54.4	11.2	9.9-12.7							35.2	6.5	5.5-7.5
Vagina							2.0	0.4	0.2-0.7							0.6	0.1	0.0-0.3
Vulva							15.6	3.2	2.5-4.0							4.6	0.7	0.5-1.2
Other female genital organs							15.8	3.1	2.4-3.9							4.2	0.8	0.5-1.2
Male genital system				635.0	143.1	138.1-148.4							73.0	18.7	16.8-20.7			
Prostate				608.2	135.4	130.5-140.5							72.6	18.6	16.7-20.6			
Testis				24.8	7.2	6.0-8.7							0.2	0.0	0.0-0.3			
Penis				0.6	0.1	0.0-0.4							0.2	0.1	0.0-0.3			
Other male genital organs				1.4	0.3	0.1-0.7							0.0	0.0	0.0-0.2			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Monroe**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	422.6	45.2	43.3-47.3	298.4	72.3	68.6-76.2	124.2	24.5	22.6-26.6	78.2	8.1	7.3-8.9	53.2	13.3	11.7-15.1	25.0	4.4	3.7-5.3
Urinary bladder (including in situ)	232.2	24.2	22.8-25.7	172.8	42.2	39.3-45.1	59.4	11.1	9.8-12.5	45.4	4.6	4.0-5.3	32.6	8.2	7.0-9.6	12.8	2.2	1.6-2.8
Kidney and renal pelvis	182.0	20.1	18.8-21.5	119.0	28.6	26.2-31.0	63.0	13.1	11.6-14.7	31.6	3.3	2.8-3.9	20.0	5.0	4.0-6.1	11.6	2.1	1.6-2.8
Ureter	5.4	0.6	0.4-0.8	4.0	0.9	0.6-1.5	1.4	0.3	0.1-0.6	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.3	0.0	0.0	0.0-0.2
Other urinary organs	3.0	0.3	0.2-0.6	2.6	0.7	0.4-1.2	0.4	0.1	0.0-0.3	1.0	0.1	0.0-0.3	0.4	0.1	0.0-0.3	0.6	0.1	0.0-0.4
Eye & orbit	5.2	0.6	0.4-0.9	1.6	0.3	0.1-0.7	3.6	0.8	0.5-1.3	0.8	0.1	0.0-0.2	0.2	0.0	0.0-0.3	0.6	0.1	0.0-0.4
Brain / other central nervous system (all behaviors)	183.6	21.1	19.7-22.6	74.2	18.6	16.7-20.6	109.4	23.5	21.5-25.6	49.4	5.5	4.8-6.3	25.4	6.3	5.2-7.5	24.0	5.0	4.1-6.0
Malignant brain / other central nervous system	54.2	6.3	5.6-7.2	28.6	7.2	6.0-8.5	25.6	5.8	4.8-6.9	41.4	4.6	4.0-5.4	21.6	5.3	4.3-6.4	19.8	4.2	3.4-5.2
Malignant brain	51.8	6.0	5.3-6.8	27.4	6.8	5.7-8.1	24.4	5.4	4.5-6.5									
Malignant other central nervous system	2.4	0.3	0.2-0.6	1.2	0.3	0.1-0.7	1.2	0.3	0.1-0.7									
Benign brain / other central nervous system#	129.4	14.8	13.6-16.0	45.6	11.4	9.9-13.0	83.8	17.7	16.0-19.6	8.0	0.9	0.6-1.2	3.8	1.0	0.6-1.6	4.2	0.8	0.5-1.2
Benign brain	10.2	1.4	1.0-1.8	6.2	1.7	1.1-2.4	4.0	1.1	0.6-1.7									
Benign other central nervous system	119.2	13.4	12.3-14.6	39.4	9.7	8.4-11.2	79.8	16.7	15.0-18.5									
Endocrine system	131.8	16.6	15.3-17.9	42.8	11.1	9.6-12.7	89.0	21.7	19.6-23.9	6.2	0.7	0.5-1.0	2.4	0.6	0.3-1.1	3.8	0.7	0.4-1.2
Thyroid	124.6	15.6	14.4-17.0	38.2	9.8	8.4-11.3	86.4	21.1	19.1-23.3	4.6	0.5	0.3-0.7	2.0	0.5	0.2-0.9	2.6	0.5	0.2-0.9
Other endocrine (including thymus)	7.2	0.9	0.6-1.3	4.6	1.3	0.8-2.0	2.6	0.6	0.3-1.0	1.6	0.2	0.1-0.4	0.4	0.1	0.0-0.4	1.2	0.3	0.1-0.6
Lymphomas	228.4	25.6	24.1-27.2	126.6	31.4	28.9-34.0	101.8	21.1	19.2-23.1	59.2	6.4	5.7-7.2	29.8	7.5	6.3-8.9	29.4	5.5	4.6-6.5
Hodgkin lymphoma	27.4	3.6	3.0-4.3	15.4	4.2	3.3-5.3	12.0	3.0	2.3-3.9	2.6	0.3	0.2-0.5	1.4	0.4	0.1-0.8	1.2	0.2	0.1-0.6
Non-Hodgkin lymphomas	201.0	22.0	20.6-23.4	111.2	27.2	24.9-29.6	89.8	18.1	16.4-19.9	56.6	6.1	5.4-6.9	28.4	7.2	6.0-8.5	28.2	5.3	4.4-6.3
Myeloma	69.2	7.2	6.5-8.1	38.0	9.1	7.9-10.6	31.2	5.9	5.0-6.9	32.6	3.4	2.9-3.9	17.8	4.3	3.4-5.3	14.8	2.6	2.0-3.3
Leukemias	144.8	15.7	14.6-17.0	84.8	21.0	19.0-23.1	60.0	11.7	10.4-13.2	60.8	6.4	5.7-7.2	32.8	8.3	7.1-9.7	28.0	5.1	4.3-6.1
Lymphocytic leukemias	79.4	8.6	7.8-9.5	47.2	11.6	10.2-13.3	32.2	6.2	5.3-7.3	16.8	1.8	1.4-2.2	9.8	2.5	1.9-3.3	7.0	1.3	0.9-1.8
Acute lymphocytic leukemia	8.6	1.2	0.8-1.6	5.8	1.6	1.1-2.4	2.8	0.8	0.4-1.3	3.8	0.5	0.3-0.7	1.6	0.4	0.2-0.8	2.2	0.5	0.2-0.9
Chronic lymphocytic leukemia	66.2	6.9	6.1-7.7	38.4	9.3	8.0-10.7	27.8	5.1	4.3-6.0	12.4	1.3	1.0-1.7	8.0	2.1	1.5-2.8	4.4	0.7	0.4-1.1
Other lymphocytic leukemias	4.6	0.5	0.3-0.8	3.0	0.8	0.4-1.3	1.6	0.4	0.2-0.8	0.6	0.1	0.0-0.2	0.2	0.0	0.0-0.3	0.4	0.1	0.0-0.4
Myeloid and monocytic leukemias	59.4	6.5	5.8-7.3	34.2	8.5	7.3-10.0	25.2	5.0	4.1-6.0	36.0	3.9	3.3-4.5	19.4	4.9	4.0-6.0	16.6	3.1	2.5-3.9
Acute myeloid leukemia	38.8	4.2	3.7-4.9	22.4	5.5	4.5-6.6	16.4	3.4	2.6-4.2	29.0	3.1	2.6-3.7	16.8	4.2	3.4-5.3	12.2	2.4	1.8-3.1
Acute monocytic leukemia	2.0	0.2	0.1-0.4	1.2	0.3	0.1-0.7	0.8	0.1	0.0-0.4	0.4	0.0	0.0-0.2	0.0	0.0	0.0-0.2	0.4	0.1	0.0-0.3
Chronic myeloid leukemia	17.8	2.0	1.6-2.4	10.2	2.7	2.0-3.5	7.6	1.4	1.0-2.0	3.4	0.4	0.2-0.6	1.0	0.2	0.1-0.6	2.4	0.4	0.2-0.8
Other myeloid/monocytic leukemias	0.8	0.1	0.0-0.2	0.4	0.1	0.0-0.4	0.4	0.1	0.0-0.3	3.2	0.3	0.2-0.5	1.6	0.4	0.2-0.9	1.6	0.2	0.1-0.5
Other leukemias	6.0	0.6	0.4-0.9	3.4	0.8	0.5-1.3	2.6	0.5	0.3-0.9	8.0	0.8	0.6-1.1	3.6	0.9	0.5-1.4	4.4	0.7	0.4-1.1
Other acute leukemias	1.6	0.2	0.1-0.3	0.8	0.2	0.0-0.5	0.8	0.1	0.0-0.4	3.8	0.4	0.2-0.6	2.2	0.5	0.3-1.0	1.6	0.3	0.1-0.6

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Monroe**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	4.4	0.5	0.3-0.7	2.6	0.6	0.3-1.0	1.8	0.4	0.2-0.7	4.2	0.4	0.3-0.7	1.4	0.4	0.1-0.8	2.8	0.4	0.2-0.8
Mesothelioma	6.4	0.7	0.5-1.0	4.0	1.0	0.6-1.6	2.4	0.4	0.2-0.8									
Kaposi sarcoma	2.6	0.3	0.1-0.5	2.6	0.7	0.3-1.1	0.0	0.0	0.0-0.2									
Myelodysplastic syndromes	41.4	4.3	3.8-5.0	25.6	6.6	5.5-7.8	15.8	2.9	2.3-3.7									
Chronic myeloproliferative disorders^	42.2	4.6	4.0-5.3	18.2	4.5	3.6-5.6	24.0	4.5	3.7-5.5									
Ill defined and unspecified sites	84.4	8.8	8.0-9.7	40.2	10.1	8.7-11.6	44.2	8.1	7.0-9.3	125.0	13.0	12.0-14.1	63.8	15.8	14.1-17.7	61.2	10.9	9.7-12.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.



**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Nassau**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	8890.8	505.8	500.9-510.7	4386.4	546.2	538.8-553.7	4504.4	481.2	474.6-487.8	2363.0	127.0	124.7-129.4	1149.2	145.4	141.6-149.3	1213.8	114.9	111.9-118.0
Oral cavity and pharynx	181.6	10.3	9.6-11.0	116.8	14.5	13.3-15.7	64.8	6.9	6.1-7.7	27.0	1.4	1.2-1.7	14.6	1.8	1.4-2.3	12.4	1.1	0.9-1.5
Lip	6.2	0.3	0.2-0.5	3.8	0.5	0.3-0.8	2.4	0.2	0.1-0.4	0.6	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.4	0.0	0.0-0.2
Tongue	57.8	3.2	2.9-3.7	38.4	4.7	4.1-5.5	19.4	2.0	1.6-2.5	5.0	0.2	0.2-0.4	2.8	0.3	0.2-0.6	2.2	0.2	0.1-0.4
Salivary gland	26.8	1.6	1.3-1.9	13.8	1.8	1.4-2.3	13.0	1.4	1.1-1.9	5.0	0.3	0.2-0.4	2.0	0.3	0.1-0.5	3.0	0.3	0.2-0.5
Floor of mouth	6.4	0.3	0.2-0.5	4.2	0.5	0.3-0.8	2.2	0.2	0.1-0.4	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.2	0.0	0.0-0.2
Gum & other mouth	28.6	1.6	1.4-1.9	15.0	2.0	1.5-2.5	13.6	1.4	1.1-1.8	5.4	0.3	0.2-0.4	2.4	0.3	0.2-0.5	3.0	0.2	0.1-0.4
Nasopharynx	9.0	0.6	0.4-0.8	6.0	0.8	0.5-1.1	3.0	0.4	0.2-0.6	1.4	0.1	0.0-0.1	1.0	0.1	0.0-0.3	0.4	0.0	0.0-0.1
Tonsil	29.2	1.6	1.4-1.9	23.6	2.8	2.3-3.4	5.6	0.6	0.4-0.9	2.2	0.1	0.1-0.2	1.6	0.2	0.1-0.4	0.6	0.1	0.0-0.2
Oropharynx	7.4	0.4	0.3-0.6	4.8	0.6	0.4-0.9	2.6	0.3	0.1-0.5	2.8	0.1	0.1-0.3	2.0	0.3	0.1-0.5	0.8	0.1	0.0-0.2
Hypopharynx	7.4	0.4	0.3-0.6	5.4	0.7	0.4-1.0	2.0	0.2	0.1-0.4	0.4	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.0	0.0	0.0-0.1
Other buccal cavity and pharynx	2.8	0.1	0.1-0.3	1.8	0.2	0.1-0.4	1.0	0.1	0.0-0.3	4.0	0.2	0.1-0.4	2.2	0.3	0.1-0.5	1.8	0.2	0.1-0.3
Digestive system	1486.6	82.6	80.7-84.6	789.2	98.6	95.4-101.8	697.4	69.7	67.3-72.2	645.2	34.6	33.4-35.9	345.6	43.0	41.0-45.2	299.6	27.8	26.3-29.3
Esophagus	73.8	4.1	3.7-4.5	54.0	6.7	5.9-7.6	19.8	1.9	1.5-2.3	49.4	2.7	2.4-3.1	36.8	4.6	3.9-5.3	12.6	1.2	0.9-1.5
Stomach	141.8	8.0	7.4-8.6	84.2	10.6	9.6-11.7	57.6	5.9	5.2-6.7	52.6	2.9	2.6-3.3	29.4	3.7	3.1-4.4	23.2	2.3	1.9-2.8
Small intestine	57.0	3.3	2.9-3.7	34.2	4.3	3.6-5.0	22.8	2.5	2.0-3.0	5.6	0.3	0.2-0.4	2.4	0.3	0.2-0.6	3.2	0.3	0.2-0.5
Colorectal	679.2	38.4	37.0-39.7	334.4	42.6	40.6-44.8	344.8	34.7	33.0-36.5	211.0	11.2	10.5-12.0	104.6	13.2	12.1-14.4	106.4	9.7	8.8-10.6
Colon excluding rectum	489.4	27.4	26.3-28.6	228.0	29.1	27.4-30.9	261.4	26.0	24.5-27.5	175.4	9.3	8.7-9.9	82.0	10.3	9.3-11.4	93.4	8.4	7.7-9.3
Cecum	99.0	5.4	4.9-5.9	42.2	5.4	4.7-6.2	56.8	5.3	4.6-5.9									
Appendix	32.0	2.1	1.8-2.5	11.6	1.6	1.2-2.1	20.4	2.6	2.1-3.2									
Ascending colon	99.2	5.4	5.0-6.0	42.4	5.3	4.6-6.1	56.8	5.5	4.9-6.2									
Hepatic flexure	23.2	1.3	1.1-1.6	11.6	1.5	1.1-2.0	11.6	1.1	0.9-1.5									
Transverse colon	41.6	2.3	2.0-2.6	20.2	2.7	2.2-3.3	21.4	2.0	1.6-2.5									
Splenic flexure	12.6	0.7	0.5-0.9	7.4	0.9	0.7-1.3	5.2	0.5	0.3-0.7									
Descending colon	30.4	1.7	1.5-2.1	16.2	2.1	1.7-2.6	14.2	1.5	1.1-1.9									
Sigmoid colon	121.2	6.8	6.3-7.4	63.0	7.9	7.0-8.8	58.2	6.0	5.3-6.8									
Large intestine, NOS	30.2	1.6	1.4-1.9	13.4	1.7	1.3-2.2	16.8	1.5	1.1-1.8									
Rectum & rectosigmoid	189.8	10.9	10.2-11.7	106.4	13.5	12.3-14.7	83.4	8.8	7.9-9.7	35.6	2.0	1.7-2.3	22.6	2.9	2.4-3.5	13.0	1.2	0.9-1.6
Rectosigmoid junction	54.8	3.1	2.7-3.5	28.2	3.5	2.9-4.2	26.6	2.7	2.3-3.3									
Rectum	135.0	7.8	7.2-8.5	78.2	10.0	9.0-11.1	56.8	6.1	5.3-6.8									
Anus, anal canal & anorectum	31.2	1.7	1.4-2.0	9.4	1.1	0.8-1.5	21.8	2.2	1.8-2.7	1.4	0.1	0.0-0.1	0.8	0.1	0.0-0.2	0.6	0.0	0.0-0.2
Liver and intrahepatic bile duct	124.2	6.7	6.2-7.3	87.6	10.3	9.3-11.4	36.6	3.7	3.1-4.3	83.8	4.5	4.1-5.0	54.2	6.6	5.8-7.4	29.6	2.9	2.4-3.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Nassau**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	98.6	5.3	4.9-5.8	72.2	8.4	7.6-9.4	26.4	2.7	2.2-3.2	54.4	2.9	2.6-3.3	39.4	4.7	4.0-5.4	15.0	1.4	1.1-1.8
Intrahepatic bile duct	25.6	1.4	1.1-1.6	15.4	1.9	1.5-2.4	10.2	1.0	0.7-1.3	29.4	1.6	1.4-1.9	14.8	1.9	1.5-2.4	14.6	1.4	1.1-1.8
Gallbladder	25.8	1.4	1.2-1.7	8.6	1.1	0.8-1.5	17.2	1.7	1.3-2.1	10.2	0.5	0.4-0.7	3.4	0.4	0.2-0.7	6.8	0.6	0.4-0.9
Other biliary	36.0	1.9	1.6-2.2	20.6	2.5	2.1-3.1	15.4	1.4	1.1-1.8	11.6	0.6	0.5-0.8	5.6	0.7	0.5-1.1	6.0	0.5	0.4-0.8
Pancreas	289.2	15.7	14.9-16.6	146.6	18.1	16.7-19.4	142.6	13.8	12.8-14.9	210.0	11.2	10.5-11.9	105.4	13.0	11.9-14.2	104.6	9.7	8.9-10.6
Retroperitoneum	7.8	0.4	0.3-0.6	3.8	0.5	0.3-0.8	4.0	0.4	0.3-0.7	0.8	0.0	0.0-0.1	0.6	0.1	0.0-0.3	0.2	0.0	0.0-0.1
Peritoneum, omentum & mesentery	7.0	0.4	0.3-0.5	0.6	0.1	0.0-0.2	6.4	0.6	0.4-0.9	3.8	0.2	0.1-0.3	0.0	0.0	0.0-0.1	3.8	0.4	0.2-0.6
Other digestive organs	13.6	0.7	0.6-1.0	5.2	0.7	0.4-1.0	8.4	0.8	0.6-1.1	5.0	0.2	0.2-0.4	2.4	0.3	0.1-0.5	2.6	0.2	0.1-0.4
Respiratory system	1025.0	56.4	54.9-58.0	473.4	59.6	57.2-62.1	551.6	54.6	52.5-56.7	508.0	27.5	26.4-28.6	253.2	32.0	30.2-33.9	254.8	24.4	23.0-25.8
Nasal cavity, middle ear & sinuses	13.0	0.7	0.6-1.0	7.6	0.9	0.7-1.3	5.4	0.6	0.4-0.8	1.2	0.1	0.0-0.2	1.0	0.1	0.0-0.3	0.2	0.0	0.0-0.1
Larynx	46.4	2.6	2.2-2.9	37.6	4.6	4.0-5.3	8.8	0.9	0.6-1.2	12.8	0.7	0.5-0.9	9.6	1.2	0.9-1.6	3.2	0.3	0.2-0.5
Lung and bronchus	961.2	52.8	51.3-54.4	425.6	53.7	51.4-56.1	535.6	52.9	50.9-55.0	492.0	26.6	25.6-27.7	241.0	30.5	28.8-32.3	251.0	24.1	22.7-25.5
Pleura	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.2	0.0	0.0-0.1	1.2	0.1	0.0-0.1	1.2	0.1	0.1-0.3	0.0	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	4.2	0.3	0.2-0.4	2.6	0.4	0.2-0.6	1.6	0.2	0.1-0.4	0.8	0.0	0.0-0.1	0.4	0.1	0.0-0.2	0.4	0.0	0.0-0.2
Bones & joints	21.0	1.3	1.1-1.6	12.6	1.7	1.3-2.2	8.4	1.0	0.7-1.4	7.6	0.5	0.3-0.7	4.2	0.6	0.3-0.9	3.4	0.4	0.2-0.6
Soft tissue (including heart)	67.8	4.3	3.8-4.8	39.6	5.4	4.7-6.2	28.2	3.4	2.8-4.0	22.6	1.3	1.1-1.6	11.2	1.5	1.1-2.0	11.4	1.2	0.9-1.6
Skin*	431.0	24.5	23.5-25.6	254.8	32.2	30.4-34.1	176.2	19.1	17.8-20.5	43.6	2.4	2.0-2.7	29.2	3.7	3.2-4.4	14.4	1.3	1.0-1.7
Melanoma of the skin	395.0	22.5	21.5-23.6	234.4	29.6	27.9-31.4	160.6	17.4	16.2-18.8	32.8	1.8	1.5-2.1	22.6	2.9	2.4-3.5	10.2	1.0	0.7-1.3
Breast	1337.4	79.6	77.6-81.6	14.0	1.8	1.4-2.4	1323.4	147.3	143.6-151.1	188.0	10.2	9.6-10.9	2.4	0.3	0.2-0.6	185.6	18.2	17.0-19.5
Breast (in situ)#	525.6	32.4	31.1-33.7	1.2	0.1	0.1-0.3	524.4	61.4	59.0-63.9									
Female genital system							538.8	56.9	54.7-59.2							144.2	14.1	13.1-15.3
Cervix uteri							48.6	6.2	5.4-7.0							12.4	1.4	1.0-1.8
Corpus uteri and NOS							322.2	32.8	31.1-34.5							59.6	5.7	5.1-6.4
Ovary							111.6	12.2	11.2-13.3							62.4	6.1	5.4-6.9
Vagina							5.4	0.6	0.4-0.8							1.2	0.1	0.0-0.2
Vulva							24.4	2.5	2.1-3.0							4.2	0.4	0.3-0.7
Other female genital organs							26.6	2.7	2.2-3.2							4.4	0.4	0.3-0.6
Male genital system				1219.8	143.9	140.2-147.7							113.4	14.4	13.3-15.7			
Prostate				1174.4	136.8	133.2-140.4							110.6	14.1	12.9-15.3			
Testis				36.2	5.9	5.1-6.9							1.0	0.1	0.0-0.3			
Penis				7.4	1.0	0.7-1.4							1.6	0.2	0.1-0.4			
Other male genital organs				1.8	0.2	0.1-0.4							0.2	0.0	0.0-0.2			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Nassau**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	788.6	43.5	42.1-44.9	563.0	70.6	67.9-73.3	225.6	22.4	21.1-23.9	130.6	6.7	6.2-7.3	86.4	10.9	9.8-12.0	44.2	3.8	3.3-4.3
Urinary bladder (including in situ)	454.6	24.6	23.5-25.6	342.8	43.3	41.2-45.4	111.8	10.6	9.7-11.6	77.8	4.0	3.6-4.4	52.8	6.8	6.0-7.6	25.0	2.1	1.8-2.6
Kidney and renal pelvis	313.8	17.8	16.9-18.8	206.4	25.5	23.9-27.1	107.4	11.2	10.3-12.3	49.2	2.6	2.2-2.9	31.6	3.8	3.3-4.5	17.6	1.5	1.2-1.9
Ureter	13.0	0.7	0.5-0.9	9.2	1.2	0.9-1.6	3.8	0.3	0.2-0.6	2.4	0.1	0.1-0.2	1.2	0.2	0.1-0.4	1.2	0.1	0.0-0.2
Other urinary organs	7.2	0.4	0.3-0.6	4.6	0.6	0.4-0.9	2.6	0.2	0.1-0.4	1.2	0.1	0.0-0.1	0.8	0.1	0.0-0.3	0.4	0.0	0.0-0.2
Eye & orbit	18.4	1.1	0.9-1.4	9.2	1.2	0.9-1.6	9.2	1.0	0.7-1.4	1.6	0.1	0.0-0.2	1.4	0.2	0.1-0.4	0.2	0.0	0.0-0.1
Brain / other central nervous system (all behaviors)	379.6	23.0	21.9-24.1	149.6	20.2	18.7-21.7	230.0	25.2	23.7-26.8	86.2	4.9	4.5-5.4	46.2	5.8	5.1-6.7	40.0	4.2	3.6-4.8
Malignant brain / other central nervous system	110.6	7.0	6.4-7.6	60.6	8.1	7.2-9.1	50.0	5.9	5.2-6.8	71.2	4.1	3.7-4.6	40.4	5.1	4.4-5.9	30.8	3.3	2.7-3.8
Malignant brain	102.8	6.4	5.8-7.0	56.0	7.4	6.6-8.4	46.8	5.5	4.8-6.3									
Malignant other central nervous system	7.8	0.6	0.4-0.8	4.6	0.7	0.4-1.1	3.2	0.4	0.2-0.7									
Benign brain / other central nervous system#	269.0	16.0	15.2-17.0	89.0	12.1	10.9-13.3	180.0	19.3	18.0-20.7	15.0	0.8	0.6-1.0	5.8	0.7	0.5-1.0	9.2	0.9	0.6-1.2
Benign brain	24.4	1.7	1.4-2.1	12.2	1.8	1.4-2.3	12.2	1.6	1.2-2.1									
Benign other central nervous system	244.6	14.3	13.5-15.2	76.8	10.3	9.2-11.4	167.8	17.7	16.5-19.0									
Endocrine system	360.8	24.3	23.2-25.5	110.2	14.8	13.5-16.1	250.6	33.5	31.6-35.5	14.2	0.8	0.6-1.0	6.6	0.9	0.6-1.3	7.6	0.7	0.5-1.0
Thyroid	338.8	23.0	21.9-24.1	96.4	13.0	11.8-14.3	242.4	32.5	30.6-34.5	10.0	0.5	0.4-0.7	4.2	0.5	0.3-0.8	5.8	0.5	0.3-0.7
Other endocrine (including thymus)	22.0	1.3	1.1-1.6	13.8	1.8	1.4-2.3	8.2	1.0	0.7-1.4	4.2	0.3	0.2-0.4	2.4	0.4	0.2-0.6	1.8	0.2	0.1-0.4
Lymphomas	452.8	26.7	25.5-27.8	242.0	31.7	29.9-33.6	210.8	22.7	21.3-24.2	100.0	5.4	4.9-5.9	55.4	7.0	6.2-7.9	44.6	4.1	3.6-4.8
Hodgkin lymphoma	49.4	3.5	3.1-4.0	26.2	3.9	3.2-4.6	23.2	3.2	2.7-3.9	5.0	0.3	0.2-0.4	2.4	0.3	0.1-0.5	2.6	0.3	0.1-0.5
Non-Hodgkin lymphomas	403.4	23.1	22.1-24.2	215.8	27.8	26.1-29.5	187.6	19.5	18.2-20.8	95.0	5.1	4.6-5.6	53.0	6.7	5.9-7.6	42.0	3.9	3.4-4.5
Myeloma	150.6	8.3	7.7-9.0	83.8	10.5	9.5-11.6	66.8	6.6	5.9-7.4	51.2	2.7	2.4-3.0	28.2	3.5	3.0-4.2	23.0	2.1	1.7-2.5
Leukemias	307.0	17.8	16.8-18.7	182.4	23.5	22.0-25.2	124.6	13.3	12.2-14.5	108.6	5.9	5.4-6.4	64.8	8.6	7.7-9.6	43.8	4.0	3.4-4.6
Lymphocytic leukemias	163.4	9.3	8.7-10.0	97.4	12.5	11.4-13.7	66.0	6.8	6.1-7.7	31.6	1.6	1.4-1.9	17.6	2.3	1.9-2.9	14.0	1.1	0.9-1.4
Acute lymphocytic leukemia	24.4	1.8	1.5-2.2	15.2	2.4	1.8-3.0	9.2	1.3	0.9-1.8	7.0	0.4	0.3-0.6	4.8	0.7	0.4-1.0	2.2	0.2	0.1-0.4
Chronic lymphocytic leukemia	130.2	7.0	6.4-7.6	75.6	9.3	8.3-10.3	54.6	5.3	4.6-6.0	22.6	1.1	0.9-1.3	11.8	1.5	1.2-2.0	10.8	0.8	0.6-1.1
Other lymphocytic leukemias	8.8	0.5	0.4-0.7	6.6	0.9	0.6-1.2	2.2	0.3	0.1-0.5	2.0	0.1	0.0-0.2	1.0	0.1	0.0-0.3	1.0	0.1	0.0-0.2
Myeloid and monocytic leukemias	129.2	7.6	7.0-8.2	76.4	9.9	8.9-11.0	52.8	5.8	5.1-6.6	58.4	3.2	2.9-3.6	35.2	4.7	4.0-5.4	23.2	2.3	1.8-2.7
Acute myeloid leukemia	83.4	4.8	4.4-5.3	50.8	6.6	5.8-7.5	32.6	3.5	3.0-4.1	53.2	3.0	2.6-3.4	32.0	4.2	3.6-5.0	21.2	2.1	1.7-2.5
Acute monocytic leukemia	2.8	0.2	0.1-0.3	2.0	0.3	0.1-0.5	0.8	0.1	0.0-0.2	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Chronic myeloid leukemia	40.4	2.4	2.1-2.8	22.4	2.9	2.3-3.5	18.0	2.1	1.7-2.6	2.6	0.1	0.1-0.2	1.8	0.2	0.1-0.4	0.8	0.1	0.0-0.2
Other myeloid/monocytic leukemias	2.6	0.1	0.1-0.2	1.2	0.2	0.1-0.3	1.4	0.1	0.0-0.3	2.6	0.1	0.1-0.3	1.4	0.2	0.1-0.4	1.2	0.1	0.0-0.3
Other leukemias	14.4	0.9	0.7-1.1	8.6	1.1	0.8-1.6	5.8	0.7	0.4-1.0	18.6	1.0	0.8-1.2	12.0	1.6	1.2-2.1	6.6	0.6	0.4-0.9
Other acute leukemias	4.2	0.2	0.1-0.4	2.2	0.3	0.1-0.5	2.0	0.2	0.1-0.4	6.8	0.4	0.3-0.5	4.6	0.6	0.4-0.9	2.2	0.2	0.1-0.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Nassau**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	10.2	0.6	0.5-0.8	6.4	0.9	0.6-1.2	3.8	0.4	0.3-0.7	11.8	0.6	0.5-0.8	7.4	1.0	0.7-1.4	4.4	0.4	0.2-0.6
Mesothelioma	17.0	0.9	0.7-1.2	12.4	1.6	1.2-2.1	4.6	0.5	0.3-0.7									
Kaposi sarcoma	7.8	0.5	0.4-0.7	5.8	0.8	0.6-1.2	2.0	0.2	0.1-0.4									
Myelodysplastic syndromes	110.6	5.8	5.4-6.4	62.8	8.2	7.3-9.1	47.8	4.3	3.7-4.9									
Chronic myeloproliferative disorders <sup>^</sup>	110.0	6.5	5.9-7.1	60.6	8.0	7.1-9.0	49.4	5.0	4.4-5.8									
Ill defined and unspecified sites	147.6	8.1	7.5-8.7	73.4	9.5	8.5-10.6	74.2	6.9	6.2-7.7	186.0	9.8	9.2-10.5	92.2	11.7	10.6-12.8	93.8	8.4	7.6-9.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

<sup>^</sup> Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Suffolk**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	9853.4	530.5	525.7-535.3	4975.0	583.7	576.3-591.2	4878.4	496.0	489.6-502.5	2703.4	142.2	139.7-144.6	1360.8	165.9	161.9-169.9	1342.6	126.3	123.2-129.4
Oral cavity and pharynx	227.2	11.8	11.1-12.6	157.4	17.6	16.4-18.9	69.8	6.8	6.1-7.6	31.0	1.6	1.4-1.9	22.0	2.6	2.1-3.2	9.0	0.9	0.6-1.2
Lip	8.4	0.4	0.3-0.6	5.2	0.6	0.4-0.9	3.2	0.3	0.2-0.5	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.0	0.0	0.0-0.1
Tongue	75.2	4.0	3.6-4.4	54.0	6.0	5.3-6.8	21.2	2.1	1.7-2.6	7.0	0.4	0.3-0.5	5.0	0.6	0.4-0.9	2.0	0.2	0.1-0.4
Salivary gland	27.2	1.5	1.2-1.7	15.8	2.0	1.5-2.5	11.4	1.1	0.8-1.5	3.2	0.2	0.1-0.3	3.0	0.4	0.2-0.6	0.2	0.0	0.0-0.1
Floor of mouth	11.2	0.6	0.4-0.7	7.8	0.9	0.6-1.2	3.4	0.3	0.2-0.5	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Gum & other mouth	30.2	1.6	1.3-1.9	16.8	1.9	1.5-2.3	13.4	1.3	1.0-1.6	7.0	0.4	0.2-0.5	4.0	0.5	0.3-0.7	3.0	0.2	0.1-0.4
Nasopharynx	7.2	0.4	0.3-0.6	5.0	0.6	0.4-0.9	2.2	0.3	0.1-0.5	2.2	0.1	0.1-0.2	1.6	0.2	0.1-0.4	0.6	0.1	0.0-0.3
Tonsil	47.2	2.3	2.0-2.7	39.0	4.1	3.5-4.7	8.2	0.8	0.5-1.0	2.4	0.1	0.1-0.2	2.0	0.2	0.1-0.4	0.4	0.0	0.0-0.1
Oropharynx	9.2	0.5	0.3-0.6	6.4	0.7	0.5-1.0	2.8	0.3	0.1-0.5	2.6	0.1	0.1-0.2	1.6	0.2	0.1-0.4	1.0	0.1	0.0-0.2
Hypopharynx	7.8	0.4	0.3-0.6	5.2	0.6	0.4-0.9	2.6	0.2	0.1-0.4	0.8	0.0	0.0-0.1	0.8	0.1	0.0-0.3	0.0	0.0	0.0-0.1
Other buccal cavity and pharynx	3.6	0.2	0.1-0.3	2.2	0.3	0.1-0.5	1.4	0.1	0.1-0.3	5.4	0.3	0.2-0.4	3.8	0.4	0.3-0.7	1.6	0.2	0.1-0.3
Digestive system	1616.2	86.1	84.1-88.0	903.2	105.8	102.6-109.0	713.0	70.1	67.8-72.5	710.0	37.0	35.8-38.3	406.4	48.2	46.1-50.4	303.6	28.3	26.9-29.8
Esophagus	92.2	4.7	4.3-5.2	72.6	8.2	7.4-9.1	19.6	1.9	1.5-2.3	72.6	3.7	3.3-4.1	60.0	6.9	6.1-7.7	12.6	1.2	0.9-1.6
Stomach	138.0	7.4	6.9-8.0	81.8	9.7	8.7-10.7	56.2	5.7	5.0-6.4	52.8	2.8	2.5-3.2	29.2	3.4	2.9-4.0	23.6	2.3	1.9-2.8
Small intestine	54.2	2.9	2.5-3.3	29.0	3.3	2.8-3.9	25.2	2.6	2.1-3.1	7.4	0.4	0.3-0.5	3.4	0.4	0.2-0.6	4.0	0.4	0.2-0.6
Colorectal	743.4	40.2	38.9-41.5	386.2	46.2	44.1-48.3	357.2	35.4	33.8-37.2	228.6	12.0	11.3-12.7	118.0	14.4	13.3-15.7	110.6	10.2	9.3-11.1
Colon excluding rectum	535.2	29.1	28.0-30.2	263.0	31.9	30.1-33.7	272.2	26.9	25.5-28.5	189.2	9.9	9.3-10.6	96.0	11.8	10.7-12.9	93.2	8.6	7.8-9.4
Cecum	105.2	5.6	5.1-6.1	49.2	5.9	5.2-6.7	56.0	5.3	4.7-6.0									
Appendix	39.2	2.4	2.1-2.8	14.2	1.9	1.4-2.4	25.0	2.9	2.4-3.5									
Ascending colon	98.8	5.3	4.8-5.8	42.2	5.3	4.6-6.1	56.6	5.3	4.7-6.0									
Hepatic flexure	27.2	1.5	1.2-1.7	13.4	1.6	1.3-2.1	13.8	1.3	1.0-1.7									
Transverse colon	47.2	2.5	2.2-2.9	24.2	2.9	2.4-3.5	23.0	2.2	1.8-2.7									
Splenic flexure	14.6	0.8	0.6-1.0	8.8	1.0	0.7-1.4	5.8	0.6	0.4-0.9									
Descending colon	36.2	2.0	1.7-2.3	20.2	2.5	2.0-3.0	16.0	1.6	1.3-2.0									
Sigmoid colon	135.6	7.3	6.8-7.9	74.2	8.6	7.8-9.6	61.4	6.3	5.6-7.1									
Large intestine, NOS	31.2	1.7	1.4-2.0	16.6	2.1	1.7-2.6	14.6	1.3	1.0-1.7									
Rectum & rectosigmoid	208.2	11.1	10.4-11.8	123.2	14.3	13.2-15.5	85.0	8.5	7.7-9.4	39.4	2.1	1.8-2.4	22.0	2.7	2.2-3.2	17.4	1.7	1.3-2.1
Rectosigmoid junction	55.2	2.9	2.6-3.3	33.2	3.8	3.3-4.5	22.0	2.1	1.8-2.6									
Rectum	153.0	8.2	7.6-8.8	90.0	10.5	9.5-11.5	63.0	6.4	5.7-7.1									
Anus, anal canal & anorectum	35.8	1.9	1.6-2.2	13.6	1.5	1.2-1.9	22.2	2.2	1.8-2.7	4.8	0.2	0.2-0.4	1.4	0.2	0.1-0.4	3.4	0.3	0.2-0.5
Liver and intrahepatic bile duct	159.6	8.2	7.6-8.8	118.6	13.2	12.1-14.3	41.0	3.9	3.3-4.5	100.8	5.2	4.8-5.7	66.4	7.7	6.9-8.6	34.4	3.2	2.7-3.7

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Suffolk**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	130.8	6.6	6.1-7.2	105.0	11.5	10.5-12.6	25.8	2.5	2.1-3.0	68.6	3.5	3.1-3.9	52.8	6.0	5.3-6.8	15.8	1.5	1.2-1.8
Intrahepatic bile duct	28.8	1.5	1.3-1.8	13.6	1.7	1.3-2.1	15.2	1.4	1.1-1.8	32.2	1.7	1.5-2.0	13.6	1.7	1.3-2.2	18.6	1.7	1.4-2.1
Gallbladder	23.8	1.3	1.1-1.6	9.8	1.2	0.9-1.7	14.0	1.4	1.1-1.8	10.8	0.6	0.4-0.8	4.4	0.6	0.3-0.8	6.4	0.6	0.4-0.9
Other biliary	32.4	1.7	1.5-2.0	16.6	2.0	1.5-2.4	15.8	1.6	1.2-2.0	8.0	0.4	0.3-0.6	5.0	0.6	0.4-0.9	3.0	0.3	0.1-0.5
Pancreas	299.2	15.8	15.0-16.6	159.8	18.7	17.4-20.1	139.4	13.4	12.4-14.5	211.6	11.1	10.4-11.8	114.0	13.5	12.4-14.7	97.6	9.1	8.3-10.0
Retroperitoneum	8.6	0.5	0.3-0.7	5.2	0.6	0.4-0.9	3.4	0.4	0.2-0.6	0.8	0.0	0.0-0.1	0.4	0.1	0.0-0.2	0.4	0.0	0.0-0.2
Peritoneum, omentum & mesentery	9.0	0.5	0.3-0.6	1.2	0.1	0.0-0.3	7.8	0.7	0.5-1.0	4.8	0.2	0.2-0.4	0.6	0.1	0.0-0.2	4.2	0.4	0.2-0.6
Other digestive organs	20.0	1.0	0.8-1.3	8.8	1.0	0.7-1.4	11.2	1.0	0.8-1.3	7.0	0.4	0.3-0.5	3.6	0.4	0.3-0.7	3.4	0.3	0.2-0.5
Respiratory system	1337.0	70.3	68.6-72.0	631.4	75.3	72.7-78.1	705.6	66.9	64.7-69.2	664.0	34.8	33.7-36.1	325.2	39.6	37.6-41.6	338.8	31.6	30.1-33.2
Nasal cavity, middle ear & sinuses	14.0	0.7	0.6-0.9	10.0	1.1	0.8-1.4	4.0	0.4	0.3-0.7	1.8	0.1	0.0-0.2	1.2	0.1	0.0-0.3	0.6	0.1	0.0-0.2
Larynx	59.0	3.0	2.7-3.4	47.2	5.4	4.7-6.1	11.8	1.1	0.8-1.4	14.4	0.8	0.6-1.0	11.2	1.3	1.0-1.7	3.2	0.3	0.2-0.5
Lung and bronchus	1260.2	66.3	64.6-68.0	571.0	68.5	65.9-71.1	689.2	65.4	63.2-67.6	646.6	33.9	32.8-35.1	311.8	38.0	36.1-39.9	334.8	31.2	29.7-32.8
Pleura	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.6	0.0	0.0-0.1	0.6	0.1	0.0-0.2	0.0	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	3.6	0.2	0.1-0.4	3.0	0.4	0.2-0.7	0.6	0.1	0.0-0.2	0.6	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.2	0.0	0.0-0.1
Bones & joints	21.4	1.4	1.1-1.7	10.6	1.4	1.1-1.9	10.8	1.4	1.0-1.8	6.8	0.4	0.3-0.6	4.6	0.6	0.4-0.9	2.2	0.3	0.1-0.5
Soft tissue (including heart)	72.8	4.1	3.7-4.6	40.0	4.8	4.1-5.5	32.8	3.6	3.0-4.2	25.6	1.4	1.2-1.7	15.2	1.9	1.5-2.4	10.4	1.0	0.8-1.4
Skin*	515.0	28.0	26.9-29.1	315.8	37.7	35.8-39.7	199.2	20.9	19.6-22.3	57.0	2.9	2.6-3.3	40.8	4.9	4.2-5.6	16.2	1.5	1.2-1.8
Melanoma of the skin	475.4	25.8	24.7-26.9	288.4	34.2	32.4-36.1	187.0	19.6	18.4-21.0	40.8	2.1	1.8-2.4	27.4	3.3	2.7-3.9	13.4	1.2	0.9-1.6
Breast	1331.0	72.8	71.0-74.6	11.8	1.3	1.0-1.7	1319.2	136.1	132.7-139.6	190.6	10.1	9.4-10.7	3.0	0.3	0.2-0.6	187.6	17.9	16.8-19.2
Breast (in situ)#	433.0	24.2	23.2-25.3	1.0	0.1	0.0-0.3	432.0	46.4	44.4-48.5									
Female genital system							566.8	56.9	54.8-59.2							163.2	15.6	14.5-16.7
Cervix uteri							55.4	6.8	6.0-7.7							17.0	1.8	1.4-2.3
Corpus uterus and NOS							331.2	32.0	30.5-33.7							58.8	5.5	4.9-6.2
Ovary							122.6	12.5	11.5-13.6							76.8	7.2	6.5-8.0
Vagina							6.4	0.7	0.4-1.0							1.6	0.2	0.1-0.3
Vulva							24.8	2.4	2.0-2.9							6.6	0.6	0.4-0.8
Other female genital organs							26.4	2.5	2.1-3.0							2.4	0.2	0.1-0.4
Male genital system				1238.0	137.1	133.6-140.6							124.4	16.0	14.8-17.3			
Prostate				1181.2	129.0	125.6-132.4							122.0	15.7	14.4-17.0			
Testis				49.6	7.1	6.3-8.1							0.8	0.1	0.0-0.3			
Penis				5.0	0.6	0.4-1.0							1.2	0.2	0.1-0.4			
Other male genital organs				2.2	0.3	0.2-0.6							0.4	0.1	0.0-0.2			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Suffolk**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	916.6	49.0	47.5-50.4	648.8	77.8	75.1-80.6	267.8	26.2	24.7-27.6	157.2	8.3	7.7-8.9	107.4	13.6	12.5-14.8	49.8	4.5	4.0-5.1
Urinary bladder (including in situ)	517.8	27.6	26.5-28.7	388.6	47.6	45.4-49.8	129.2	12.3	11.3-13.3	93.8	5.0	4.5-5.4	65.2	8.5	7.6-9.4	28.6	2.6	2.2-3.1
Kidney and renal pelvis	377.6	20.2	19.3-21.2	246.0	28.5	26.9-30.2	131.6	13.2	12.1-14.3	58.8	3.1	2.7-3.4	39.2	4.7	4.1-5.5	19.6	1.8	1.4-2.2
Ureter	14.8	0.8	0.6-1.0	9.6	1.2	0.9-1.6	5.2	0.5	0.3-0.8	2.0	0.1	0.1-0.2	0.8	0.1	0.0-0.3	1.2	0.1	0.0-0.3
Other urinary organs	6.4	0.4	0.2-0.5	4.6	0.6	0.4-0.9	1.8	0.2	0.1-0.3	2.6	0.1	0.1-0.2	2.2	0.3	0.1-0.5	0.4	0.0	0.0-0.1
Eye & orbit	17.2	1.0	0.8-1.2	9.4	1.1	0.8-1.5	7.8	0.9	0.6-1.2	2.2	0.1	0.1-0.2	1.2	0.1	0.0-0.3	1.0	0.1	0.0-0.3
Brain / other central nervous system (all behaviors)	460.6	26.1	25.0-27.3	182.0	22.7	21.2-24.3	278.6	29.0	27.5-30.7	99.0	5.2	4.8-5.7	53.4	6.1	5.4-6.9	45.6	4.5	3.9-5.1
Malignant brain / other central nervous system	128.6	7.6	7.0-8.3	69.6	8.7	7.8-9.7	59.0	6.7	5.9-7.6	82.4	4.4	3.9-4.8	45.2	5.1	4.5-5.9	37.2	3.7	3.2-4.3
Malignant brain	123.0	7.3	6.7-7.9	66.2	8.2	7.3-9.2	56.8	6.4	5.7-7.2									
Malignant other central nervous system	5.6	0.4	0.2-0.5	3.4	0.5	0.3-0.7	2.2	0.3	0.1-0.5									
Benign brain / other central nervous system#	332.0	18.5	17.6-19.4	112.4	14.1	12.9-15.3	219.6	22.3	21.0-23.8	16.6	0.9	0.7-1.1	8.2	1.0	0.7-1.4	8.4	0.8	0.5-1.1
Benign brain	43.4	2.7	2.4-3.1	20.6	2.7	2.2-3.3	22.8	2.7	2.2-3.3									
Benign other central nervous system	288.6	15.8	14.9-16.6	91.8	11.3	10.3-12.5	196.8	19.6	18.3-20.9									
Endocrine system	380.2	23.8	22.7-25.0	109.8	13.6	12.4-14.8	270.4	34.0	32.1-35.9	12.8	0.7	0.5-0.9	5.8	0.7	0.4-1.0	7.0	0.7	0.5-1.0
Thyroid	361.8	22.8	21.7-23.9	99.0	12.3	11.2-13.4	262.8	33.2	31.3-35.1	10.2	0.5	0.4-0.7	4.8	0.6	0.4-0.8	5.4	0.5	0.3-0.8
Other endocrine (including thymus)	18.4	1.1	0.8-1.3	10.8	1.3	1.0-1.7	7.6	0.8	0.6-1.2	2.6	0.1	0.1-0.2	1.0	0.1	0.0-0.3	1.6	0.1	0.1-0.3
Lymphomas	505.4	28.0	26.9-29.2	276.0	33.4	31.6-35.2	229.4	23.8	22.4-25.3	96.8	5.2	4.7-5.7	56.0	7.0	6.2-7.9	40.8	3.9	3.3-4.5
Hodgkin lymphoma	52.4	3.4	3.0-3.9	28.4	3.7	3.1-4.3	24.0	3.2	2.6-3.8	4.6	0.3	0.2-0.4	1.8	0.2	0.1-0.5	2.8	0.3	0.2-0.5
Non-Hodgkin lymphomas	453.0	24.6	23.6-25.7	247.6	29.7	28.0-31.5	205.4	20.6	19.3-22.0	92.2	4.9	4.5-5.4	54.2	6.8	6.0-7.7	38.0	3.6	3.1-4.1
Myeloma	167.6	8.8	8.2-9.5	97.8	11.4	10.4-12.5	69.8	6.7	6.0-7.5	53.8	2.8	2.5-3.2	28.4	3.4	2.9-4.0	25.4	2.3	2.0-2.8
Leukemias	376.2	20.8	19.9-21.8	224.4	27.5	25.9-29.2	151.8	15.5	14.4-16.7	108.2	5.9	5.4-6.4	65.2	8.3	7.4-9.3	43.0	4.1	3.5-4.7
Lymphocytic leukemias	215.8	11.8	11.1-12.6	133.4	16.0	14.8-17.3	82.4	8.4	7.6-9.3	27.2	1.5	1.2-1.7	16.0	2.1	1.7-2.6	11.2	1.0	0.8-1.3
Acute lymphocytic leukemia	30.0	2.1	1.8-2.5	18.2	2.6	2.1-3.2	11.8	1.7	1.2-2.1	6.2	0.4	0.2-0.5	3.2	0.4	0.2-0.7	3.0	0.3	0.2-0.6
Chronic lymphocytic leukemia	174.8	9.1	8.5-9.8	106.4	12.4	11.4-13.5	68.4	6.5	5.8-7.2	19.2	1.0	0.8-1.2	11.6	1.5	1.2-2.0	7.6	0.6	0.4-0.9
Other lymphocytic leukemias	11.0	0.6	0.5-0.8	8.8	1.0	0.7-1.4	2.2	0.2	0.1-0.4	1.8	0.1	0.0-0.2	1.2	0.2	0.1-0.3	0.6	0.1	0.0-0.2
Myeloid and monocytic leukemias	144.0	8.1	7.5-8.7	82.2	10.4	9.4-11.5	61.8	6.4	5.7-7.2	60.8	3.3	3.0-3.7	36.4	4.6	4.0-5.4	24.4	2.4	1.9-2.8
Acute myeloid leukemia	90.4	5.1	4.6-5.6	51.2	6.5	5.7-7.3	39.2	4.1	3.5-4.7	52.2	2.9	2.5-3.2	31.0	3.9	3.3-4.6	21.2	2.0	1.7-2.5
Acute monocytic leukemia	4.8	0.3	0.2-0.4	2.6	0.3	0.2-0.6	2.2	0.2	0.1-0.4	0.6	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.2	0.0	0.0-0.1
Chronic myeloid leukemia	47.2	2.7	2.3-3.0	27.8	3.5	2.9-4.2	19.4	2.0	1.6-2.4	5.0	0.3	0.2-0.4	3.0	0.4	0.2-0.7	2.0	0.2	0.1-0.4
Other myeloid/monocytic leukemias	1.6	0.1	0.0-0.2	0.6	0.1	0.0-0.2	1.0	0.1	0.0-0.2	3.0	0.2	0.1-0.3	2.0	0.3	0.1-0.5	1.0	0.1	0.0-0.2
Other leukemias	16.4	0.9	0.7-1.1	8.8	1.1	0.8-1.5	7.6	0.7	0.5-1.0	20.2	1.1	0.9-1.3	12.8	1.6	1.2-2.1	7.4	0.7	0.5-1.0
Other acute leukemias	5.6	0.3	0.2-0.4	2.6	0.3	0.2-0.6	3.0	0.3	0.1-0.5	6.4	0.4	0.2-0.5	3.4	0.5	0.3-0.7	3.0	0.3	0.2-0.5

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Suffolk**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	10.8	0.6	0.4-0.8	6.2	0.8	0.5-1.1	4.6	0.5	0.3-0.7	13.8	0.7	0.6-0.9	9.4	1.1	0.8-1.5	4.4	0.4	0.3-0.6
Mesothelioma	14.8	0.8	0.6-1.0	10.6	1.4	1.0-1.8	4.2	0.4	0.3-0.7									
Kaposi sarcoma	4.2	0.2	0.1-0.3	3.4	0.4	0.2-0.6	0.8	0.1	0.0-0.2									
Myelodysplastic syndromes	131.6	7.0	6.5-7.6	74.8	9.7	8.7-10.7	56.8	5.2	4.6-5.8									
Chronic myeloproliferative disorders <sup>^</sup>	119.0	6.5	6.0-7.1	60.4	7.4	6.6-8.3	58.6	5.7	5.1-6.4									
Ill defined and unspecified sites	166.6	9.0	8.4-9.7	81.8	10.4	9.4-11.4	84.8	8.1	7.3-8.9	217.4	11.4	10.8-12.2	110.0	13.5	12.3-14.7	107.4	10.0	9.1-10.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

<sup>^</sup> Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.



**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**Westchester**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	5780.6	475.7	470.1-481.3	2830.6	519.7	511.0-528.5	2950.0	449.1	441.6-456.7	1438.6	111.8	109.1-114.5	686.6	127.4	123.1-131.8	752.0	102.1	98.7-105.5
Oral cavity and pharynx	113.2	9.2	8.4-10.0	78.0	13.9	12.6-15.4	35.2	5.3	4.5-6.2	17.6	1.3	1.1-1.7	11.6	2.1	1.6-2.7	6.0	0.8	0.5-1.2
Lip	3.0	0.2	0.1-0.4	1.8	0.3	0.1-0.6	1.2	0.2	0.1-0.4	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Tongue	36.0	2.9	2.5-3.4	27.4	4.8	4.0-5.7	8.6	1.3	1.0-1.8	5.0	0.4	0.2-0.6	3.8	0.7	0.4-1.1	1.2	0.2	0.1-0.4
Salivary gland	15.6	1.3	1.0-1.6	9.8	1.9	1.4-2.5	5.8	0.9	0.6-1.3	3.2	0.2	0.1-0.4	2.6	0.5	0.3-0.9	0.6	0.1	0.0-0.3
Floor of mouth	3.2	0.2	0.1-0.4	1.8	0.3	0.1-0.6	1.4	0.2	0.1-0.4	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Gum & other mouth	18.8	1.6	1.2-1.9	8.8	1.6	1.1-2.1	10.0	1.5	1.1-2.0	2.4	0.2	0.1-0.3	1.0	0.1	0.0-0.4	1.4	0.2	0.1-0.4
Nasopharynx	5.4	0.5	0.3-0.8	4.2	0.8	0.5-1.3	1.2	0.2	0.1-0.5	0.4	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.2	0.0	0.0-0.2
Tonsil	20.2	1.6	1.3-2.0	15.6	2.7	2.1-3.4	4.6	0.7	0.4-1.0	1.2	0.1	0.0-0.2	0.8	0.2	0.0-0.4	0.4	0.1	0.0-0.2
Oropharynx	3.2	0.3	0.1-0.4	2.6	0.5	0.2-0.8	0.6	0.1	0.0-0.3	2.0	0.2	0.1-0.3	1.4	0.2	0.1-0.5	0.6	0.1	0.0-0.3
Hypopharynx	6.6	0.5	0.4-0.8	5.2	1.0	0.6-1.4	1.4	0.2	0.1-0.4	1.0	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.4	0.1	0.0-0.2
Other buccal cavity and pharynx	1.2	0.1	0.0-0.2	0.8	0.1	0.0-0.4	0.4	0.1	0.0-0.2	2.4	0.2	0.1-0.3	1.2	0.2	0.1-0.5	1.2	0.2	0.1-0.4
Digestive system	982.6	79.2	77.0-81.5	523.0	96.4	92.6-100.2	459.6	65.9	63.2-68.8	400.0	31.2	29.8-32.6	212.8	38.9	36.6-41.4	187.2	25.2	23.6-27.0
Esophagus	45.2	3.6	3.1-4.1	31.2	5.7	4.8-6.7	14.0	1.9	1.5-2.5	32.6	2.6	2.2-3.0	22.2	4.2	3.4-5.0	10.4	1.4	1.0-1.8
Stomach	104.4	8.6	7.8-9.3	60.2	11.4	10.1-12.8	44.2	6.5	5.6-7.4	38.4	3.0	2.6-3.5	21.6	4.0	3.2-4.8	16.8	2.4	1.9-3.0
Small intestine	36.6	3.0	2.6-3.5	21.0	3.9	3.2-4.7	15.6	2.3	1.8-2.9	6.0	0.5	0.3-0.7	4.8	0.9	0.6-1.3	1.2	0.2	0.1-0.4
Colorectal	431.0	35.1	33.6-36.7	217.6	40.6	38.2-43.2	213.4	30.9	29.0-32.9	126.2	9.8	9.0-10.6	61.2	11.3	10.1-12.7	65.0	8.7	7.7-9.7
Colon excluding rectum	302.8	24.6	23.4-25.9	147.6	27.8	25.8-30.0	155.2	22.2	20.6-23.9	98.6	7.6	6.9-8.3	48.6	9.0	7.8-10.2	50.0	6.6	5.8-7.5
Cecum	56.6	4.5	4.0-5.0	25.4	4.7	3.9-5.6	31.2	4.3	3.6-5.1									
Appendix	22.2	2.0	1.7-2.5	9.2	1.8	1.3-2.4	13.0	2.2	1.7-2.9									
Ascending colon	56.4	4.5	3.9-5.0	26.0	5.0	4.2-6.0	30.4	4.0	3.4-4.8									
Hepatic flexure	11.2	0.9	0.7-1.2	5.6	1.1	0.8-1.7	5.6	0.7	0.5-1.1									
Transverse colon	30.0	2.3	2.0-2.8	14.2	2.7	2.1-3.4	15.8	2.1	1.6-2.6									
Splenic flexure	11.2	0.9	0.7-1.2	6.0	1.1	0.7-1.6	5.2	0.7	0.5-1.1									
Descending colon	20.6	1.7	1.4-2.1	12.4	2.3	1.7-2.9	8.2	1.3	0.9-1.8									
Sigmoid colon	73.6	6.2	5.5-6.9	38.8	7.2	6.2-8.4	34.8	5.4	4.6-6.3									
Large intestine, NOS	21.0	1.6	1.3-2.0	10.0	1.9	1.4-2.5	11.0	1.4	1.1-1.9									
Rectum & rectosigmoid	128.2	10.5	9.7-11.4	70.0	12.8	11.5-14.2	58.2	8.8	7.8-9.9	27.6	2.2	1.8-2.6	12.6	2.4	1.8-3.0	15.0	2.1	1.6-2.6
Rectosigmoid junction	31.4	2.6	2.2-3.0	17.8	3.3	2.6-4.0	13.6	2.1	1.6-2.7									
Rectum	96.8	7.9	7.2-8.7	52.2	9.5	8.4-10.8	44.6	6.7	5.8-7.7									
Anus, anal canal & anorectum	25.4	2.0	1.7-2.4	7.8	1.3	1.0-1.9	17.6	2.6	2.1-3.2	2.6	0.2	0.1-0.4	1.0	0.2	0.1-0.4	1.6	0.2	0.1-0.5
Liver and intrahepatic bile duct	95.6	7.5	6.9-8.3	66.8	11.6	10.4-13.0	28.8	4.2	3.5-5.0	56.4	4.4	3.9-5.0	37.4	6.6	5.7-7.6	19.0	2.7	2.2-3.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry**  
**Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**  
**Westchester**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	77.0	6.1	5.5-6.7	56.6	9.7	8.6-11.0	20.4	3.0	2.4-3.7	37.6	2.9	2.5-3.4	27.4	4.8	4.0-5.7	10.2	1.5	1.1-2.0
Intrahepatic bile duct	18.6	1.5	1.2-1.8	10.2	1.9	1.4-2.5	8.4	1.2	0.8-1.6	18.8	1.5	1.2-1.8	10.0	1.8	1.3-2.4	8.8	1.2	0.9-1.7
Gallbladder	17.2	1.3	1.1-1.7	6.6	1.2	0.8-1.7	10.6	1.5	1.1-1.9	7.6	0.6	0.4-0.9	2.2	0.5	0.2-0.8	5.4	0.7	0.5-1.1
Other biliary	24.0	1.9	1.6-2.3	12.4	2.2	1.7-2.9	11.6	1.6	1.2-2.1	3.6	0.3	0.2-0.4	1.4	0.2	0.1-0.5	2.2	0.3	0.1-0.5
Pancreas	183.4	14.5	13.6-15.5	91.2	16.9	15.3-18.5	92.2	12.7	11.5-13.9	118.2	9.1	8.4-9.9	56.8	10.4	9.2-11.7	61.4	8.1	7.2-9.1
Retroperitoneum	6.8	0.6	0.4-0.8	4.2	0.8	0.5-1.3	2.6	0.4	0.2-0.8	1.0	0.1	0.0-0.2	1.0	0.2	0.1-0.5	0.0	0.0	0.0-0.2
Peritoneum, omentum & mesentery	6.4	0.5	0.3-0.7	0.2	0.0	0.0-0.2	6.2	0.9	0.6-1.3	3.4	0.3	0.2-0.5	1.0	0.2	0.1-0.4	2.4	0.4	0.2-0.7
Other digestive organs	6.6	0.5	0.4-0.7	3.8	0.7	0.4-1.1	2.8	0.4	0.2-0.7	4.0	0.3	0.2-0.5	2.2	0.4	0.2-0.8	1.8	0.2	0.1-0.4
Respiratory system	639.2	50.8	49.0-52.6	300.0	55.5	52.7-58.5	339.2	47.5	45.3-49.9	318.6	24.8	23.6-26.1	153.0	28.4	26.4-30.6	165.6	22.1	20.6-23.7
Nasal cavity, middle ear & sinuses	9.6	0.8	0.6-1.1	6.0	1.2	0.8-1.7	3.6	0.5	0.3-0.8	1.6	0.1	0.1-0.3	1.0	0.2	0.1-0.5	0.6	0.1	0.0-0.3
Larynx	31.2	2.5	2.1-2.9	25.4	4.6	3.8-5.5	5.8	0.9	0.6-1.3	8.0	0.6	0.4-0.9	7.0	1.3	0.9-1.8	1.0	0.2	0.0-0.4
Lung and bronchus	594.6	47.1	45.4-48.9	266.2	49.3	46.7-52.1	328.4	46.0	43.7-48.3	308.0	24.0	22.8-25.2	144.0	26.8	24.8-28.9	164.0	21.8	20.3-23.4
Pleura	0.8	0.1	0.0-0.2	0.6	0.1	0.0-0.3	0.2	0.0	0.0-0.2	0.6	0.0	0.0-0.2	0.6	0.1	0.0-0.4	0.0	0.0	0.0-0.2
Trachea, mediastinum, other respiratory	3.0	0.3	0.2-0.5	1.8	0.4	0.2-0.8	1.2	0.2	0.1-0.5	0.4	0.0	0.0-0.1	0.4	0.1	0.0-0.3	0.0	0.0	0.0-0.2
Bones & joints	10.4	1.0	0.8-1.3	6.0	1.2	0.8-1.7	4.4	0.8	0.5-1.3	2.4	0.2	0.1-0.4	1.2	0.2	0.1-0.5	1.2	0.3	0.1-0.5
Soft tissue (including heart)	36.2	3.3	2.8-3.8	19.0	3.8	3.1-4.7	17.2	2.9	2.3-3.6	13.8	1.2	0.9-1.5	6.4	1.2	0.8-1.8	7.4	1.1	0.8-1.6
Skin*	249.8	20.4	19.3-21.6	145.4	27.2	25.3-29.4	104.4	15.4	14.1-16.9	30.2	2.3	1.9-2.7	17.8	3.2	2.6-4.0	12.4	1.5	1.1-2.0
Melanoma of the skin	227.4	18.6	17.5-19.7	132.6	24.7	22.9-26.7	94.8	14.1	12.8-15.5	20.6	1.6	1.3-1.9	12.4	2.2	1.7-2.9	8.2	1.0	0.7-1.4
Breast	923.6	78.7	76.4-81.1	11.4	2.1	1.6-2.8	912.2	144.5	140.2-148.9	113.8	9.2	8.4-10.0	1.4	0.2	0.1-0.5	112.4	16.3	14.9-17.7
Breast (in situ)#	331.8	29.2	27.8-30.7	0.4	0.1	0.0-0.3	331.4	55.0	52.3-57.8									
Female genital system							334.0	51.0	48.5-53.6							92.8	12.9	11.7-14.2
Cervix uteri							35.2	6.3	5.4-7.3							7.8	1.2	0.8-1.7
Corpus uterus and NOS							191.8	28.4	26.6-30.3							39.4	5.4	4.7-6.2
Ovary							79.4	12.4	11.2-13.8							40.6	5.7	4.9-6.6
Vagina							3.0	0.4	0.2-0.8							1.0	0.1	0.0-0.4
Vulva							13.6	1.8	1.4-2.4							3.0	0.4	0.2-0.6
Other female genital organs							11.0	1.6	1.2-2.1							1.0	0.1	0.0-0.3
Male genital system				805.6	142.0	137.5-146.5							82.0	15.5	14.0-17.1			
Prostate				776.2	135.3	131.0-139.8							81.4	15.4	13.9-16.9			
Testis				26.0	5.9	5.0-7.1							0.0	0.0	0.0-0.2			
Penis				3.2	0.6	0.4-1.0							0.6	0.1	0.0-0.3			
Other male genital organs				0.2	0.0	0.0-0.2							0.0	0.0	0.0-0.2			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018  
Westchester**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	474.4	38.2	36.6-39.8	332.0	61.3	58.3-64.4	142.4	20.8	19.2-22.4	67.0	5.1	4.5-5.7	47.0	8.8	7.7-10.0	20.0	2.6	2.1-3.2
Urinary bladder (including in situ)	276.4	21.9	20.7-23.1	201.6	37.5	35.2-39.9	74.8	10.5	9.4-11.6	40.6	3.0	2.6-3.5	28.8	5.4	4.6-6.4	11.8	1.5	1.1-1.9
Kidney and renal pelvis	188.2	15.6	14.6-16.6	124.2	22.6	20.8-24.5	64.0	9.8	8.7-11.0	23.0	1.8	1.5-2.2	16.0	3.0	2.3-3.7	7.0	1.0	0.7-1.4
Ureter	6.2	0.5	0.3-0.7	3.6	0.7	0.4-1.2	2.6	0.4	0.2-0.6	2.0	0.1	0.1-0.3	1.0	0.2	0.1-0.5	1.0	0.1	0.0-0.3
Other urinary organs	3.6	0.3	0.2-0.4	2.6	0.4	0.2-0.8	1.0	0.1	0.0-0.4	1.4	0.1	0.0-0.2	1.2	0.2	0.1-0.5	0.2	0.0	0.0-0.2
Eye & orbit	12.8	1.1	0.8-1.4	5.6	1.0	0.7-1.5	7.2	1.1	0.8-1.6	0.6	0.0	0.0-0.1	0.4	0.1	0.0-0.3	0.2	0.0	0.0-0.2
Brain / other central nervous system (all behaviors)	265.2	22.9	21.6-24.2	100.8	19.3	17.6-21.1	164.4	26.0	24.2-27.9	47.0	3.9	3.4-4.4	23.4	4.4	3.7-5.3	23.6	3.4	2.8-4.1
Malignant brain / other central nervous system	72.2	6.5	5.8-7.2	37.4	7.4	6.3-8.5	34.8	5.7	4.9-6.7	37.8	3.2	2.7-3.7	20.2	3.8	3.1-4.7	17.6	2.6	2.1-3.3
Malignant brain	65.4	5.8	5.2-6.5	33.6	6.6	5.6-7.7	31.8	5.2	4.4-6.1									
Malignant other central nervous system	6.8	0.7	0.5-0.9	3.8	0.8	0.5-1.2	3.0	0.6	0.3-0.9									
Benign brain / other central nervous system#	193.0	16.4	15.3-17.5	63.4	11.9	10.6-13.3	129.6	20.3	18.7-22.0	9.2	0.7	0.5-1.0	3.2	0.6	0.4-1.0	6.0	0.8	0.5-1.1
Benign brain	16.4	1.6	1.3-2.0	8.2	1.6	1.2-2.2	8.2	1.6	1.1-2.1									
Benign other central nervous system	176.6	14.8	13.8-15.8	55.2	10.3	9.1-11.6	121.4	18.7	17.2-20.3									
Endocrine system	226.6	21.6	20.3-22.9	68.4	13.4	12.0-14.9	158.2	29.4	27.3-31.6	8.2	0.6	0.4-0.9	4.8	0.9	0.6-1.3	3.4	0.4	0.2-0.7
Thyroid	212.6	20.3	19.1-21.7	60.8	11.9	10.6-13.4	151.8	28.4	26.3-30.5	5.8	0.4	0.3-0.6	3.4	0.6	0.4-1.0	2.4	0.3	0.1-0.5
Other endocrine (including thymus)	14.0	1.3	1.0-1.6	7.6	1.5	1.0-2.1	6.4	1.1	0.7-1.5	2.4	0.2	0.1-0.4	1.4	0.3	0.1-0.6	1.0	0.2	0.0-0.4
Lymphomas	321.2	27.1	25.7-28.5	172.8	32.9	30.7-35.2	148.4	22.6	20.9-24.3	54.4	4.2	3.7-4.8	25.2	4.6	3.9-5.6	29.2	3.9	3.3-4.6
Hodgkin lymphoma	31.8	3.2	2.7-3.7	17.0	3.5	2.8-4.3	14.8	2.9	2.2-3.6	2.8	0.2	0.1-0.4	1.0	0.2	0.1-0.4	1.8	0.2	0.1-0.5
Non-Hodgkin lymphomas	289.4	23.9	22.7-25.2	155.8	29.4	27.3-31.6	133.6	19.7	18.2-21.3	51.6	4.0	3.5-4.5	24.2	4.5	3.7-5.4	27.4	3.7	3.0-4.4
Myeloma	112.0	9.1	8.4-9.9	63.0	11.7	10.4-13.1	49.0	7.1	6.2-8.0	34.8	2.7	2.3-3.2	16.0	3.0	2.4-3.8	18.8	2.5	2.0-3.0
Leukemias	223.4	18.7	17.6-19.9	132.4	25.1	23.2-27.2	91.0	13.7	12.4-15.1	62.6	4.8	4.2-5.3	34.0	6.3	5.4-7.4	28.6	3.7	3.1-4.4
Lymphocytic leukemias	125.4	10.5	9.7-11.4	78.6	14.8	13.4-16.4	46.8	7.0	6.1-8.0	12.8	1.0	0.7-1.3	8.6	1.6	1.2-2.2	4.2	0.5	0.3-0.8
Acute lymphocytic leukemia	19.0	2.0	1.6-2.5	11.6	2.5	1.9-3.2	7.4	1.6	1.1-2.2	3.4	0.3	0.2-0.5	2.0	0.4	0.2-0.7	1.4	0.2	0.1-0.5
Chronic lymphocytic leukemia	100.8	8.0	7.3-8.8	62.2	11.5	10.2-12.9	38.6	5.3	4.6-6.2	9.0	0.7	0.5-0.9	6.2	1.2	0.8-1.7	2.8	0.3	0.2-0.5
Other lymphocytic leukemias	5.6	0.5	0.3-0.7	4.8	0.9	0.5-1.3	0.8	0.1	0.0-0.3	0.4	0.0	0.0-0.1	0.4	0.1	0.0-0.3	0.0	0.0	0.0-0.2
Myeloid and monocytic leukemias	88.0	7.4	6.7-8.2	48.6	9.3	8.1-10.6	39.4	6.0	5.2-7.0	35.8	2.8	2.4-3.2	18.8	3.5	2.8-4.3	17.0	2.3	1.8-2.8
Acute myeloid leukemia	57.0	4.8	4.3-5.4	32.0	6.2	5.3-7.3	25.0	3.8	3.1-4.5	30.0	2.3	1.9-2.7	15.2	2.8	2.2-3.6	14.8	2.0	1.5-2.5
Acute monocytic leukemia	3.0	0.3	0.1-0.4	1.4	0.3	0.1-0.6	1.6	0.3	0.1-0.5	0.4	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.4	0.0	0.0-0.2
Chronic myeloid leukemia	27.4	2.3	1.9-2.7	15.0	2.8	2.2-3.5	12.4	2.0	1.5-2.6	2.6	0.2	0.1-0.3	1.4	0.2	0.1-0.5	1.2	0.1	0.0-0.3
Other myeloid/monocytic leukemias	0.6	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.4	0.0	0.0-0.2	2.8	0.2	0.1-0.4	2.2	0.4	0.2-0.8	0.6	0.1	0.0-0.3
Other leukemias	10.0	0.8	0.6-1.1	5.2	1.0	0.7-1.5	4.8	0.6	0.4-1.0	14.0	1.0	0.8-1.3	6.6	1.2	0.8-1.7	7.4	0.9	0.6-1.3
Other acute leukemias	2.2	0.2	0.1-0.3	1.2	0.2	0.1-0.5	1.0	0.1	0.0-0.4	4.2	0.3	0.2-0.5	2.0	0.4	0.2-0.7	2.2	0.3	0.1-0.5

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry  
Cancer Incidence and Mortality by Site of Cancer and Gender, 2014-2018**

**Westchester**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	7.8	0.6	0.4-0.8	4.0	0.8	0.5-1.2	3.8	0.5	0.3-0.8	9.8	0.7	0.5-1.0	4.6	0.8	0.5-1.3	5.2	0.6	0.4-1.0
Mesothelioma	12.2	1.0	0.7-1.2	9.0	1.7	1.2-2.3	3.2	0.4	0.3-0.7									
Kaposi sarcoma	3.8	0.3	0.2-0.5	3.4	0.7	0.4-1.1	0.4	0.0	0.0-0.2									
Myelodysplastic syndromes	64.0	5.0	4.5-5.6	37.0	7.2	6.2-8.4	27.0	3.5	2.9-4.2									
Chronic myeloproliferative disorders <sup>^</sup>	68.2	5.7	5.1-6.4	33.6	6.3	5.4-7.4	34.6	5.2	4.4-6.1									
Ill defined and unspecified sites	95.2	7.3	6.7-8.0	47.6	8.9	7.8-10.1	47.6	6.3	5.4-7.2	102.0	7.8	7.1-8.5	52.8	9.9	8.8-11.2	49.2	6.3	5.5-7.1

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2020

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

\* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

<sup>^</sup> Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.